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Abstract	  
Tumors	   were	   traditionally	   classified	   based	   on	   morphological	   and	  immunohistochemical	   characteristics	   into	   adenocarcinoma,	   large	   cell	   carcinoma,	  squamous	  cell	  carcinoma	  and	  small	  cell	  carcinoma.2	  In	  extensive	  genomic	  analyses	  of	  lung	  tumors	  within	  the	  past	  decade	  several	  genetic	  alterations	  were	  identified	  in	  certain	  subtypes	  that	  have	  been	  proven	  to	  be	  useful	  targets	   for	  specific	  molecular	  therapies,	   such	   as	   mutant	   EGFR	   that	   predict	   response	   to	   EGFR	   inhibitors	   in	  adenocarcinoma.	   With	   the	   increasing	   number	   of	   genetic	   alterations	   identified	   in	  lung	   cancer	   that	   are	   or	   might	   be	   suitable	   for	   targeted	   therapies,	   traditional	  diagnostic	  approaches	  become	  more	  and	  more	  insufficient.	  	  This	   thesis	  aimed	   at	   investigating	  genetic	   characteristics	  of	  all	  histological	  subtypes	   of	   lung	   tumors	   to	   define	   a	   genetically	   informed	   classification	   of	   lung	  cancers	   and	   to	   explore	   the	   eligibility	   of	   new	   molecular	   targets	   for	   targeted	  therapies.	  To	  identify	  genetic	  subgroups,	  mutations	  in	  selected	  genes,	  genome-­‐wide	  copy	   number	   alterations	   and	   gene	   expression	   patterns	   were	   analyzed	   in	   1,255	  clinically	  annotated	  lung	  tumors.	  Most	  genomic	  alterations	  segregated	  with	  one	  of	  the	  major	  histological	  subtypes	  adeno-­‐,	  squamous	  or	  small	  cell	  carcinoma	  but	  were	  not	   exclusive	   for	  one.	   In	   rare	   cases	   subtype-­‐specific	   genetic	  alterations	  were	   also	  identified	  in	  other	  subtypes,	  emphasizing	  the	  need	  for	  reevaluating	  current	  genetic	  tests	   that	   are	   mainly	   assigned	   to	   specific	   histological	   subtypes.	   Large	   cell	  carcinomas	  that	  are	  morphologically	  and	  clinically	  heterogeneous	  did	  not	  reveal	  a	  distinct	  pattern	  of	  genetic	  alterations.	  Most	  of	  the	  tumors	  of	  this	  subtype	  could	  be	  reassigned	   to	   one	   of	   the	   other	   subtypes	   based	   on	   their	   genetic	   and	   expression	  profiles.	   Thus,	   immunohistochemical	   and	   genetic	   tests	   should	   be	   considered	   for	  sub-­‐classifying	  tumors	  of	  this	  subtype	  into	  clinically	  relevant	  groups.	  Furthermore,	  in	   this	   study	   alterations	   in	   the	   tyrosine	   kinases	   FGFR1	   and	   FGFR3	   have	   been	  identified	   that	   –	   based	   on	   functional	   analyses	   -­‐	   might	   be	   eligible	   for	   targeted	  therapies	  in	  lung	  cancer	  patients.	  	  The	  described	  mutational	  catalog	  of	  primary	  lung	  tumors	  provides	  detailed	  information	  to	  further	  guide	  lung	  cancer	  diagnostics	  and	  treatment.	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Zusammenfassung	  
Das	   Bronchialkarzinom	   ist	   die	   häufigste	   tödliche	   Krebserkrankung	   mit	   einer	  mittleren	   Fünfjahres-­‐Überlebensrate	   von	   nur	   15%.	   Morphologisch	   werden	   die	  maligne	   Tumore	   in	   die	   vier	   Haupttypen	   Kleinzelliges	   (SCLC),	   Adeno-­‐	   (AD),	  Platten-­‐	  (SQ)	  und	  Großzelliges	  (LCC)	  Karzinom	  eingeteilt,	  wobei	  die	  letzten	  drei	  als	  Nichtkleinzellige	   Karzinome	   zusammengefasst	   werden.	   Diese	   Einteilung	   erwies	  sich	   als	   notwendig	   bei	   der	   Wahl	   von	   Chemotherapeutika,	   hatte	   jedoch	   für	   die	  Nichtkleinzelligen	  Karzinome	  keine	  prognostische	  Relevanz.	  Als	  neue	  Technologien	  genomische	   Untersuchungen	   ermöglichten,	   wurde	   deutlich,	   dass	   Tumore	   durch	  eine	   Vielzahl	   von	   genetischen	   Veränderungen	   charakterisiert	   sind.	   Genetische	  Alterationen	  können	  zu	  einer	  veränderten	  Genexpression	  führen	  und	  Zellen	  durch	  den	   Erwerb	   neuer	   zellulärer	   Eigenschaften	   einen	   Wachstumsvorteil	   gegenüber	  normalen	  Zellen	  verschaffen.	  Der	  Einsatz	  von	  zielgerichteten	  Substanzen,	  die	  eine	  Inhibierung	  veränderter	  enzymatischer	  Prozesse	   in	  Tumorzellen	  bedingen,	   führte	  erstmals	   zu	   verbesserten	   Therapieergebnissen	   in	   Patientengruppen	   mit	  spezifischen	   genetischen	  Merkmalen.	  Zum	  Beispiel	  wurde	   2004	   gezeigt,	   dass	  die	  Hemmung	   des	   Epidermalen	   Wachstumsfaktor	   Rezeptors	   mit	   Erlotinib,	   einem	  niedermolekularen	  Inhibitor	  der	  die	  Tyrosinkinasedomäne	  des	  Rezeptors	  blockiert,	  zu	   einem	   verlängerten	   progressionsfreien	   Überleben	   in	   Patienten	   führt,	   deren	  Tumor	  eine	  genetische	  Aberration	  in	  diesem	  Rezeptor	  aufweisen.3,4	  Derartige	  neue	  Therapiemöglichkeiten	   führten	   zu	   drastischen	   Veränderungen	   in	   der	  Tumorklassifizierung	   von	   einer	   Histologie-­‐basierten	   hin	   zu	   einer	   kombinierten	  morphologischen	  und	  molekularen	  Diagnostik	  zur	  Stratifizierung	  von	  Patienten	  für	  individualisierte,	  zielgerichtete	  Therapien.	  	  In	   der	   hier	   präsentierten	   Studie	   wurden	   erstmals	   Lungentumore	   aller	  histologischen	   Subtypen	   genetisch	   analysiert,	   mit	   dem	   Ziel	   eine	   umfassende	  genetische	   Charakterisierung	   dieser	  Krebsart	   zu	   erlangen	   und	   klinisch	   relevante	  Subgruppen	   zu	   identifizieren,	   die	   als	   Grundlage	   einer	   neuen,	   molekularen	  Klassifikation	   dienen	   könnten.	   Dafür	   wurden	   mehr	   als	   1,000	   Tumore	   auf	  somatische	   chromosomale	   Aberrationen	   und	   Genmutationen	   hin	   untersucht.	  Die	  
	  8	  
Genexpression	  wurde	  von	  einem	  Teil	  der	  Tumore	  analysiert.	  Mutationsfrequenzen	  wurden	   in	   Genen	   untersucht,	   die	   bereits	   in	   vorherigen	   Studien	   in	   diversen	  Krebsarten	   als	  Onkogene	  oder	   Tumorsuppressorgene	  bestätigt	  wurden.	   In	   dieser	  Studie	   wurden	   mehrere	   neue	   potentielle	   Tumormarker	   in	   Lungentumoren	  identifiziert.	   Dazu	   gehören	   Aberrationen	   des	   Fibroblasten	   Wachstumsfaktor	  Rezeptors	   (FGFR),	   dessen	   Genkopien	   häufig	   in	   Plattenepithelkarzinomen	   erhöht	  waren	  (FGFR1)	  oder	  in	  seltenen	  Fällen	  dessen	  Genbereich,	  der	  für	  die	  extrazelluläre	  Region	   des	   Rezeptors	   kodiert,	   mutiert	  war	   (FGFR3).	   In	   beiden	   Fällen	   wurde	   in	  funktionellen	  Experimenten	  die	  Sensitivität	  gegenüber	  FGFR-­‐Inhibitoren	  gezeigt.	  	  In	   den	   histologische	   Subtypen	   AD,	   SQ	   und	   SCLC	   wurden	   jeweils	  charakteristische	   genetische	   Aberrationen	   beschrieben.	   Genalterationen,	   die	  typisch	   für	   einen	   bestimmten	   histologischen	   Subtyp	   waren,	   wurden	   in	   seltenen	  Fällen	  ebenfalls	   in	  Tumoren	  anderer	  Subtypen	  gefunden.	  So	  wurden	  zum	  Beispiel	  Mutationen	   in	  EGFR	  und	  KRAS,	   zwei	  Gene	   die	   häufig	   im	  Adenokarzinom	  alteriert	  sind,	  auch	  in	  Plattenepithel	  Tumoren	  identifiziert.	  Tumore	  des	  LCC	  Subtyps	  ließen	  kein	   spezifisches	   Markerprofil	   erkennen,	   stattdessen	   zeigten	   sie	   Mutationen,	  Genkopienzahl-­‐Veränderungen	   und	   Genexpressionsprofile,	   die	   typisch	   für	   die	  andere	   Subtypen	   sind.	   Mit	   Hilfe	   immunohistologisch	   nachweisbarer	  linienspezifischer	   Antigene	   konnte	   die	   Mehrzahl	   der	   LCC	   in	   andere	  Lungenkrebs-­‐Subtypen	  klassifiziert	  werden,	  die	   typische	  genetische	  Aberrationen	  aufwiesen.	  	  Um	  effektive	  Strategien	   für	  die	  molekulare	  Diagnostik	   zu	  entwickeln	   ist	   es	  von	  hoher	  Bedeutung	  das	  Auftreten	  relevanter	  Marker	  in	  Tumoren	  zu	  kennen.	  Die	  hier	  präsentierten	  Ergebnisse	   lassen	  erahnen,	  dass	  Einzelgen-­‐basierte	  molekulare	  Diagnostik,	  wie	  sie	  heute	  erfolgt,	  nicht	  mehr	  lange	  effizient	  sein	  wird.	  Da	  zahlreiche	  Therapeutika	  gegen	  molekulare	  Marker	  bereits	  in	  fortgeschrittenen	  Studienphasen	  getestet	   werden,	   wird	   eine	   effiziente	   Analyse	   von	   Tumoren	   zur	   molekularen	  Diagnose	   nur	   im	   Multiplexverfahren	   sinnvoll	   sein.	   Da	   in	   seltenen	   Fällen	   klinisch	  relevante	   Subtypen-­‐charakteristische	   Aberrationen	   auch	   in	   Tumoren	   anderer	  Subtypen	   identifiziert	   wurden,	   sollten	   Tumore	   nicht	   auf	   Grund	   der	   Morphologie	  von	   molekularen	   Tests	   ausgeschlossen	   werden.	   Dies	   betrifft	   insbesondere	   die	  heterogene	   Gruppe	   der	   LCC,	   die	   Genaberrationen	   aufweisen,	   die	   typisch	   für	   alle	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anderen	   Subtypen	   sind.	   Ob	   sich	   aus	   der	   Patientenstratifizierung	   auf	   Grund	  molekularer	   Marker	   eine	   Verbesserung	   der	   Prognose	   für	   Lungenkrebspatienten	  ergibt,	  wird	  sich	  in	  entsprechenden	  Studien	  zeigen.	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Abbreviations	  
The	  international	  system	  of	  units	  (SI	  units)	  was	  used	  in	  this	  thesis.	  	  AD	   adenocarcinoma	  of	  the	  lung	  ALK	   anaplastic	  lymphoma	  receptor	  tyrosine	  kinase;	  cytogenetic	  band:	  	   2p23	  BCR	   breakpoint	  cluster	  region;	  cytogenetic	  band:	  22q11.23	  BRAF	   v-­‐raf	  murine	  sarcoma	  viral	  oncogene	  homolog	  B1;	  cytogenetic	  band:	  	   7q34	  	  BRCA1/2	   breast	  cancer	  1	  and	  2,	  early	  onset;	  cytogenetic	  band:	  17q21	  (1),	  	   13q12.3	  (2)	  CA	   carcinoid	  of	  the	  lung	  CD56	   synonym:	  neural	  cell	  adhesion	  molecule	  (NCAM)	  CDKN2A	   cyclin-­‐dependent	  kinase	  inhibitor	  2A;	  cytogenetic	  band:	  9p21	  CK5/6	   cytokeratin	  5	  and	  6	  CK7	   cytokeratin	  7	  EGFR	   epidermal	  growth	  factor	  receptor;	  cytogenetic	  band:	  7p12	  EML4	   echinoderm	  microtubule	  associated	  protein	  like	  4;	  cytogenetic	  band:	  	   2p21	  ERBB2	   v-­‐erb-­‐b2	  erythroblastic	  leukemia	  viral	  oncogene	  homolog	  2,	  synonym:	  HER2;	  cytogenetic	  band:	  17q12	  ERK	   extracellular-­‐signal-­‐regulated	  kinase;	  cytogenetic	  band:	  22q11	  FCS	   fetal	  calf	  serum	  	  FFPE	   Formaline	  fixed	  paraffin	  embedded	  H&E	  	   hematoxylin	  and	  eosin	  staining	  HRAS	   	   v-­‐Ha-­‐ras	  Harvey	  rat	  sarcoma	  viral	  oncogene	  homolog;	  cytogenetic	  	   	   band:	  11p15.5	  IHC	   immunohistochemistry	  KEAP1	   Kelch-­‐Like	  ECH-­‐Associated	  Protein	  1;	  cytoband:	  19p13	  KRAS	   v-­‐Ki-­‐ras2	  Kirsten	  rat	  sarcoma	  viral	  oncogene	  homolog;	  cytogenetic	  band:12p12.1	  	  LCC	   large	  cell	  carcinoma	  of	  the	  lung	  LCNEC	   large	  cell	  neuroendocrine	  carcinoma	  Mb	   megabase	  (1Mb	  =	  1	  mio.	  base	  pairs)	  MAPK	   Mitogen-­‐activated	  protein	  kinase	  MEK	   mitogen-­‐activated	  and	  extracellular-­‐signal-­‐regulated	  kinase	  kinase,	  synonym:	  MAPKK,	  MEK1;	  cytogenetic	  band:	  15q22.1-­‐q22.33	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Driver	   mutation:	   is	   a	   genetic	   alteration	   that	   is	   sufficient	   to	   confer	   growth	   and	  survival	   advantage	   to	   a	   cell	   and	   whose	   inhibition	   leads	   to	   cell	   death	   of	   cells	  harboring	  this	  alteration.	  
Five-­‐year	   survival	   rate:	   is	   the	  percentage	  of	  patients	  who	   live	  at	   least	   five	  years	  after	  being	  diagnosed	  with	  cancer.	  
Kaplan-­‐Meier	   survival	   curve:	   shows	   the	  probability	   of	   survival	   in	   a	   given	   time	  frame	  taking	  patient	  information	  into	  account	  where	  definite	  endpoint	  observation	  (date	   of	   death)	   is	   missing.	   For	   these	   censored	   cases	   date	   of	   last	   follow-­‐up	  determines	  the	  endpoint	  of	  observation.	  
Median	  survival	  time:	  is	  the	  time	  since	  diagnosis	  when	  relative	  survival	  is	  at	  50%	  (time	  when	  half	  of	  the	  patients	  have	  survived).	  
Targeted	  Therapy:	  is	  a	  type	  of	  treatment	  that	  uses	  small	  molecules	  or	  monoclonal	  antibodies	  that	  were	  designed	  to	  target	  and	  thereby	  inhibiting	  the	  action	  of	  certain	  proteins	  or	  other	  molecules	  in	  cancer	  cells.	  
Tumorigenesis:	  is	  the	  formation	  and	  development	  of	  tumors.	  
Overall	  survival:	  is	  a	  term	  used	  to	  denote	  the	  percentage	  of	  patients	  who	  are	  alive	  after	  a	  specified	  duration	  of	  time	  after	  being	  diagnosed	  with	  cancer	  (often	  reported	  as	  5-­‐year	  survival	  rate;	  for	  example	  a	  5-­‐year	  survival	  rate	  of	  5%	  means	  that	  5%	  of	  the	  patients	  are	  alive	  after	  five	  years).	  
Progression-­‐free	  survival:	  is	  the	  time	  from	  start	  of	  treatment	  until	  progression	  of	  the	  disease.	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1. Cancer	  One	  out	  of	   three	  people	  will	  get	  cancer	   in	  the	  course	  of	   their	   lives	  and	  one	  out	  of	  four	  of	  them	  will	  die	  of	  it.	  Every	  day	  about	  20.000	  people	  worldwide	  die	  of	  cancer,	  which	   is	   therefore	   the	   second	  most	   common	   cause	   of	   death	   after	   cardiovascular	  disease	  (7.6	  vs.	  17	  million	  deaths	  in	  2008,	  respectively).	  Due	  to	  population	  growth	  and	  increased	  longevity,	  statistical	  trends	  suggest	  an	  increase	  of	  the	  total	  numbers	  of	  annual	  cancer	  deaths	  to	  approximately	  13	  million	  by	  the	  year	  2030.5	  	  
1.1. Cancer	  is	  a	  disease	  of	  the	  genome	  Cancer	   initiation	   and	   tumorigenesis	   is	   a	   multifactorial,	   multistage	   process.	   The	  mechanisms	  inducing	  cancer	  development	  are	  at	  this	  point	  not	  fully	  understood	  for	  every	  cancer	  type.	  Several	  toxins	  have	  been	  linked	  to	  certain	  cancer	  types	  such	  as	  aflatoxin	  and	  alcohol	  abuse	  to	  liver	  cancer,	  asbestos	  to	  mesothelioma,	  and	  cigarette	  smoking	   to	   lung	   cancer.6	   Furthermore,	   epidemiological	   studies	   and	   functional	  analyses	   revealed	   that	   a	   variety	   of	   pathogens	   are	   associated	   with	   many	   cancer	  types	   to	   either	   induce	   tumor	   formation	   or	   to	   contribute	   to	   tumorigenesis.	  Most	  prominently,	  cervical	  cancer	  was	  found	  to	  be	  induced	  by	  human	  papilloma	  viruses	  and	  liver	  cancer	  by	  hepatitis	  V	  viruses.	  Regardless	  of	  the	  initiating	  factors,	  tumors	  are	  characterized	  to	  accumulate	  several	  alterations	  in	  the	  genome	  of	  somatic	  cells	  inevitably	   leading	   to	   cellular	   transformation.	   Tumors	   consequently	   arise	   from	  somatic	  evolution.	  Genetic	  changes	  that	   lead	  to	  enhanced	  or	  disrupted	   function	  of	  gene	  products	  in	  the	  affected	  cell,	  can	  eventually	  confer	  a	  selective	  proliferation	  and	  thus	   lead	   to	   the	   malignant	   phenotype.7	   Classically	   it	   is	   believed	   that	   a	   tumor	  emerges	   from	   a	   single	   mutated	   cell	   by	   clonal	   expansion	   and	   acquisition	   of	  additional	   alterations	   during	   proliferation.7	   Today	   it	   is	   assumed	   that	   in	   certain	  cancer	  types	  tumor	  mass	  formation	  is	  driven	  only	  by	  the	  proliferation	  of	  a	  distinct	  subpopulation	   of	   cells,	   which	   have	   enhanced	   self-­‐renewal	   potential	   and	   are	   also	  responsible	  for	  tumor	  heterogeneity.8,9	  	  	   The	  idea	  that	  cancer	  is	  caused	  by	  genomic	  alterations	  arose	  in	  the	  early	  20th	  century	   when	   Boveri	   postulated	   that	   aberrations	   affecting	   chromosomes	   are	  associated	   with	   malignant	   growth	   of	   tissue.10	   In	   1959,	   the	   Philadelphia	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Chromosome,	   later	   identified	   to	   be	   a	   reciprocal	   translocation	   of	   chromosomes	   9	  and	  22	  causing	  a	  fusion	  of	  the	  BCR	  and	  ABL	  genes,	  was	  discovered	  in	  patients	  with	  Chronic	   Myeloid	   Leukemia	   (CML).11	   Since	   then	   and	   with	   technological	   advances	  various	   cancer	   types	   have	   been	   studied	   by	   global	   sequencing	   and	   SNP	   (single	  nucleotide	   polymorphism)	   array	   analyses	   with	   the	   aim	   to	   identify	   genetic	  alterations	   to	   understand	   molecular	   changes	   underlying	   cancer.12-­‐18	   From	   the	  unexpected	   high	   amount	   of	   genetic	   alterations	   identified	   in	   those	   studies	   the	  majority	  are	  found	  to	  be	  specific	  for	  certain	  cancer	  types.	  Only	  a	  limited	  number	  of	  genes	   are	   repeatedly	   mutated	   across	   many	   cancer	   types	   (for	   example	   BRAF,	  
CDKN2A,	   KRAS,	   PIK3CA,	   PTEN,	   and	   TP53)	   suggesting	   their	   impact	   on	   the	  tumorigenic	  phenotype.19,20	  	  It	  became	  apparent	  that	  tumor	  formation	  is	  in	  general	  not	  caused	  by	  a	  single	  genetic	  event	  but	  requires	  several	  alterations	  affecting	  proto-­‐oncogenes	  and	  tumor	  suppressor	  genes	  that	  in	  combination	  stimulate	  uncontrolled	  growth,	  division	  and	  survival	  of	   the	  cell.19,21,22	  The	   flood	  of	   sequencing	  data	  revealed	   that	  cancer	   types	  are	  distinguishable	  by	  different	  landscapes	  of	  somatic	  alterations	  and	  that	  tumors	  of	   the	   same	   type	   can	   present	   different	   genetic	   alterations.16,18,23	   Despite	   the	  heterogeneity	   of	   tumors,	   all	   cancer	   types	   share	   the	   same	   characteristics	   that	  distinguish	  them	  from	  normal	  cells,	  the	  so-­‐called	  Hallmarks	  of	  Cancer,	  summarized	  by	  Hanahan	  and	  Weinberg	  in	  2011.22	  Cancer	  cells	  a. sustain	   proliferative	   signaling	   by	   producing	   growth	   signals	   (for	   instance	  PDGF	   production	   in	   glioblastoma),	   structural	   alterations	   or	   increase	   of	  receptors	   to	   facilitate	   ligand-­‐independent	   signaling	   (for	   example	   ERBB2	  overexpression	  in	  breast	  and	  stomach	  cancer),	  	  b. overcome	   negative	   regulation	   of	   proliferation,	   which	   mainly	   depends	   on	  tumor	  suppressor	  genes	  such	  as	  RB	  and	  TP53,	  	  c. evade	   programmed	   cell	   death	   by	   up-­‐regulation	   of	   anti-­‐apoptotic	   and	  survival	  signals	  and	  down	  regulation	  of	  pro-­‐apoptotic	  factors,	  	  d. are	   replicative	   immortal	   through	   expression	   of	   telomerase,	   that	   adds	  telomere	   repeats	   to	   chromosome	   ends	   whose	   shortening	   with	   every	  replication	  step	  would	  eventually	  lead	  to	  senescence,	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e. induce	  angiogenesis,	  the	  formation	  of	  blood	  vessels,	  to	  provide	  the	  growing	  tumor	  with	  nutrients	  and	  oxygen	  and	  evacuate	  metabolic	  waste	  and	  carbon	  dioxide	  by	  inductive	  signals	  (for	  example	  VEGF)	  or	  expression	  of	  angiogenic	  factors	  caused	  by	  oncogenes	  (for	  example	  KRAS	  or	  MYC),	  f. invade	   surrounding	   tissue	   and	   spread	   to	   distant	   sites	   of	   the	   organism	  (metastasis),	  g. accumulate	   genetic	   alterations	   that	   can	   affect	   single	   nucleotides	   within	  specific	   genes	   up	   to	   complete	   chromosomes	   due	   to	   replication	   errors	   or	  deficiencies	  in	  repair	  mechanisms,	  	  h. are	  supplied	  with	  growth	  and	  survival	  factors,	  signals	  inducing	  angiogenesis,	  invasion	  and	  metastasis	  through	  inflammatory	  cells	  infiltrating	  the	  tumor,	  i. metabolize	  glucose	  through	  glycolysis	  which	  allows	  metabolic	  intermediates	  to	   be	   used	   for	   biosynthesis	   of	  macromolecules	   required	   for	   cell	   assembly,	  and	  	  j. evade	   the	   immune	   system	   that	   has	   been	   associated	   with	   suppression	   of	  tumor	  formation	  in	  mice.	  	  	  
1.2. Pathways	  that	  are	  altered	  in	  human	  cancer	  Heterogeneous	   cell-­‐signaling	   pathways	   are	   disrupted	  promoting	   cells	   to	   generate	  their	   own	   mitogenic	   signals,	   resist	   growth-­‐inhibitory	   signals,	   evade	   apoptosis,	  proliferate	   inordinate,	  and	  eventually	   invade	  and	  metastasize	   to	  other	  sites	  of	   the	  body.7	  Signaling	  pathways	  generally	  proceed	   from	   the	   cell	   surface,	   to	   cytoplasmic	  intermediates	   to	   nuclear	   transcription	   factors	   leading	   to	   transcription	   of	   effector	  genes	   involved	   in	   specific	   cellular	   processes.	   If	   alterations	   occur	   in	   any	   of	   the	  proteins	   involved	   in	   cellular	   signaling	   pathways,	   accurate	   transduction	   might	   no	  longer	   be	   assured,	   which	   can	   result	   in	   cell	   transformation.	   Most	   genes	   that	   are	  frequently	   altered	   in	   cancer	   encode	   signaling	  molecules,	   such	   as	   protein	   kinases	  that	  transfer	  phosphate	  groups	  from	  adenosine	  triphosphate	  to	  specific	  amino	  acid	  residues	   (serine,	   threonine	   or	   tyrosine)	   and	   thereby	   modifying	   the	   functional	  properties	   of	   their	   substrates,	   phosphatases	   that	   counteract	   protein	   kinases	   by	  removing	   phosphate	   residues	   on	   target	   proteins,	   guanosine	   triphosphate	  (GTP)-­‐binding	  proteins,	  and	  transcription	  factors.	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   The	  Ras-­‐Raf-­‐MEK	  and	  PI3K-­‐Akt	  pathways	  are	  the	  most	  frequently	  disrupted	  signaling	  pathways	   in	  cancer	  (Figure	  1).7	  Despite	  high	  complexity	  of	  cell	  signaling	  networks	  in	  each	  pathway,	  specific	  key	  regulators	  are	  involved	  that	  propagate	  in	  a	  linear	  fashion.	  Activation	  of	  these	  pathways	  is	  mediated	  by	  binding	  of	  a	  ligand	  to	  a	  tyrosine	   kinase	   receptor	   (for	   example,	   binding	   of	   the	   epidermal	   growth	   factor	  (EGF)	  to	  the	  EGF	  receptor	  (EGFR)	  or	  the	  fibroblast	  growth	  factor	  (FGF)	  to	  the	  FGF	  receptor	  (FGFR)).	  In	  the	  Ras-­‐Raf-­‐MEK	  pathway	  a	  guanosine	  exchange	  factor	  (GEF)	  binds	   to	   the	   dimerized	   and	   autophosphorylated	   receptor	   and	   catalyzes	   the	  exchange	   of	   the	   Ras-­‐bound	   guanosine	   diphosphate	   (GDP)	   against	   guanosine	  triphosphate	   (GTP).	   This	   exchange	   activates	   Ras,	   an	   intracellular	  membrane-­‐associated	   GTPase,	   that	   promotes	   phosphorylation	   and	   thereby	  activation	  of	  several	  downstream	  effectors.	  One	  of	  the	  most	   important	  effectors	   is	  B-­‐Raf.	  Phosphorylated	  B-­‐Raf	  activates	   the	  kinases	  MEK1/2,	  which	   in	   turn	  activate	  the	  kinases	  ERK1/2.	  ERK	  is	  translocated	  into	  the	  nucleus	  where	  it	  activates	  several	  transcription	  factors	  that	   initiate	  expression	  of	  cyclines	  and	  cytokines	  (that	  play	  a	  major	   role	   in	   the	   cell	   cycle)	   and	   growth	   factors	   amongst	   others.	   The	   immediate	  result	  is	  the	  activation	  of	  cell	  proliferation.	  	  	   In	  the	  PI3K-­‐AKT	  pathway	  first	  PI3K	  is	  activated	  either	  through	  transfer	  of	  a	  phosphate	  from	  the	  tyrosine	  kinase	  receptor	  dimers	  or	  from	  membrane-­‐associated	  active	  GTP-­‐bound	  Ras	  proteins	  (i.e.,	  H-­‐Ras,	  K-­‐Ras	  and	  N-­‐Ras).	  PI3K	  phosphorylates	  the	   membrane	   component	   phosphatidylinositol-­‐4,5-­‐bisphosphat	   (PIP2)	   to	   PIP3.	  The	  function	  of	  PI3K	  can	  be	  antagonized	  by	  the	  phosphatase	  and	  tumor	  suppressor	  PTEN	   (phosphatase	   and	   tensin	   homolog)	   that	   converts	   PIP3	   back	   to	   PIP2.	   PIP3	  activates	   AKT	   that	   can	   then	   inhibit	   apoptosis	   and	   activate	   translation	   (through	  activation	  of	  mTOR	  and	  the	  S6K	  transcription	   factor).	  The	  PI3K-­‐AKT	  pathway	  can	  also	  be	  activated	  by	  dimerization	  of	  other	  receptors	  such	  as	  ErbB2,	  which	  does	  not	  need	  a	  ligand	  for	  activation	  but	  forms	  heterodimers	  with	  other	  receptor	  monomers	  of	  the	  same	  family	  (i.e.,	  EGFR,	  ErbB3	  or	  ErbB4)	  when	  their	  ligand	  is	  bound.7,24	  	   Several	  other	  pathways	  regulate	  cell	  proliferation,	  apoptosis	  and	  DNA	  repair.	  Cell	  divisions	  are	  controlled	  during	  cell	  cycle	  by	  several	  proteins	   that	  suppress	  or	  activate	   transition	   from	   one	   state	   to	   the	   next	   involving	   DNA	   synthesis	   (S	   phase),	  mitosis	   (M	   phase)	   and	   gaps	   (G	   phases)	   where	   integrity	   of	   the	   cell	   is	   assured	   at	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certain	  checkpoints.	  Two	  proteins	  are	  mainly	  involved	  in	  the	  cell	  cycle	  control:	  Rb	  controls	   the	   progression	   into	   S	   phase	   and	   p53	   regulates	   expression	   of	  proliferation-­‐inhibiting	   and	   apoptosis-­‐promoting	   proteins	   in	   response	   to	   DNA	  damage.	  If	  Rb	  or	  p53	  are	  disrupted	  cells	  can	  divide	  irrespective	  of	  alterations	  in	  the	  DNA	  sequence.7	  	  	  










































insertional	   mutagenesis	   screens	   in	   mice	   revealed	   preferential	   co-­‐mutations	   of	  specific	   combinations	   of	   genes	   that	   causes	   uncontrolled	   cell	   proliferation	   and	  eventually	   leading	   to	   tumor	   formation.25	   It	   has	   been	   widely	   accepted	   that	  alterations	   in	   proteins	   within	   the	   same	   signaling	   pathway	   tend	   to	   be	   mutually	  exclusive.7	  	  	  	  
1.3. Oncogenes	  and	  Tumor	  Suppressor	  Genes	  Genes	  that	  control	  cell	  growth	  and	  proliferation	  in	  normal	  cells	  can	  be	  grouped	  into	  two	  classes:	  proto-­‐oncogenes	  and	  tumor	  suppressor	  genes	  (TSG).	  Whereas	  specific	  alterations	   in	   proto-­‐oncogenes	   lead	   to	   activation	   of	   their	   function,	   alterations	   in	  TSGs	  lead	  to	  their	  inactivation	  (Figure	  2).7,26	  Proto-­‐oncogenes	   often	   encode	   proteins	   that	   stimulate	   cell	   division	   and	  decrease	  or	   inhibit	   cell	   differentiation	  and	   cell	   death	  by	   receiving	  and	  processing	  growth-­‐stimulatory	   signals	   that	   originate	   in	   the	   extracellular	   matrix.7,26	  Proto-­‐oncogenes	   have	   been	   identified	   at	   all	   levels	   of	   all	   signal	   transduction	  cascades	   and	   include	   receptor	   growth	   factors	   (e.g.,	   EGF,	   VEGF),	   receptor	   and	  non-­‐receptor	  tyrosine	  kinases	  (e.g.,	  ALK,	  EGFR	  and	  VEGFR;	  and	  ABL1,	  respectively),	  serine-­‐threonine	   kinases	   (e.g.,	   Akt	   and	   B-­‐Raf),	   G-­‐proteins	   (e.g.,	   Ras),	   and	  transcription	   factors	   (e.g.,	  Myc).	   Activating	   alterations	   in	   proto-­‐oncogenes	   lead	   to	  continuous	  activation	  or	  increased	  production	  of	  the	  gene	  products	  and	  thus	  to	  an	  enhancement	   of	   the	   malignant	   phenotype.7	   Mutated	   proto-­‐oncogenes	   are	   called	  oncogenes.	  Alterations	  involve	  substitutions	  of	  single	  or	  multiple	  nucleotides	  (e.g.,	  mutations	   in	   codon	   12	   and	   13	   in	   the	   RAS	   genes	   in	   different	   cancers	   as	   well	   as	  mutations	  in	  the	  ELREA	  motif	  in	  EGFR	  in	  lung	  tumors18),	  gene	  amplifications	  (e.g.,	  
ERBB2	   amplification	   in	   breast	   cancer7,27)	   or	   chromosomal	   rearrangements	   (e.g.,	  
ALK	  rearrangements	  in	  lung	  cancer28).	  Those	  alterations	  are	  typically	  dominant	  in	  nature,	  meaning	  an	  alteration	  in	  only	  one	  allele	  is	  sufficient	  in	  order	  to	  observe	  the	  mutant	  phenotype	  (Figure	  2).7	  Thus,	  different	  mechanisms	  can	  lead	  to	  an	  activation	  of	   proto-­‐oncogenes.	   For	   example,	   alterations	   in	   receptor	   proteins	   may	   lead	   to	  ligand-­‐independent	   dimerization	   and	   thereby	   constitutive	   activation	   of	  downstream	  signaling.	  Modifications	  in	  the	  extracellular	  domain	  can	  lead	  to	  stable	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dimerization	   of	   two	   transmembrane	   receptors	   such	   as	   FGFR	   harboring	   a	  corresponding	   alteration.	   The	   fibroblast	   growth	   factor	   (FGF)	   receptor	   family	  consists	  of	   four	  transmembrane	  tyrosine	  kinase	  receptors	  (FGFR1,	  FGFR2,	  FGFR3,	  and	   FGFR4)	   that	   are	   activated	   by	   ligand	   dependent	   dimerization	   leading	   to	   a	  conformational	  shift	  and	  thereby	  intracellular	  transphosphorylation	  of	  the	  tyrosine	  kinase	   domains.29	  Aberrant	   FGF	   signaling	   has	   been	   described	   in	   several	   cancers,	  but	   alterations	   in	   the	   receptor	   are	   most	   common	   in	   bladder	   cancer,	   where	  approximately	  50%	  of	   the	   tumors	  harbor	   a	  mutation	   in	  FGFR3.29	  The	  majority	  of	  those	   alterations	   occur	   in	   the	   extracellular	   domain	   of	   the	   receptor	   with	   the	  substitution	  of	  serine	  with	  cysteine	  at	  amino	  acid	  (AA)	  position	  249	  being	  the	  most	  prevalent.	   This	   alteration	   leads	   to	   ligand	   independent	   constitutive	   dimerization	  through	   formation	   of	   an	   intermolecular	   cysteine	   disulfide	   bridge	   and	   thereby	  activation	  of	  the	  receptor.29	  Also	  alterations	  in	  the	  intracellular	  domain	  of	  receptors,	  such	  as	  the	  kinase	  domain	  of	  EGF	  receptor,	  can	  constitutively	  activate	  the	  protein.	  Such	   activating	   mutations	   mainly	   occur	   in	   the	   adenosine	   triphosphate	  (ATP)-­‐binding	   pocket	   of	   the	   protein.30	   About	   90%	   of	   alterations	   found	   in	   EGFR	  affected	   the	   amino	   acid	   sequence	   ELREA	   (746	   to	   750)	   and	   a	   leucine	   at	   position	  858.31	   Mutant	   EGFR	   has	   multiple	   tyrosine	   residues	   phosphorylated	   at	   the	  C-­‐terminus	   in	   the	   absence	   of	   the	   ligand,32	   thereby	   leading	   to	   the	   constitutive	  activation	   of	   downstream	   signaling	   without	   extracellular	   stimulation.	   ERBB2	   is	  closely	  related	  to	  EGFR	  and	  frequently	  overexpressed,	  for	  example	  in	  breast	  cancer,	  leading	   to	   expression	   levels	   that	   may	   be	   100	   times	   higher	   than	   in	   normal	   cells	  which	  promotes	  spontaneous	  receptor	  dimerization	  in	  the	  absence	  of	  a	  ligand.33,34	  
KRAS	   activating	   mutations	   occur	   in	   codon	   12	   or	   13	   that	   encode	   for	   a	   protein	  fragment	  adjacent	  to	  the	  GDP/GTP	  binding	  pocket	  and	  thereby	  negatively	  regulate	  the	   function	  of	   the	  protein;	  mutations	   in	   this	   region	   consequently	   lock	   the	  K-­‐Ras	  protein	   in	   the	   active	   state.	   In	   normal	   cells	   transmission	   of	   growth-­‐promoting	  signals	  from	  cell	  surface	  receptors	  through	  Ras	  is	  balanced	  through	  binding	  of	  GTP	  (active	  state)	  and	  hydrolysis	  of	  GTP	  to	  GDP	  (inactive	  state).	  If	  mutated,	  its	  ability	  to	  hydrolyze	   GTP	   is	   inactivated	   and	   downstream	   signaling	   thus	   remains	   activated	  independent	   of	   an	   extracellular	   stimulus,	   which	   usually	   initiates	   the	   signaling	  cascade.	  Proto-­‐oncogenes	  can	  also	  be	  activated	  through	  fusion	  of	  DNA-­‐sequences	  of	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two	  different	  genes	   that	   can	   lead	   to	  a	  consecutive	  activation	  of	   the	  gene	  product.	  One	  example	  is	  the	  fusion	  between	  DNA-­‐sequence	  encoding	  for	  the	  N-­‐terminus	  of	  EML4	  with	  the	  sequence	  encoding	  for	  the	  receptor	  tyrosine	  kinase	  domain	  of	  ALK.	  EML4	  mediates	   the	   ligand-­‐independent	   homodimerization	   and	   thus	   activation	   of	  the	  gene	  product	  even	  in	  cells	  where	  ALK	  is	  normally	  not	  expressed	  or	  active.35,36	  	   Alterations	   in	   TSGs	   on	   the	   other	   hand	  mainly	   lead	   to	   loss	   of	   function	   and	  (following	  the	  Knudson	  2	  hit	  hypothesis)	  most	  alterations	  occurring	  in	  these	  genes	  are	  recessive;	  both	  alleles	  need	  to	  be	  mutated	  in	  order	  to	  completely	  inactivate	  the	  function	  of	  the	  gene.7	  TSGs	  control	  the	  cell	  cycle	  in	  normal	  cells	  through	  stimulation	  of	   differentiation	   or	   inhibition	   of	   proliferation	   of	   the	   cell	   (e.g.,	   pRb,	   CDKN2A	   and	  p53),	  stimulation	  of	  apoptosis	  (e.g.,	  p53),	  and	  they	  are	  also	  involved	  in	  DNA	  damage	  recognition	   and	   DNA	   repair	   (e.g.,	   BRCA1	   and	   2,	   and	   p53).	   Even	   though	   TSGs	  involved	   in	   DNA	   repair	   do	   not	   directly	   control	   cell	   proliferation,	   cells	   that	  compromise	  their	  ability	  to	  repair	  DNA	  damages	  can	  acquire	  additional	  mutations	  in	  other	  TSGs	  or	  proto-­‐oncogenes.	  	  	   To	   inactivate	   a	   TSG	   either	   the	   whole	   chromosomal	   region	   needs	   to	   be	  deleted	  in	  both	  chromatids	  during	  mitosis	  or	  two	  independent	  somatic	  alterations	  are	   required.	  Often	   a	   mutation	   in	   one	   copy	   of	   the	   gene	   occurs	   sporadically.	   The	  other	   gene	   copy	   is	   then	   either	   lost	   through	   mitotic	   recombination	   (i.e.	  recombination	  of	  the	  chromosome	  arm	  carrying	  the	  mutation	  and	  the	  one	  carrying	  the	  wild	  type	  allele	  during	  mitosis	  eventually	  leading	  to	  a	  daughter	  cell	  lacking	  both	  wild	  type	  alleles),	  gene	  conversion	  (i.e.	  chromosome	  with	  the	  wild	  type	  allele	  uses	  the	  other	  chromosome	  with	  mutant	  allele	  as	  a	  template	  during	  DNA	  replication)	  or	  loss	  of	  the	  entire	  chromosome	  carrying	  the	  wild	  type	  allele	  during	  mitosis.	  Mitotic	  recombination	   or	   chromosomal	   losses	   occur	   between	   one	   and	   two	   magnitudes	  more	  frequently	  per	  cell	  generation	  than	  mutations	  and	  are	  therefore	  more	  likely	  to	  contribute	   to	   alteration	   of	   the	   second	   allele	   than	   another	  mutation.7	  The	   two-­‐hit	  hypothesis	  was	  postulated	  in	  1971	  to	  explain	  symptoms	  of	  inherited	  and	  sporadic	  retinoblastoma,	  where	  children	  develop	  tumors	  in	  one	  eye	  only	  or	   in	  both	  eyes	  in	  association	   to	   family	  history	  of	   the	  disease.37	  Germline	  mutations	   in	   the	  TSG	  RB1	  predispose	  individuals	  to	  the	  development	  of	  tumors	  in	  both	  eyes	  early	  in	  life	  and	  they	   have	   a	   high	   risk	   of	   developing	   other	   tumors	   later	   in	   life.	   Sporadic	   RB1	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mutations	  on	  the	  other	  hand	  may	  cause	  one	  tumor	  in	  one	  eye	  only	  and	  surgery	  can	  cure	   the	  patient.7	   In	   individuals	  who	   inherited	  one	  mutant	  allele,	   the	  gene	  can	  be	  inactivated	  by	  mutation	  of	  the	  normal	  allele	  whereas	  without	  an	  inherited	  mutation	  two	  mutations	  need	  to	  occur	  in	  the	  same	  cell	  in	  order	  to	  inactivate	  the	  gene.	  Since	  mutation	   rate	   is	   equal	   for	   both	   alleles,	   inactivation	   of	   the	   gene	  with	   an	   inherited	  mutant	  allele	  occurs	  more	  frequent	  than	  inactivation	  by	  mutation	  of	  both	  alleles	  in	  the	  normal	  gene.	  	  	  
	  	  	  	  	   	  Figure	  2	  Proto-­‐oncogenes	  and	   tumor	   suppressor	  genes	   regulate	   the	   cell	  proliferation.	  An	  alteration	   in	   one	   copy	   of	   the	   proto-­‐oncogene	   or	   inactivation	   of	   both	   copies	   of	   a	   tumor	  suppressor	  gene	  (TSG)	  can	  cause	  excessive	  cell	  proliferation	  and	  can	  therefore	  contribute	  to	  cancer.	  (Picture	  adapted	  from	  Alberts.	  Molecular	  Biology	  of	  the	  Cell.	  5th	  edition)	  	  	   Whereas	   proto-­‐oncogenes	   can	   be	   activated	   by	   alterations	   only	   at	   limited	  positions	  within	  the	  gene,	  TSGs	  can	  be	  inactivated	  through	  alterations	  of	  any	  kind	  at	   almost	   every	   site	   in	   the	   gene.7	   As	   aforementioned,	   there	   are	   several	   types	   of	  alterations	   that	   can	   affect	   single	   nucleotides,	   whole	   genes,	   long	   chromosomal	  regions,	  chromosome	  arms	  or	  complete	  chromosomes.7	  	  	  	  
2. Somatic	  genomic	  alterations	  Somatic	   mutations	   are	   changes	   in	   the	   sequence	   of	   the	   genome	   that	   result	   from	  unrepaired	  DNA	  damage	  and	  occur	  in	  only	  those	  cells,	  which	  do	  not	  belong	  to	  the	  germline	   reproductive	   cell	   system;	   somatic	   mutations	   will	   therefore	   not	   be	  inherited	  to	  the	  next	  generation.	  Few	  germ-­‐line	  mutations	  had	  been	  described	  that	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are	   associated	  with	   specific	   patterns	   of	   tumor	   formation.	   Often	   these	   alterations	  affect	  TSGs	  or	  weak	  oncogenes	   that	  allow	  normal	  development	  but	  predispose	   to	  tumor	  formation	  often	  in	  early	  years	  as	  for	  instance	  in	  retinoblastoma	  (see	  above).	  	  Somatic	  alterations	  that	  confer	  selective	  growth	  advantage	  on	  cells	  underlie	  all	   cancers.7	   In	  normal	   cells	  genetic	  alterations	  will	  be	   corrected	  or	   cells	  undergo	  apoptosis	   when	   alterations	   are	   severe,	   thus	   only	   specific	   alterations	   that	   will	   be	  tolerated	  and	   alter	   the	   function	   of	   gene	  products	   contribute	   to	   transformation	   of	  the	   cell.	   Recurrence	   of	   alterations	   across	   and	   within	   certain	   cancer	   subtypes	  suggests	   a	   selective	   advantage	   for	   such	   events.	  During	   transformation	   cells	   lose	  cell-­‐cycle	   control	   and	   precision	   of	   DNA	   replication	   that	   might	   change	   the	  chromosomal	  structure	  and	  copy	  number	  and	  cause	  mutations	  in	  the	  genome.	  The	  most	   common	   alterations	   include	   nucleotide	   substitution	   mutations	   and	   small	  insertion	   and	   deletions,	   copy	   number	   gains	   and	   losses,	   and	   chromosomal	  rearrangements.38	  	  	  
Somatic	   mutations	   can	   occur	   spontaneously	   through	   replication	   and	  recombination	  mistakes	  during	  mitosis	  or	  can	  be	  induced	  by	  radiation	  or	  chemical	  mutagens	  that	  either	  directly	  modify	  nucleotides	  or	  cause	  errors	  during	  replication.	  Changes	   of	   nucleotides	   (i.e.,	   the	   exchange,	   deletion	   or	   insertion	   of	   certain	  nucleotides)	  in	  the	  coding	  sequence	  of	  a	  gene	  can	  cause	  changes	  in	  the	  amino	  acid	  (AA)	   sequence	   that	   -­‐	   if	   the	   alteration	   does	   not	   result	   in	   failure	   of	   transcription	   -­‐	  might	   alter	   the	   structure	   and	   consequently	   the	   function	   of	   the	   gene	   product.	  Mutations	  can	  affect	  single	  or	  multiple	  nucleotides.	  Single	  nucleotide	  changes	  that	  alter	  the	  AA	  are	  called	  non-­‐synonymous	  mutations	  (further	  divided	  into	  missense	  mutations,	   if	   the	   nucleotide	   change	   causes	   a	   change	   of	   the	   AA	   and	   nonsense	  mutations,	   if	   resulting	   AA	   encodes	   for	   a	   stop	   codon	   that	   causes	   premature	  termination	  of	  the	  protein	  during	  translation).	  Mutations	  in	  the	  coding	  region	  that	  do	  not	  cause	  changes	  in	  the	  amino	  acid	  sequence	  are	  called	  synonymous	  or	  silent.	  It	  is	  believed	  that	  synonymous	  mutations	  do	  not	  contribute	  to	  any	  structural	  changes	  of	  the	  gene	  product	  but	  can	  influence	  gene	  expression	  through	  altered	  folding	  of	  the	  mRNA	  during	  transcription.39	  Deletions	  and	  insertions	  in	  coding	  regions	  that	  do	  not	  comprise	   a	  multitude	   of	   three	  nucleotides	   and	   thereby	   shift	   the	   coding	   sequence	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after	   the	   affected	   nucleotide(s)	   are	   known	   as	   frameshift	   alterations.	   These	  alterations	   change	   the	   complete	   AA	   sequence	   and	   increase	   the	   probability	   of	  introducing	  a	  stop	  codon	  that	  again	  will	  lead	  to	  a	  premature	  transcription	  stop	  and	  abnormal	  gene	  products.40	  TSG	  often	  harbor	  frameshift	  or	  nonsense	  mutations	  that	  disrupt	   the	   function	   of	   the	   gene	   product	   whereas	   these	   types	   of	   alterations	   are	  rarely	   found	   in	   oncogenes.	   Most	   oncogenes	   harbor	  missense	  mutations	   affecting	  only	   specific	  AAs	   (so-­‐called	  hotspots)	  mostly	   in	   regulatory	   regions	   of	   the	  protein	  that	   cause	   continuous	   activity	   of	   the	   mutated	   protein.7,41	   In	   KRAS,	   for	   example,	  oncogenic	  missense	  mutations	  occur	  mainly	  in	  two	  consecutive	  glycine	  residues	  at	  AA	  position	  12	  and	  13.	  EGFR	  is	  frequently	  altered	  through	  small	  in-­‐frame	  deletions	  encompassing	   the	   five	  AA	   from	  codons	  746	   to	  750	  (exon	  19	  ELREA	  motif)	  or	   the	  missense	  mutation	  resulting	  in	  a	  substitution	  of	  leucine	  with	  arginine	  at	  codon	  858	  in	  the	  kinase	  domain	  leading	  to	  a	  constitutively	  active	  mutant	  protein.42	  	  
Genome	   copy	   number	   changes	   through	   amplifications,	   deletions,	   chromosome	  loss	  or	  duplication	  as	  well	  as	  changes	  in	  gene	  and	  chromosome	  structure	  through	  chromosomal	   translocation,	   inversion	   or	   other	   rearrangements,	   mainly	   occur	  during	  recombination	  due	  to	  unequal	  crossing-­‐over,	  exon-­‐shuffling	  (one	  exon	  from	  gene	  1	   is	   inserted	   into	  gene	  2)	  or	   transposition	   (transfer	  of	   a	  DNA	  segment	   from	  one	  site	  to	  another	  on	  the	  same	  or	  different	  chromosome).7	  Gene	  amplification	  may	  lead	   to	   increased	   expression	   of	   the	   gene	   product	   and	   by	   this	   to	   a	   selective	  advantage	  during	  cell	  growth	  (e.g.,	  amplification	  in	  EGFR	  in	  lung	  cancer	  or	  ERBB2	  in	  breast	   cancer	   are	   associated	   with	   increased	   expression	   of	   the	   respective	  protein).34,43,44	   Copy	   number	   amplification	   is	   a	   frequent	   event	   which	   causes	  increased	  gene	  expression	  of	  oncogenes,	  whereas	  deletions	  rather	  inactivate	  tumor	  suppressor	  genes.38,44	  	  	  
Structural	   rearrangements	   in	   the	   genome	   are	   caused	   by	   breakage	   of	   the	   DNA	  double	  helices	  and	  rejoining	  of	  chromosomal	  ends	  at	  different	  locations	  within	  the	  same	  or	  on	  a	  different	  chromosome.	  Translocations	  can	  generate	  fusion	  genes	  that	  encode	  proteins	  with	  novel	  properties.	  For	  example,	  an	  inversion	  on	  chromosome	  2	  brings	   the	   coding	   region	   of	   the	   regulatory	   domain	   of	   the	   EML4	   gene	   in	   close	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proximity	  to	  the	  gene	  region	  of	  the	  proto-­‐oncogene	  ALK	  encoding	  for	  the	  catalytic	  domain.	   The	   resulting	   chimeric	   fusion	   protein	   is	   constitutively	   active.	   Some	  proto-­‐oncogenes	   are	   involved	   in	   different	   translocations,	   for	   example,	   several	  fusion	  partner	  for	  the	  kinases	  ALK	  or	  ROS1	  have	  been	  identified	  in	  different	  cancer	  types	  resulting	  in	  an	  increased	  kinase	  activity.45,46	  	  	  	  
3. Lung	  Cancer	  	  Lung	  cancer	   is	  worldwide	   the	  most	  commonly	  diagnosed	  cancer	   type	   in	  men	  and	  the	   fourth	   in	   women,	   with	   1.1	   and	   0.52	  million	   new	   cases	   registered	   in	   2008.47	  Lung	  cancer	  rates	  have	  reached	  a	  plateau	  for	  men	  in	  many	  regions	  of	  the	  world	  but	  continue	   to	   rise	   in	   women.	   Differences	   in	   lung	   cancer	   incidences	   are	   mainly	   a	  consequence	  of	  gender	  disparity	  of	  cigarette	  smoking,	  which	  is	  the	  number	  one	  risk	  factor	   for	   lung	   cancer5	   and	   may	   also	   explain	   the	   higher	   percentage	   of	   never-­‐smokers	   in	   female	   lung	   cancer	  patients.	   Furthermore,	  epidemiologic	   associations	  explain	  the	  prevalence	  of	  lung	  cancer	  but	  these	  are	  not	  well	  defined	  yet.6	  	  Overall	   lung	   cancer	   is	   the	   number	   one	   cause	   of	   cancer-­‐related	   deaths	  accounting	   for	  1.38	  million	  deaths	   annually.5	  Only	  half	   of	   all	   lung	   cancer	  patients	  will	   survive	   for	   one	  year	   after	  diagnosis	   and	  only	  15%	  are	   alive	   after	   five	   years.6	  Survival	  time	  depends	  on	  growth	  of	  the	  tumor	  and	  whether	  it	  is	  local	  or	  has	  spread	  from	   its	   original	   location.	   In	   general,	   survival	   is	   better	   the	   earlier	   the	   tumor	   is	  detected.	  Only	  15%	  of	  the	  lung	  cancer	  cases	  are	  diagnosed	  at	  an	  early	  stage	  with	  a	  localized	  tumor	  when	  five-­‐year	  survival	  rate	  is	  greater	  than	  50%.6	  Whereas	   in	  the	  past	  40	  years	  for	  many	  other	  cancer	  types	  median	  survival	  time	  improved	  due	  to	  a	  combination	  of	   preventive	   care,	   early	  detection	  and	  better	   treatments	   (e.g.,	   colon	  and	  breast	  cancer),	  survival	  rates	  in	  lung	  cancer	  patients	  improved	  barely	  (from	  11	  to	  20	  weeks	  with	  standard	  therapies).48	  	  
3.1. Histology	  and	  Classification	  Tumors	   of	   the	   lung	   can	   arise	   from	   the	   epithelium,	   lymphs,	   mesothelium	   or	   soft	  tissue.	   Epithelial	   tumors	   (carcinoma)	   are	  most	   common	   and	   exhibit	   the	   greatest	  diversity.	   They	   can	   be	   divided	   into	   four	   major	   types:	   adenocarcinoma,	   large	   cell	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carcinoma,	  squamous	  cell	  carcinoma,	  and	  small	  cell	  carcinoma.	  Mixed	  tumors	  exist	  and	  are	  mainly	  classified	  according	  to	  the	  most	  predominant	  cell	  type	  found.	  Small	  cell	   cancers	   (SCLC)	  account	   for	  about	  15%	  of	   lung	  cancer	  cases	  and	  are	  clinically	  distinguished	  from	  others,	  because	  they	  respond	  well	  to	  chemotherapy.	  Tumors	  of	  the	   other	   three	   types,	   combined	   into	   non-­‐small	   cell	   carcinomas,	   are	   removed	  surgically	   if	   possible.	   Carcinoids	   represent	   a	   fifth	   class	   that	   comprises	   benign	  tumors.	  Resected	  lung	  tumors	  are	  classified	  based	  on	  morphology	  according	  to	  the	  WHO	  criteria,	  supported	  by	  immunohistochemistry	  in	  case	  of	  poorly	  differentiated	  tumor	  samples.2	  	  
Non-­‐small	  cell	  carcinoma	  	  Non-­‐small	   cell	   lung	   cancers	   (NSCLC)	   are	   staged	   (I	   -­‐	   IV)	   according	   to	   established	  international	   criteria	   and	   grouped	   based	   on	   the	   TNM	   classification	   system	  combining	  tumor	  size	  and	  location	  (T),	  lymph	  node	  involvement	  (N)	  and	  presence	  of	   distant	   metastasis	   (M).	   In	   general,	   higher	   stage	   (overall	   and	   within	   each	  category)	  correlates	  with	  a	  poorer	  prognosis	  with	  a	  five-­‐year	  survival	  of	  about	  60%	  for	   stage	   I	   (T1-­‐2,	  N0,	  M0;	   primary	   tumor	   has	   not	   spread	   to	   other	   sites)	   and	   less	  than	  5%	  for	  stage	  IV	  (TX,	  NX,	  M1)	  disease.5,6	  The	  major	  aim	  of	  staging	  is	  to	  select	  cases	   suitable	   for	   surgery,	   which	   offers	   the	   highest	   possibility	   for	   a	   cure.	  Furthermore,	  staging	  helps	   to	   identify	  those	  candidates	  eligible	   for	  chemotherapy	  and	   radiotherapy	   and	   specific	   treatment	   options	   that	   are	   approved	   for	   advanced	  stage	   non-­‐small	   cell	   lung	   cancer.	   The	   term	   non-­‐small	   cell	   lung	   cancer	   does	   not	  reveal	   taxonomic	   precision	   in	   diagnosing	   these	   tumors	   and	   should	   therefor	   be	  avoided.	  	  
Adenocarcinoma	  	  The	   proportion	   of	   adenocarcinoma	   (AD)	   in	   lung	   cancer	   has	   increased	   from	  approximately	  5%	  in	  the	  1950th	  to	  about	  40%	  and	  is	  now	  the	  most	  common	  type	  of	  NSCLC.	   This	   trend	   can	   be	   explained	   by	   the	   fact	   that	   filtered	   cigarettes	   became	  available	  and	  people	  inhaled	  deeper	  into	  their	  lungs.49	  ADs	  occur	  mainly	  peripheral	  in	   the	   lung	   and	   in	   order	   to	   further	   distinguish	   them	   from	   the	   morphologically	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similar	   metastatic	   AD	   the	   transcription	   factor	   TTF-­‐1,	   which	   is	   expressed	   in	   the	  alveolar	  epithelium	  in	  the	  periphery	  of	  the	  lung,	  serves	  as	  a	  useful	  marker.	  ADs	  are	  characterized	   by	   either	  mucus	   formation,	   which	  may	   be	   discrete	   or	   intracellular	  (solid	   adenocarcinoma)	   or	   by	   distinct	   growth	   patterns	   such	   as	   acinar	   growth,	  papillar	  differentiation	  or	  a	  single-­‐layer	  spread	  along	  bronchioles	  (characteristic	  for	  bronchioloalveolar	  carcinoma	  (BAC))	  and	  the	  alveolar	  septum.	  They	  show	  frequent	  histologic	  heterogeneity	  that	  are	  more	  common	  than	  tumors	  consisting	  purely	  of	  a	  single	  pattern	  of	   solid	  adenocarcinoma	  with	  mucin	   formation,	  acinar,	  papillary	  or	  bronchioloalveolar	   adenocarcinoma.2	   BACs	   are	   characterized	   by	   proliferation	   of	  type	  II	  pneumocytes	  and/or	  clara	  cells	  in	  a	  lepidic	  fashion	  along	  the	  alveolar	  walls	  without	  destruction	  of	  lung	  architecture	  and	  are,	  in	  cases	  with	  predominant	  lepidic	  growth	   pattern,	   associated	   with	   100%	   or	   near	   100%	   disease-­‐free	   survival	   after	  complete	  resection.50-­‐52	  Patients	  with	  predominantly	  acinar	  and	  papillary	  or	  solid	  adenocarcinoma	  have	  a	  five-­‐year	  survival	  of	  about	  70%	  and	  40%,	  respectively.52	  	  The	  2004	  WHO	  Classification	  of	  adenocarcinoma	  has	  been	  revised	   in	  2011	  by	  a	  multidisciplinary	  expert	  panel	  representing	  the	  IASLC,	  the	  American	  Thoracic	  Society	  and	  the	  European	  Respiratory	  Society.	  The	  major	  adjustment	   involved	  the	  diagnosis	   of	   BAC,	   because	   the	   criteria	   for	   this	   classification	   were	   not	   clear	   and	  could	   range	   from	  pure	  BAC	   to	  mixed	  adenocarcinoma	  with	  minor	   components	  of	  BAC	  pattern.	   Prognosis	   therefore	  widely	   ranged	   from	  a	  100%	   to	  a	  10%	   five-­‐year	  survival	   rate.53	  BAC	   is	   now	   subdivided	   into	   categories	   that	   correlate	  with	   clinical	  outcome	  ((a)	  adenocarcinoma	  in	  situ	  (noninvasive,	   lepidic	  pattern),	  (b)	  minimally	  invasive	  adenocarcinoma	  (predominantly	  lepidic	  pattern	  and	   invasion	  of	  less	  than	  5	  mm	   into	   the	   surrounding	   tissue),	   (3)	   lepidic	   predominant	   adenocarcinoma,	   (4)	  invasive	   (mucinous	   or	   nonmucinous,	   invasion	   of	   more	   than	   5	  mm)).	   Further	  micropapillary	   adenocarcinoma,	   which	   was	   not	   part	   of	   the	   2004	   WHO	  Classification,	   emerged	   as	   an	   important	   variant	   of	   papillary	   adenocarcinoma.51,54	  Pictures	   of	   hematoxylin-­‐eosin	   stained	   tumor	   sections	   in	   Figure	   3	   demonstrate	  characteristic	  features	  of	  the	  five	  major	  subtypes	  of	  adenocarcinoma	  that	  were	  first	  presented	  at	  the	  13th	  World	  Lung	  Conference	  in	  San	  Francisco,	  USA	  in	  200955	  and	  published	  by	  Travis	  et	  al.	  in	  2011.	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  lepidic	   	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  papillary	  	   	   	  	  	  	  	  	  micropapillary	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  solid	  Figure	  3	  Morphology	  of	  histological	  subtypes	  of	  adenocarcinoma.	  Lepidic:	  neoplastic	  cells	  grow	   along	   preexisting	   alveolar	   structures,	   Papillary:	   glandular	   cells	   grow	   along	   central	  fibrovascular	   cores.	   Micropapillary:	   small	   papillary	   tufts	   of	   tumor	   cells	   that	   lack	  fibrovascular	   cores	   lying	  apparently	   free	   in	  alveolar	   spaces,	  Acinar:	   tumor	  cells	   surround	  round-­‐	   to	   oval-­‐shaped	   neoplastic	   glands	   with	   a	   central	   luminal	   space,	   Solid:	   polygonal	  tumor	  cells	   form	  sheets	  without	   recognizable	  patterns	  of	  adenocarcinoma.	   (hematoxylin-­‐eosin,	  black	  bars	  correspond	  to	  200	  µm)	  	  
Large	  cell	  carcinoma	  Traditionally	   large	  cell	  carcinoma	  (LCC)	  is	  an	  exclusion	  diagnosis.	  The	  term	  refers	  to	  a	  barely	  differentiated,	  non–small	  cell	  cancer,	  in	  which	  neither	  the	  characteristics	  of	  adenocarcinoma	  nor	  those	  of	  squamous	  or	  small	  cell	  carcinoma	  are	  detectable.	  They	  account	   for	  approximately	  10%	  of	  all	   lung	  tumors,	  of	  which	  about	  one	  third	  are	   large	  cell	   carcinoma	  with	  neuroendocrine	  differentiation	   (LCNEC)	   that	  have	  a	  poorer	  prognosis	  than	  the	  other	  large	  cell	  carcinoma.	  LCNECs	  are	  characterized	  by	  generally	   large	   tumor	   cells	   that	   grow	   in	   distinct	   organoid,	   trabecular	   or	   insular	  growth	   patterns,	   a	   prominent	   nucleoli	   and	   high	   mitotic	   rates	   (75	   mitoses	   per	  2mm2).	   One	   of	   the	   neuroendocrine	   immunohistochemical	   markers	   (CD56,	  Synaptophysin	  and	  Chromogranin)	   is	   sufficient	   for	   confirmation	  of	   this	  diagnosis.	  Half	  of	  the	  LCNEC	  cases	  express	  TTF-­‐1.2	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  Figure	   4	   Large	   cell	   carcinoma	   of	   the	   lung.	   This	   lesion	   does	   not	   exhibit	   specific	  differentiation	   (left).	   Cells	   have	   abundant	   cytoplasm	   with	   large	   nuclei	   and	   prominent	  nucleoli	   (right).	   (hematoxylin-­‐eosin,	   black	   bars	   correspond	   to	   200	   µm	   (left)	   and	   20	   µm	  (right))	  	  	  
Squamous	  cell	  carcinoma	  Squamous	  cell	  carcinomas	  (SQ)	  mainly	  arise	  centrally	  in	  the	  main	  stem,	   lobar	  and	  segmental	   bronchi	   and	   are	   characterized	   by	   intra-­‐cytoplasmatic	   keratinization	   or	  intercellular	   bridges.	   The	  majority	   of	   squamous	   cell	   carcinomas	   express	   p63	   and	  cytokeratins	   5/6	   and	   very	   few	   express	   thyroid	   transcription	   factor-­‐1	   (TTF-­‐1)	   or	  cytokeratin	  7	  (CK7).	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	   	  	  	   	  Figure	   5	   Classical	   morphological	   features	   of	   squamous	   cell	   carcinoma	   of	   the	   lung.	   Left:	  keratinizing,	  arrow	  indicates	  keratinized	  cells	   forming	  cell	  pearls.	  Right:	  non-­‐keratinizing:	  no	   clear	   keratinization,	   pearls	   or	   intercellular	   bridges	   are	   present.	   (hematoxylin-­‐eosin,	  original	  magnification	  20x)	  	  
Small	  cell	  carcinoma	  Small	   cell	   carcinomas	   (SCLC)	   are	   classified	   into	   limited	   (restricted	   to	   one	  hemithorax,	  LD)	  or	  extensive	  disease	  (with	  distant	  metastasis,	  ED)	  with	  a	  five-­‐year	  survival	  of	  5-­‐10%	  and	  less	  than	  5%,	  respectively.6	  The	  American	  Joint	  Commission	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on	   Cancer	   TNM	   staging	   system	   is	   less	   frequently	   applied	   for	   SCLC	   because	  treatment	   options	   do	   not	   differ	   much	   between	   these	   detailed	   stages.	   Without	  treatment	  median	   survival	   is	   only	   2	   to	   4	  months	   but	   can	  be	  up	   to	   24	   for	   limited	  disease	  and	  up	  to	  9	  months	  for	  extensive	  disease	  when	  applying	  currently	  available	  first-­‐line	   therapies.56	   Approximately	   70%	   of	   SCLC	   cases	   are	   metastatic	   at	  presentation,56	  which	  limits	  localized	  treatment	  such	  as	  surgery	  or	  radiation.	  	  Tumor	  cells	  of	  SCLC	  are	  characterized	  by	  a	  high	  nuclear	  to	  cytoplasmic	  rate,	  granular	   nuclear	   chromatin	   (salt	   and	   pepper	   chromatin	  pattern),	   absent	   nucleoli	  and	   nuclear	   molding,	   where	   nuclei	   conform	   to	   one	   another.	   In	   most	   cases	  immunohistochemistry	   is	   positive	   for	   TTF-­‐1,	   CD56,	   Synaptophysin,	   and	  Chromogranin.2	  	  	  
	  	  	  	  	  	  	  	  	  	  	   	   	  	  	  	   	  Figure	   6	   One	   small	   cell	   carcinoma	   case.	   Right:	   A	   magnified	   view	   shows	   the	   typical	  cytological	   features	   of	   small	   cell	   carcinoma:	   no	   nucleoli,	   „salt	   and	   pepper“	   chromatin	  pattern,	   nuclear	  molding	   (arrow),	   and	   high	  mitotic	   activity	   (mitotic	   cell	   (dashed	   arrow).	  (hematoxylin-­‐eosin,	  black	  bars	  correspond	  to	  200	  µm	  (left)	  and	  20	  µm	  (right))	  	  
Carcinoid	  	  Carcinoids	   (CA)	   are	   rare	   neuroendocrine	   lung	   tumors	   that	   account	   for	  approximately	  2%	  of	  newly	  diagnosed	  cases.	  They	  arise	  from	  neurosecretory	  cells	  of	  bronchial	  mucosa	  and	  are	   classified	   into	   typical	   and	  atypical	   carcinoids	  with	   a	  five-­‐year	   survival	   of	   greater	   than	   90%	   and	   50-­‐60%,	   respectively.	   Nine	   out	   of	   10	  newly	   diagnosed	   carcinoid	   cases	   are	   typical.	   These	   tumors	   are	   less	   aggressively	  malignant	   than	   atypical	   carcinoids	  and	  a	   five-­‐year	   survival	   is	   observed	   in	   almost	  100%	   of	   the	   cases.	   At	   presentation	   10-­‐15%	   of	   typical	   and	   40-­‐50%	   of	   atypical	  carcinoids	  have	  metastasized	  to	  regional	   lymph	  nodes	  and	  beyond.	  Carcinoids	  are	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characterized	   by	   growth	   of	   uniform	   polygonal	   cells	   with	   granular	   chromatin,	  inconspicuous	  small	  uniformly	  round	  nucleoli	  and	  marginal	  to	  moderate	  amount	  of	  cytoplasm	   that	   are	   arranged	   in	   distinct	   organoid,	   trabecular	   or	   insular	   growth	  patterns.	  Tumors	  with	  typical	  morphology	  have	  less	  than	  2	  mitosis	  per	  2	  mm2	  and	  atypical	  2	  to	  10	  mitosis	  per	  2	  mm2.	  Only	  atypical	  carcinoids	  exhibit	  foci	  of	  necrosis.2	  Histological	  heterogeneity	  of	  carcinoids	  and	  other	  subtypes	  is	  rare.	  More	  than	  80%	  of	   carcinoids	   are	   positive	   for	   cytokeratins	   and	   for	   at	   least	   one	   neuroendocrine	  marker.2	  	  	  
	   	  Figure	  7	  Typical	  carcinoid.	  (hematoxylin-­‐eosin,	  black	  bars	  correspond	  to	  50	  µm)	  	  
Rare	  lung	  tumors	  Carcinomas	  with	  pleomorphic,	  sarcomatoid	  or	  sarcomatous	  elements	  that	  contain	  a	  sarcoma	   (malignant	   bone,	   cartilage	   or	   skeletal	   muscle)	   or	   sarcoma-­‐like	   (spindle	  and/or	  giant	  cell)	  component	  are	  globally	  rare	  and	  account	  for	  0.1-­‐0.4%	  of	  all	  lung	  malignancies.	   They	   are	   highly	   correlated	   with	   smoking	   history	   and	   pursue	   an	  aggressive	  clinical	  course.57,58	  The	  latest	  WHO	  Classification	  of	  the	  Lung	  requires	  a	  minimum	   of	   10%	   sarcomatoid	   pattern	   (spindle	   and/or	   giant	   cells)	   for	   a	   positive	  diagnosis.2	  Despite	  several	  adaptions	  in	  the	  classification	  system,	  diagnosis	  of	  such	  cases	  remains	  difficult.	  	  	  
3.2. Treatment	  options	  of	  lung	  cancer	  Lung	  cancer	  is	  mostly	  diagnosed	  at	  an	  advanced	  stage	  when	  prognosis	  is	  poor	  and	  curative	   treatment	   options	   are	   limited.5,6	   Prognosis	   and	   treatment	   decisions	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depend	  on	  the	  stage	  and	  subtype	  but	  also	  on	  the	  patient’s	  age	  and	  general	  health.	  In	  early	   stage	   lung	   tumors	   surgery	   is	   the	   most	   promising	   therapy.	   Adjuvant	  chemotherapy	  improves	  progression-­‐free	  survival	  by	  eliminating	  remaining	  cancer	  cells	  and	  metastasized	  cancer	  cells	  in	  brain,	  liver	  or	  bone.59	  Chemotherapeutics	  are	  antineoplastic	   agents	   that	   inhibit	   DNA	   replication	   by	   various	   mechanisms	   and	  thereby	   kill	   the	   cells.	   These	   agents	   are	   toxic	   for	   every	   cell	   and	   since	   they	   are	  systemically	  applied,	  they	  cause	  several	  severe	  side	  effects,	  such	  as	  suppression	  of	  the	   immune	   system,	   reduction	   of	   white	   and	   red	   blood	   cells,	   and	   oral	   and	  gastrointestinal	  mucositis.	  Tumor	  therapy	  can	  also	   involve	  radiotherapy,	  either	  by	  specifically	   targeting	   the	   tumor	  using	  high-­‐energy	   radiation	  beams	  or	   radioactive	  substances	  that	  are	  delivered	  to	  the	  whole	  body.	  	  Patients	   with	   SCLC	   are	   treated	   with	   chemotherapy	   and	   radiation	   or	  chemotherapy	  alone,	  if	  the	  tumor	  has	  spread	  to	  other	  sites.	  Despite	  a	  response	  rate	  of	   more	   than	   80%	   for	   limited	   disease	   and	   up	   to	   80%	   for	   extensive	   disease,	   the	  cancer	   almost	   always	   returns	   and	   patients	   eventually	   die	   within	   two	   years.60	  Patients	   with	   early	   stage	   NSCLC	   undergo	   surgery	   and	   may	   receive	   additional	  chemotherapy	  and/or	  radiation	  therapy	  whereas	  late	  stage	  NSCLC	  patients	  are	  only	  treated	   with	   chemotherapy	   and/or	   radiation	   therapy.	   For	   therapeutic	   purposes	  NSCLC	  has	  traditionally	  been	  considered	  as	  a	  single	  disease	  separated	   from	  SCLC.	  Advances	   in	   thoracic	   medical	   oncology	   have	   challenged	   the	   relevance	   of	   these	  diagnostic	   categories	   since	  molecules	   expressed	   in	   tumors	   have	   been	   associated	  with	   enhanced	   response	   to	   certain	   cytotoxic	   agents.	   Two	   new	   agents,	   namely	  bevacizumab	   (an	   antibody	   against	   the	   vascular	   epithelia	   growth	   factor)	   and	  pemetrexed	   (an	   antifolate	   that	   inhibits	   thymidylate	   synthetase	   (TS),	   an	   enzyme	  involved	   in	   purine	   and	   pyrimidine	   synthesis)	   caused	   severe	   bleeding	   or	   had	   no	  effect	  in	  patients	  with	  SQ,	  respectively.	  Inhibition	  of	  TS	  with	  pemetrexed	  improved	  PFS	   and	   OS	   in	   AD	   and	   LCC	   but	   not	   in	   SQ	   (12.6	   vs.	   9.4	  months).61	   High	   baseline	  expression	   of	   TS	   in	   SQ	   compared	   to	   AD	   is	   thought	   to	   be	   the	   reason	   for	   the	   low	  efficacy	  of	  pemetrexed	  in	  SQ.62	  Through	  the	  identification	  of	  genetic	  alterations	  in	  EGFR	  and	  ALK	  in	  lung	  AD	  that	   confer	   susceptibility	   to	   therapeutic	   agents	   and	   KRAS	  mutations	   that	   were	  associated	  with	  resistance	  to	  these	  agents,	   it	  became	  inevitable	  to	  identify	  patient	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populations	   to	   guide	   treatment	   decisions.	   Today	   testing	   for	   EGFR	  mutations	   and	  
ALK	   rearrangements	   is	   considered	   to	   be	   the	   standard	   of	   care	   in	   advanced-­‐stage	  lung	   ADs	   to	   identify	   patients	   suitable	   for	   treatment	   with	   tyrosine	   kinase	  inhibitors.63	   Guidelines	   recommend	   testing	   for	   these	   alterations	   in	   AD	   and	  carcinomas	  admixed	  with	  an	  AD	  component,	  because	  alterations	  in	  EGFR	  and	  ALK	  segregated	   with	   this	   subtype.63,64	   Pathologists	   therefore	   identify	   ADs	   -­‐	   using	  immunohistochemistry	  if	  required.	  The	  KRAS	  mutation	  status	  is	  often	  evaluated	  to	  exclude	   patients	   from	   treatment	   with	   tyrosine	   kinase	   inhibitors	   (TKI).	   Almost	  100%	  of	  mutations	  identified	  in	  KRAS	  in	  lung	  cancer	  occur	  in	  exons	  2	  and	  3,	  thus,	  sequencing	  only	  two	  exons	  is	  sufficient	  to	  identify	  almost	  one	  third	  of	  AD	  patients	  who	   are	   not	   suitable	   for	   treatment	   with	   TKIs.	   This	   strategy	   has	   proven	   to	   be	  successful	   in	   clinical	   routine.65	  The	   importance	   of	   genetically	   stratifying	   patients	  with	   great	   care	   has	   been	   demonstrated	   in	   AD	   cases	   where	   the	   response	   rate	   to	  erlotinib	  in	  unselected	  patients	  was	  9%	  and	  median	  time	  to	  progression	  was	  three	  months.66	  By	   contrast,	   advanced	  NSCLC	   patients	  who	  were	   selected	   according	   to	  their	   EGFR	  mutation	   status	   showed	   a	   response	   rate	   of	   68%	   and	   mean	   time	   to	  progression	  was	  12	  months	  upon	   treatment	  with	  TKI67.	   Furthermore,	   it	   could	  be	  shown	  that	  first-­‐line	  treatment	  with	  TKIs	  was	  superior	  to	  standard	  chemotherapy	  in	  EGFR-­‐mutant	  AD	  cases,4	  which	  had	  been	  confirmed	  in	  independent	  randomized	  clinical	   trials.68,69	   Patients	   with	   ALK-­‐rearranged	   AD	   who	   were	   treated	   with	  crizotinib	   showed	   a	   response	   rate	   of	   57%	  with	   a	   progression	   free	   survival	   of	   at	  least	   six	   months	   in	   72%	   of	   the	   cases.70	   Similarly	   promising	   response	   rates	   to	  targeted	  therapies	  were	  recently	  reported	  in	  patients	  harboring	  genetic	  alterations	  in	  DDR2	  or	  FGFR	  mainly	   found	   in	   lung	  SQ,	  as	  well	  as	   in	  RET	  and	  ROS	  identified	   in	  lung	   AD.71-­‐73	   In	   several	   currently	   active	   clinical	   trials	   response	   to	   new	   tyrosine	  kinase	   inhibitors	   is	   tested.	   For	   example,	   BGJ398	   that	   has	   been	   developed	   to	  selectively	   target	   FGFR	   is	   tested	   in	   a	   phase	   I	   trial	   in	   patients	   with	   FGFR1-­‐	   or	  
FGFR2-­‐amplified	   and	   FGFR3-­‐mutant	   solid	   tumors.73,74	   Several	   multi-­‐kinase	  inhibitors	  that	  were	  approved	  for	  other	  molecular	  targets	  or	  other	  cancer	  types	  are	  tested	   in	   phase	   II	   studies	   such	   as	   dasatinib	   (approved	   in	   patients	   with	   CML)	   in	  
DDR2-­‐mutant	   SQ	   patients,	   sunitinib	   (approved	   for	   treatment	   of	   renal	   cell	  carcinoma)	  and	  vandetanib	  (approved	   for	   treatment	  of	  medullary	   thyroid	  cancer)	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in	  RET-­‐rearranged	  AD	   and	  NSCLC	  patients,	   respectively,	   and	   crizotinib	   (approved	  for	   ALK-­‐rearranged	   NSCLC)	   in	   ROS1-­‐rearranged	   NSCLC	   patients.74,75	   Many	   more	  drugs	   that	   show	  potential	   as	   cancer	   therapies	   in	   preclinical	  models	   are	   tested	   in	  genetically	   defined	   patient	   cohorts.	   Because	   FDA	   guidelines	   are	   adapted	   to	  accelerated	  drug	  approval	  (for	  example	  approval	  based	  on	  tumor	  shrinkage	  and	  not	  overall	   survival,	   as	   tumor	   shrinkage	   is	   assumed	   to	   reflect	   improved	   clinical	  outcome)	   an	   exponential	   increase	   of	   approved	   targeted	   therapies	   for	   genetically	  defined	  subpopulations	  in	  (lung)	  cancer	  within	  next	  few	  years	  is	  likely.	  With	  advanced	  knowledge	  with	  regard	  to	  application	  of	  chemotherapeutics	  in	  selected	  patient	  groups62	  and	  the	  success	  of	  targeted	  therapy	  over	  conventional	  chemotherapy	   in	   genetically	   selected	   populations,	   it	   became	   apparent	   that	   the	  traditional	   distinction	   between	   NSCLC	   and	   SCLC	   is	   no	   longer	   sufficient	   for	  treatment	  decisions.	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Objective	  of	  this	  study	  
	  Genetic	  mechanisms	   of	   carcinogenesis	   differ	   between	   tumor	   types	   depending	   on	  intrinsic	  and	  environmental	  cues	  causing	  the	  disease	  as	  well	  as	  on	  the	  cell	  type	  and	  site	  of	  origin.7	  Treatment	  of	  cancer	  patients	  has	  changed	  within	  the	  last	  decade	  in	  which	   targeted	   therapies	   aiming	   for	   the	   functional	   activity	   of	   certain	   altered	  proteins	   has	   proven	   to	   be	   successful	   in	   many	   tumor	   types	   including	   specific	  subtypes	   of	   lung	   cancer.76	   Thus,	   it	   became	   urgent	   to	   renew	   the	   traditional	  histomorphological-­‐based	   classification	   of	   lung	   tumors	   to	   a	   genetically	   informed	  classification	  to	  provide	  genetically	  informed	  medicine.	  	  	  The	  major	  goal	  of	  my	  thesis	  was	  to	  identify	  genomic	  alterations	  in	  lung	  cancer	  that	  I) segregate	  with	  different	  histological	  subtypes,	  	  II) predict	  clinical	  phenotype	  and	  	  III) may	  serve	  as	  new	  targets	  for	  cancer	  treatment	  with	  molecule	  inhibitors.	  	  	  Therefore	   primary	   lung	   tumors	   of	   all	   histological	   subtypes	  were	   annotated	  with	  genomic,	  histomorphological	  and	  clinical	  information	  to	  define	  a	  novel,	  biologically	  informed	   classification	   of	   lung	   tumors.	   Genomic	   alterations	   were	   detected	   on	  chromosomal	  and	  gene	  expression	  level.	  Mutations	  in	  specific	  genes	  (for	  example,	  
BRAF,	  EGFR,	  ERBB2,	  FGFR2,	  KEAP1,	  KRAS,	  NFE2L2,	  PIK3CA,	  STK11,	  and	  TP53)	  were	  analyzed	   using	   direct	   DNA	   sequencing	   in	   1,127	   cases;	   copy	   number	   alterations	  were	  analyzed	  using	  Affymetrix	  SNP	  6.0	  arrays	  in	  1,032	  cases	  and	  gene	  expression	  using	   the	   Illumina	   HumanHT-­‐12	   BeadChip	   in	   261	   cases.	   In	   order	   to	   functionally	  characterize	   newly	   identified	   mutations,	   genes	   were	   expressed	   in	   interleukin-­‐dependent	  Ba/F3	  cells	  and	  NIH3T3	  cells	   and	   the	   transforming	  capacity	   tested	  by	  interleukin-­‐independent	   or	   anchorage-­‐independent	   growth	   assays	   in	   the	   given	  cells.	   In	   collaboration	   with	   WHO	   pathologists	   573	   cases	   were	   pathological	  reviewed.	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1. Characteristics	   of	   the	   Clinical	   Lung	   Cancer	   Genome	   Project	   study	  
population	  Primary	   lung	   tumors	  were	   collected	   from	   different	   institutions	   from	  Europe	   and	  Australia	  with	  the	  aim	  to	  assemble	  an	  unbiased	  collection	  that	  authentically	  reflect	  the	  disease	  in	  a	  Caucasian	  population.	  The	  majority	  of	  tumors	  were	  resected	  before	  the	  Clinical	  Lung	  Cancer	  Genome	  Project	   (CLCGP)	  was	   initiated	   in	   2008	  when	   the	  era	  of	  personalized	   targeted	  therapy	  was	   just	  about	   to	  evolve.	  Clinical	  data	   for	  all	  cases	  collected	  for	  the	  CLCGP	  are	  summarized	  in	  Table	  1.	  	  	  Table	   1.	   Summary	   of	   clinical	   characteristics	   of	   all	   specimen	   collected	   for	   this	   study	   and	  1,255	  cases	  that	  were	  suitable	  for	  analyses	  of	  genetic	  alterations	  and	  gene	  expression.	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Clinical	   information	   were	   available	   for	   most	   of	   the	   patients	   and	   included	  personal	  characteristics	  (age,	  sex	  and	  smoking	  status),	  histology,	  tumor	  stage,	  and	  overall	  survival.	  Lung	  cancer	  is	  a	  disease	  of	  the	  elderly5	  also	  reflected	  in	  our	  sample	  set	  by	  the	  median	  age	  at	  diagnosis	  of	  65	  years.	  The	  majority	  (66%)	  of	  patients	  with	  lung	   cancer	  were	   males	   of	   whom	   93%	   had	   a	   history	   of	   smoking	   whereas	   lung	  cancer	  in	  women	  was	  associated	  with	  smoking	  in	  only	  73%	  of	  the	  cases.	  Regarding	  the	   major	   histological	   subtypes,	   adenocarcinoma	   (AD)	   was	   the	   most	   frequently	  observed	   subtype	   overall	   (45%)	   and	   in	   women	   (54%	   vs.	   37%	   in	   men).	  Squamous	  cell	   carcinoma	   (SQ)	   was	   the	   second	   most	   frequent	   subtype	   overall	  (34.2%)	   and	   the	   most	   frequent	   type	   of	   lung	   cancer	   in	   men	   (43%	   vs.	   17%	   in	  women).	   Small	  cell	   carcinoma	   (SCLC)	   incidence	   is	   approximately	   15%5	   but	   was	  underrepresented	   in	  our	  sample	  cohort	  (about	  5%).	  Treatment	  recommendations	  for	  SCLC	  did	  not	   involve	  surgery	  therefore	  most	  SCLC	  cases	  that	  were	   included	   in	  our	   sample	   set	   were	   either	  mistaken	   for	   non-­‐small	   cell	   lung	   cancer	   (NSCLC)	   at	  diagnosis	   or	   resected	   post-­‐mortem.	   Carcinoid	   (CA)	   accounted	   for	   5-­‐6%	   of	   all	  tumors.	  	  	   About	  15%	  of	  all	  cases	  in	  this	  study	  were	  advanced	  stage	  tumors	  which	  did	  not	  approximate	  the	  true	   incidence	  of	  advanced	  stage	   lung	  cancer	  of	  about	  60%.6	  According	   to	   current	   treatment	   recommendations	   lung	  cancer	  patients	  diagnosed	  in	  early	  stages	  (I	  and	  II)	  by	  the	  oncologist	  are	  considered	  candidates	  for	  surgery	  as	  a	  first	  therapeutic	  option.	  Surgery	  for	  stage	  IIIA	  patients	  with	  cancer	  metastasized	  to	  lymph	  nodes	  in	  the	  same	  lung	  or	  chest	  wall	  is	  considered	  reasonable	  as	  first	  line	  treatment	   whereas	   patients	   with	   advanced	   lung	   cancer	   (stage	   IIIB	   or	   IV)	   are	  considered	   unresectable	   and	   suitable	   for	   concurrent	   radiation	   only.	   Hence	   lung	  tumor	   of	   advanced	   stages	   should	   be	   available	   only	   in	   case	   of	   SCLC	   autopsies	   but	  these	   autopsy	   cases	   accounted	   for	   only	   20%	   of	   all	   stage	   IIIB/IV	   cases.	   The	  remaining	   80%	   of	   the	   late	   stages	   cases	  were	   not	   SCLC	   autopsy	   cases	   and	   were	  available	  due	  to	  the	  following	  reasons:	  Stages	  used	  in	  the	  analysis	  were	  assessed	  by	  the	   pathologist	   which	   can	   differ	   from	   those	   made	   by	   the	   oncologist	   who	   might	  underestimated	   the	   true	   stage	   but	   had	   given	   treatment	   recommendations	   for	  surgery,	  also	  specimen	  could	  have	  been	  resected	  for	  the	  purpose	  of	  diagnosis	  only	  without	  intention	  to	  cure	  by	  surgery.	  The	  median	  survival	  is	  associated	  with	  stage	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at	   diagnosis	   and	  was	   longest	   in	   stage	   I	   (145	  months)	   and	   lowest	   in	   stage	   IV	   (17	  months)	  patients.	  The	  median	  observation	  time	  for	  stage	  I	  patients	  was	  33	  months.	  	  This	   cohort	   represents	   the	   largest	   group	   of	   lung	   tumors	   of	   all	   histological	  subtypes	  genetically	  analyzed	  until	  now.	  	  	  	  
2. Central	  pathological	  review	  	  (in	  collaboration	  with	  Elisabeth	  Brambilla,	  CHU	  Albert	  Michallon	  and	  William	  D.	  
Travis,	  Memorial	  Sloan	  Kettering	  Cancer	  Center)	  In	   this	   study	   diagnostic	   accuracy	   and	   uniformity	   was	   of	   importance	   to	   interpret	  results	   obtained	   from	   genetic	   analyses.	   Diagnostic	   disagreement	   between	  pathologists	  can	  have	  different	  reasons	  and	  can	  vary	  widely.77	  Therefore	  two	  lung	  cancer	   pathologists	   (EB	   and	  WDT)	   reviewed	   in	   total	  615	   specimens	   in	   a	   blinded	  fashion	   to	   confirm	   original	   diagnoses	   or	   reclassify	   tumors.	   Both	   pathologists	   are	  experts	  in	  lung	  pathology	  and	  are	  editors	  and	  authors	  of	  the	  WHO	  Classification	  of	  the	   Lung.2	   For	   583	   tumors	   a	   final	   diagnosis	   was	   made;	   182	   supported	   by	  immunohistochemistry	   (Figure	   8).	   For	   the	   remaining	   cases	   lack	   of	   clear	  morphological	   characteristics	   and	   immunohistochemical	   staining	   permit	  interpretation.	  Of	  535	  cases	  original	  diagnosis	  was	  available.	  	   Eleven	   percent	   of	   originally	   diagnosed	   ADs	   were	   reclassified	   to	   other	  subtypes:	  to	  LCNEC	  (5%),	  SQ	  (2.8%),	  LCC	  (2.3%),	  SCLC	  or	  sarcomatoid	  carcinoma	  (0.5%	   each).	  Reclassification	   of	   SQs	   to	   other	   subtypes	  was	   13.7%:	   to	   AD,	   LCC	  or	  LCNEC	   (4.1%	   each),	   sarcomatoid	   carcinoma	   or	   SCLC	   (0.7%	   each).	   Eighty	   three	  percent	  of	  SCLC	  cases	  were	  confirmed	  (one	  of	  15	  cases	  admixed	  with	  LCNEC),	  11%	  were	  reclassified	   to	  LCNEC	  and	  6%	  to	  AD.	  Of	  52	  LCNECs	  83%	  were	  confirmed	  as	  such	   (admixture	  with	   other	   entities	   in	   about	   30%	  of	   these	   cases	  –	  admixed	  with	  AD	  (1),	  SQ	  (2)	  or	  SCLC	  (9))	  and	  15%	  were	  reclassified	  to	  SCLC.	  One	  LCNEC	  case	  was	  reclassified	  as	  atypical	  CA.	  Of	  48	  original	  diagnosed	  LCC	  cases	   (excluding	  LCNEC)	  91%	  were	  reclassified	  by	  morphology	  and	  immunohistochemistry	  as	  described	   in	  the	  following:	  11	  cases	  were	  reclassified	  as	  AD,	  13	  as	  SQ,	  1	  as	  mixed	  AD	  and	  SQ,	  14	  as	   neuroendocrine	   carcinomas	   (LCNEC	   (n=7),	   LCNEC	   combined	   with	   SQ	   (n=1),	  SCLC	  (n=3),	  SCLC	  combined	  with	  LCNEC	  (n=2),	  SCLC	  combined	  with	  SQ	  (n=1)),	  and	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4	   cases	   as	   sarcomatoid	   carcinoma.	   Five	   LCC	   cases	   remained	  LCC	   (TTF-­‐1	   and	  p63	  expression	  negative	  by	  immunohistochemistry).	  	  	   The	  majority	  of	  AD,	  SQ,	  SCLC	  and	  LCNEC	  were	  confirmed	  whereas	  most	  LCC	  were	  reclassified	  into	  one	  of	  the	  other	  subtypes	  based	  on	  immunohistochemistry.	  	  	  	  
	  Figure	   8	   Results	   of	   reclassification	   of	   535	   lung	   tumors	   based	   on	   morphology	   and	  immunohistochemistry.	   Frequencies	   of	   reclassification	   are	   plotted	   for	   the	   major	  histological	   subtypes	   (original	  diagnosis).	  LCNEC	   is	  presented	  separately	   from	  other	  LCC.	  (LCNEC.mixed:	  LCNEC	  combined	  with	  SCLC	  (in	  AD,	  LCC	  or	  SCLC)	  or	  combined	  with	  SQ	  (in	  AD	  and	  LCC)).	  	  	  	  
3. Estimation	  of	  specimen	  mix-­‐ups	  in	  this	  cohort	  	  Sample	   mix-­‐ups	   in	   clinical	   studies	   can	   arise	   during	   data	   management,	   sample	  collection	   and	   handling.	   This	   problem	   became	   apparent	   in	   rare	   cases,	   where	  predictions	   of	   sex	   from	   SNP	   6.0	   arrays	   did	   not	   match	   the	   original	   annotation.	  Frequency	   of	   sample	  mix-­‐up	   in	   the	   CLCGP	  was	   estimated	   by	   comparing	   average	  copy	  numbers	  from	  SNP	  6.0	  array	  data	  of	  the	  gonosomes	  X	  and	  Y.	  In	  females	  only	  background	   hybridization	   on	   the	   Y-­‐chromosome	   should	   be	  measured	  whereas	   in	  male	  signals	  of	  both	  chromosomes	  must	  be	  detected.	  Therefore	  copy	  number	  ratio	  X/Y	   must	   be	   higher	   in	   females.	   Calculating	   this	   ratio	   revealed	   a	   discrepancy	  between	  the	  prediction	  using	  SNP	  6.0	  copy	  number	  data	  and	  original	  annotation	  in	  13	  out	  of	  1,032	  cases.	  Based	  on	  this	  calculation	  the	  total	  mix-­‐up	  rate	  was	  computed	  to	  2.8%.	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4. Genetic	  alterations	  in	  lung	  tumors	  Known	  cancer	  genes	  are	  differentially	  altered	  in	  many	  cancer	  types.	  As	  for	  example	  lung	  tumors	  frequently	  harbor	  mutations	  in	  EGFR,	  alterations	  in	  this	  gene	  are	  quite	  rare	  in	  breast	  or	  skin	  cancer.78	  To	  determine	  frequencies	  of	  somatic	  mutations	  and	  chromosomal	  rearrangements	  in	  known	  cancer	  genes	  and	  chromosomal	  gains	  and	  losses	   across	   the	   genome	   for	   lung	   cancer,	   tumors	   were	   analyzed	   accordingly.	  Genome-­‐wide	  copy	  number	  alterations	  were	  analyzed	  in	  1,032	  cases.	  In	  contrast,	  to	  assess	  mutation	  frequencies	  specific	  sites	  or	  exons	  in	  genes	  known	  to	  be	  frequently	  mutated	   (hotspots)	   in	   lung	   cancer	   were	   tested.	   Thereby	   in	   1,127	   cases	   327	  different	   mutation	   sites	   in	   the	   following	   26	   genes	   were	   tested	   using	   mass	  spectrometry:	  ABL1,	  AKT2,	  ALK,	  BRAF,	  CDK4,	  DDR2,	  EGFR,	  EPHA3,	  EPHA5,	  ERBB2,	  
ERBB4,	   FGFR1,	   FGFR2,	   FGFR3,	   FGFR4,	   FLT3,	   HRAS,	   JAK2,	   KDR,	   KIT,	   KRAS,	   NRAS,	  
NTRK1,	  NTRK3,	  PDGFRA,	  and	  PIK3CA	  (Table	   3).	   Furthermore,	   specific	   exons	  were	  analyzed	  using	  Sanger	  sequencing	  in	  1,127	  cases	  (EGFR,	  KRAS,	  STK11,	  and	  TP53)	  or	  844	   cases	   (BRAF,	  ERBB2,	  FGFR2,	  KEAP1,	  NFE2L2,	  and	  PIK3CA)	   (Table	  4).	  For	   832	  lung	   tumor	   cases	   copy	   number	   and	   also	  mutation	   data	  were	   available.	  To	   assess	  frequencies	   of	   chromosomal	   rearrangements	   affecting	   ALK,	   RET	   and	   ROS1,	   FFPE	  material	  of	   lung	  tumors	  was	  collected	   in	  an	   independent	  effort	  as	  for	  the	  primary	  fresh	  frozen	  cases.	  In	  total	  602	  cases	  were	  analyzed	  for	  rearrangements	  in	  ALK,	  362	  in	   RET	   and	   211	   in	   ROS1	   using	   fluorescence	   in	   situ	   hybridization	   (FISH).	   ROS1	  rearrangements	  were	  analyzed	  mainly	  in	  AD.	  The	  overlap	  of	  these	  cases	  with	  those	  that	   were	   analyzed	   for	   copy	   number	   alterations	   and/or	   mutations	   was	   79%	   for	  
ALK,	  69%	  for	  RET	  and	  64%	  for	  ROS1.	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4.1. Somatic	  copy	  number	  alterations	  in	  lung	  tumors	  	  Of	  1,032	  tumor	  cases	  with	  SNP	  data	  the	  histological	  subtype	  was	  available	  for	  992.	  Segmented	   copy	   number	   data	   were	   visualized	   using	   the	   Integrated	   Genomics	  Viewer	  (www.broadinstitute.org)	  (Figure	  9).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Figure	   9	   Genome-­‐wide	   copy	   number	   alterations	   in	   992	   lung	   tumors.	   Cases	   are	   sorted	  according	   their	  histological	   subtype	   and	   copy	   number	   alterations	   (amplifications	   in	   red,	  deletions	  in	  blue)	  plotted	  along	  the	  human	  genome	  (chromosomes	  1	  to	  22,	  centromers	  as	  red	   lines).	   Each	   row	   represents	  one	   case.	  On	   the	   right	   estimated	   purity	   is	   given	   for	   667	  samples	  (median	  calculated	  per	  histological	  subtype	   in	  red).	  AD	  (n=421),	  CA	  (n=69),	  LCC	  (n=101),	  SCLC	  (n=63),	  SQ	  (n=338).	  	  	   Lung	   tumor	   cases	   sorted	   according	   their	   histological	   subtype	   revealed	  distinct	  patterns	  of	  somatic	  copy	  number	  alterations	  (SCNA)	  (Figure	  9),	  where	  ADs	  showed	   less	   frequently	   high	   amplitude	   alterations	   compared	   to	   SCLCs	   and	   SQs.	  Only	  few	  CA	  cases	  had	  copy	  number	  changes	  mainly	  affecting	  whole	  chromosomal	  arms	   or	   chromosomes.	   CA	   and	   SCLC,	   both	   neuroendocrine	   tumor	   types,	   showed	  high	  purity	   (median	  purity	  86%	  and	  95%,	   respectively),	  meaning	   that	   admixture	  with	  non-­‐tumor	  cells	  (such	  as	  fibroblasts	  and	  lymphocytes)	  in	  the	  extracted	  tissue	  was	  low.	  Purity	  was	  similar	  for	  AD,	  LCC	  and	  SQ	  (median	  purity	  44%,	  54%	  and	  43%,	  respectively).	   Within	   each	   subtype	   cases	   with	   low	   purity	   also	   showed	   low	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amplitude	  copy	  number	  alterations	  (mainly	  in	  the	  lower	  part	  within	  each	  subtype)	  compared	  to	  those	  that	  were	  highly	  pure	  in	  regard	  to	  tumor	  cells.	  	  	  
	  	  	  	  	  	  	  	  	  	   	   	  Figure	  10.	  Frequencies	  of	  copy	  number	  gains	  (red,	  cutoff	  3.0)	  and	  losses	  (blue,	  cutoff	  1.3)	  across	  1,032	   lung	   tumor	   cases	   calculated	   for	   adjoining	  1	  MB	   fragments	   using	   segmented	  copy	  number	  data	  are	  represented	  along	  the	  genome	  (chromosomes	  1	  to	  22	  in	  the	  middle,	  centromers	  in	  red).	  	   Examining	  copy	  number	  alterations	  across	  all	   tumor	  samples	  revealed	  that	  certain	   regions	   were	   more	   often	   amplified	   than	   deleted	   and	   vice	   versa.	   Copy	  number	  gains	  (cutoff	  3)	  and	  losses	  (cutoff	  1.3)	  were	  calculated	  using	  median	  copy	  number	  of	  adjoining	  1	  MB	  fragments	  across	  the	  genome.	  As	  illustrated	  in	  Figure	  10	  frequencies	  of	  amplifications	  and	  deletions	  differed	  between	  chromosomal	  regions	  across	  all	  tumor	  samples.	  For	  example	  1q,	  3q,	  5p,	  8q	  and	  focal	  regions	  on	  11q,	  12q	  and	  14q	  were	  frequently	  amplified	  but	  infrequently	  deleted,	  whereas	  3p,	  5q,	  8p,	  9p,	  15q,	  and	  16q	  were	  mainly	  deleted	  but	  rarely	  amplified.	  	   In	   order	   to	   identify	   significantly	   altered	   chromosomal	   regions	   across	   lung	  tumors,	  a	  rank	  sum-­‐based	  algorithm	  was	  applied	  to	  segmented	  copy	  number	  data	  of	  1,032	  cases.	  In	  contrast	  to	  other	  existing	  methods	  this	  algorithm	  is	  not	  sensitive	  to	   tumor	   purity	   (i.e.	   admixture	   with	   non-­‐cancerous	   cells)	   that	   could	   otherwise	  masks	   the	   amplitude	   of	   copy	   number	   alterations	   and	   thereby	   leading	   to	  underestimation	   of	   true	   frequencies	   across	   lung	   tumors.	   In	   brief,	   ranks	   were	  assigned	   to	   genomic	   positions	   using	   raw	   copy	   number	   for	   each	   tumor	   case	  individually.	  Upper	  and	   lower	  quantiles	  of	   these	  ranks	  defined	  between	  amplified	  and	   deleted	   regions,	   respectively	   (the	  more	   narrow	   the	   quantiles,	   the	  more	   focal	  the	  peak).	  Further,	  to	  identify	  significantly	  altered	  regions,	  ranks	  were	  summed	  up	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for	   each	   genomic	   location.	   Finally,	   multiple	   hypothesis	   testing	   was	   taken	   into	  account	  by	  using	  the	  Benjamini-­‐Hochberg	  method.	  	  Table	   2	   Significant	   copy	   number	   alterations	   identified	   in	   1,032	   lung	   tumors.	  (abbreviations:	  Amp=Amplification,	  Del=Deletion,	  Chr.=Chromosome)	  
Region_name	   Type	   Cytoband	   Chr.	   Start	   End	   Size_Mb	  
1p34	  (MYCL1)	   Amp	   1p34.2	   1	   39649410	   40611223	   0.96	  
3q26-­‐29	  (SOX2)	   Amp	   3q26.1-­‐3q29	   3	   162577624	   196416603	   33.84	  
5p15	  (PRDM9)	   Amp	   5p15.2-­‐5p15.1	   5	   9268161	   36668232	   27.40	  
7p11	  (EGFR)	   Amp	   7p11.2	   7	   54354000	   55628997	   1.27	  
8p12-­‐11	  (FGFR1)	   Amp	   8p12-­‐8p11	   8	   36630445	   39731149	   3.10	  
8q24	  (MYC)	   Amp	   8q24.21	   8	   127899488	   130018973	   2.12	  
11q13	  (CCND1)	   Amp	   11q13.2-­‐11q13.3	   11	   68617234	   69944674	   1.33	  
14q13	  (NKX2-­‐1)	   Amp	   14q13.2-­‐14q13.3	   14	   35533908	   36619261	   1.09	  
1p13	   Del	   1p13.3-­‐1p13.2	   1	   110801228	   116635628	   5.83	  
3p26	   Del	   3p26.3-­‐3p26.2	   3	   35346	   11252648	   11.22	  
4q34-­‐35	   Del	   4q34.2-­‐4q34.3	   4	   177144874	   191261905	   14.12	  
5q15-­‐21	   Del	   5q15-­‐5q21.1	   5	   94179269	   97962777	   3.78	  
6p22-­‐21	   Del	   6p22.1-­‐6p21.33	   6	   28842983	   33440115	   4.60	  
8p23-­‐21	   Del	   8p23.3-­‐8p21.3	   8	   21255	   32807956	   32.79	  
9p24-­‐22	  (PTPRD)	   Del	   9p24.3-­‐9p22.3	   9	   374058	   19436252	   19.06	  
9p21	  (CDKN2A)	   Del	   9p21.3	   9	   21578969	   22209276	   0.63	  
16q23	   Del	   16q23.2-­‐16q23.3	   16	   78712684	   87607274	   8.89	  
18q21	   Del	   18q21.31-­‐18q21.32	   18	   52682781	   55807278	   3.12	  
19p13	   Del	   19p13.3	   19	   41911	   3314202	   3.27	  
22q13	   Del	   22q13.32-­‐22q13.33	   22	   47039194	   49581322	   2.54	  	   Using	   this	   approach	   eight	   amplified	   and	   twelve	   deleted	   regions	   were	  identified	  across	   all	   lung	   tumors	   (Table	  2).	  Size	  of	   amplified	   regions	   ranged	   from	  approximately	  1	  Mb	  including	  six	  genes	  to	  almost	  34	  Mb	  engulfing	  146	  genes.	  The	  eight	  amplified	  regions	  contained	  a	  median	  of	  15	  genes.	  Deleted	  regions	  ranged	  in	  size	   from	   0.63	  Mb	   (9p21	   engulfing	   the	   tumor	   suppressor	   gene	   CDKN2A)	   to	  approximately	   32	  Mb	   (182	   genes)	  with	   a	   median	   of	   55	   genes	   in	   the	   12	   deleted	  regions.	  At	   least	  one	   functionally	  validated	  oncogene	  was	  identified	   in	  each	  of	  the	  eight	  amplified	  regions,	  for	  example	  SOX2	  in	  3p,79,80	  FGFR1	  in	  8p81,82	  and	  NKX2-­‐1	  in	  14q83	   (Table	  2).	  Except	   for	  1p	   and	  8p	   significantly	   amplified	   and	  deleted	   regions	  were	  identified	  on	  different	  chromosomal	  arms.	  	  The	   region	   9p21	   engulfing	   the	   tumor	   suppressor	   gene	   CDKN2A	  was	   the	  most	  frequently	  deleted	  region	  across	  all	   lung	  tumors	  (Figure	  11).	   In	  cases	  with	  a	  deletion	   in	  one	  of	   the	  twelve	  deleted	  regions,	  9p21	  was	  affected	   in	  approximately	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40%	  of	   the	  cases.	  The	   second	  and	   third	  most	   frequently	  deleted	   regions	   in	   cases	  harboring	  only	  one	  deletion	  were	  8p23-­‐21	  and	  22q13	  respectively	  (each	  occurred	  in	  approximately	  13%	  of	  the	  cases).	  Deletions	   in	  3p	  were	   frequent	  across	  all	   lung	  tumors	  but	  were	  rarely	  found	  as	  a	  single	  deletion	  event	  in	  tumors	  (<	  4%).	  The	  most	  frequently	  affected	  region	   in	  cases	  that	  had	  multiple	  deletions	  was	  3p	  (in	  15.5%),	  followed	  by	  9p21	  (14%)	  and	  8p23-­‐21	  (12%).	  	  	  
	  Figure	  11	  Incidence	  of	  deletions	   in	   lung	  tumors	  within	  twelve	  significant	  deleted	  regions.	  Median	   copy	   number	  was	   calculated	   for	   significantly	   deleted	   regions	   (Table	  2)	  per	   case.	  Copy	   number	   1.3	  was	  used	   as	   the	   cutoff	   to	  determine	   tumor	   cases	  with	   deletion	   in	   the	  particular	   region.	   Cases	  were	   counted	   according	   occurrence	   of	   deletions	   in	   one	   or	  more	  regions.	  Width	  of	  the	  bars	  illustrates	  length	  of	  the	  regions	  on	  the	  chromosome.	  	  	   Overall,	  chromosomal	  losses	  through	  deletion	  were	  more	  frequent	  than	  gains	  through	  amplification	  in	  lung	  tumors.	  Regions	  that	  were	  frequently	  amplified	  were	  rarely	  deleted	  and	  vice	  versa.	  Whereas	  in	  all	  significantly	  amplified	  regions	  at	  least	  one	   oncogene	   was	   identified,	   known	   cancer	   genes	   were	   not	   found	   in	   any	   of	   the	  deleted	  regions.	  	  	  
4.2. The	  mutation	  spectrum	  in	  lung	  tumors	  	  Across	   all	   lung	   tumors	   KRAS	   was	   the	   most	   frequently	   mutated	   gene	   (16.2%),	  followed	  by	  EGFR	  (7.2%),	  KEAP1	  (6.7%),	  PIK3CA	  (5.2%),	  NFE2L2	  (4.5%),	  and	  BRAF	  (2%)	  (Figure	  12).	  Of	  note,	  due	  to	  recent	  findings	  that	  suggest	  KEAP1	  (the	  negative	  regulator	   of	   NFE2L2)	   to	   be	   a	   tumor	   suppressor84	   it	   will	   be	   mentioned	   as	   such	  throughout	  this	  dissertation.	  ROS1	  rearrangements	  were	  detected	  in	  3	  ADs	  (overall	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frequency	  1.4%).	  Two	  of	  the	  three	  cases	  with	  a	  ROS1	  fusion	  were	  male,	  both	  with	  a	  history	  of	  smoking	  and	  median	  age	  at	  diagnosis	  was	  68	  years	  (see	  Appendix,	  Table	  7).	  Ten	  cases	  with	  an	  ALK	  fusion	  were	  identified.	  In	  six	  out	  of	  eight	  cases	  that	  were	  available	   for	   further	  FISH	  analysis	  EML4	  was	  determined	  as	   the	   fusion	  partner	  of	  
ALK.	  The	  median	  age	  at	  diagnosis	   in	  ALK	  positive	  ADs	  was	  56	  vs.	  64	  years	   in	   the	  total	   patient	   cohort	   (see	   Appendix,	   Table	   7).	   In	   this	   cohort	   no	   case	   with	   a	   RET	  fusion	  was	  identified	  (0/	  362).	  TP53,	  which	  is	  the	  most	  frequently	  mutated	  TSG	  in	  cancer86,	   was	   mutated	   in	   53.6%	   of	   all	   lung	   tumors.	   STK11,	   the	   second	   most	  frequently	  mutated	  TSG	  in	  lung	  cancer,87	  was	  mutated	  in	  9.9%	  of	  all	  cases.	  In	  Figure	  12	  mutations	   in	   STK11	  and	  TP53	  are	   displayed	   only	   for	   cases	   harboring	   another	  mutation	  in	  any	  given	  oncogene	  or	  KEAP1.	  	  
	  Figure	   12	   Genetic	   alterations	   in	   oncogenes	   and	   tumor	   suppressors	   per	   case	   and	  frequencies	   in	  %	  across	   all	   lung	   tumors	   are	   presented.	   Green	   bars	   indicate	   co-­‐occurring	  alterations.	   Thin	   lines	   represent	   cases	   that	   were	   not	   tested	   in	   the	   given	   gene.	  Rearrangements	  are	  marked	  with	  an	  asterisk.	  	  	  	   In	  Figure	  13	  the	  distribution	  of	  mutations	  per	  protein	  is	  presented	  whereby	  for	   deletions	   and	   insertions	   only	   the	   first	   amino	   acid	   was	   included	   in	   the	  calculation.	   In	   EGFR	   and	   ERBB2	   the	   most	   common	   alterations	   occurred	   in	   the	  intracellular	   kinase	   domain:	   in	   EGFR	   in-­‐frame	   deletions	   within	   the	   ELREA	  motif	  (amino	  acid	  positions	  746	  to	  750)	  in	  exon	  19	  (>	  40%)	  and	  L858R	  in	  exon	  21	  (28%)	  and	   in	  ERBB2	  exon	  20	   insertions.	  BRAF	  mutations	  were	   found	   at	   five	   amino	  acid	  positions	  in	  exon	  11	  and	  15:	  464,	  466,	  469	  in	  exon	  11	  (62%	  of	  all	  BRAF	  mutations),	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600	  and	  601	  in	  exon	  15.	  In	  PIK3CA	  70%	  of	  the	  mutations	  occurred	  in	  codons	  542	  and	  545	   in	   the	  helical	  domain	  both	  resulting	   in	  amino	  acid	  change	   from	  glutamic	  acid	  to	  lysine.	  In	  all	  RAS	  genes	  the	  majority	  of	  mutations	  occurred	  at	  codon	  12.	  In	  
FGFR2	  mutations	   were	   found	   in	   the	   region	   coding	   for	   the	   extracellular	   ligand	  binding	   and	   the	   intracellular	   kinase	   domain.	   In	  FGFR3	  only	   few	  known	  mutation	  sites	  were	   analyzed	   and	  mutations	   found	   in	   the	   extracellular	   domain.	   In	  NFE2L2	  two	   hotspot	   regions	   within	   exon	   2	   were	   identified;	   63%	   of	   the	   mutations	   were	  found	   in	   amino	   acid	   20	   to	   34	   and	   others	   in	   73	   to	   97.	  Mutations	   in	   TSGs	  KEAP1,	  
STK11	  and	  TP53	  were	  distributed	  across	   the	  whole	  gene	  with	  no	  specific	  hotspot	  regions.	  	  	  	  
	  Figure	  13	  Mutation	  distribution	  within	  proteins.	  Protein	  schemata	  are	  given	  with	  domains	  (lower	   part),	   regions	   that	   were	   analyzed	   (middle	   part,	   grey	   shades	   indicate	   sequencing	  coverage)	  and	  distribution	  of	  mutations	  detected	  within	  genes	  (upper	  part).	  	  	   Most	   oncogene	   mutations	   or	   rearrangements	   were	   exclusive	   to	   other	  alterations,	   consistent	  with	   the	  notion	   that	   they	  are	  driver	  alterations	  (Figure	  12;	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green	   lines	   indicate	   cases	  with	   alterations	   in	  multiple	   genes,	   Table	  8).	  Of	   the	   five	  most	  frequent	  mutated	  oncogenes	  (KRAS,	  EGFR,	  PIK3CA,	  NFE2L2,	  and	  BRAF)	  EGFR,	  
KRAS	  and	  NFE2L2	  had	  a	  co-­‐occurrence	  rate	  with	  mutations	  in	  other	  oncogenes	  or	  
KEAP1	  of	  less	  than	  10%	  (8.6%,	  6.6%	  and	  7.9%,	  respectively).	  In	  five	  BRAF	  mutant	  cases	   also	  KRAS	  or	  NRAS	  was	   altered.	  Of	   cases	  mutated	   in	  PIK3CA,	  36%	   (20/56)	  also	   had	   a	   mutation	   in	   EGFR,	   ERBB2,	   DDR2,	   HRAS,	   KRAS,	   NRAS	   or	   FGFR.	   This	  promiscuity	  of	  PIK3CA	  mutations	  has	  been	  observed	  before;88	  thus,	  mutant	  PIK3CA	  may	  be	  necessary	  but	  insufficient	  to	  drive	  oncogenic	  transformation	  in	  these	  cases.	  In	   genes	   that	   were	   found	   mutated	   in	   less	   than	   ten	   cases	   across	   all	   samples	   the	  co-­‐occurrence	  rate	  with	  mutations	   in	  other	  oncogenes	  was	  at	   least	  35%	  (three	  of	  eight	  FGFR2,	   four	   of	   six	  DDR2,	   two	   of	   five	  NRAS,	   two	   of	   three	  FGFR3,	  one	   of	   two	  
CDK4	  and	  HRAS	  mutated	  cases	  harbored	  at	  least	  one	  additional	  mutation	  in	  another	  oncogene)	  with	   the	   exception	   of	   the	   three	   cases	  with	  ROS1	   rearrangements	   -­‐	  no	  further	   alteration	   in	   the	   analyzed	   oncogenes	  was	   identified	   in	   those	   cases.	   One	  
KRAS	  mutant	  case	  harbored	  a	  somatic	  EGFR	  mutation	  that	  has	  not	  been	  previously	  described	   (substitution	   of	   lysine	   to	   arginine	   at	   position	   714,	   K714N).	   K714N	  mutant	   NIH3T3	   cells	   did	   not	   form	   colonies	   in	   soft	   agar	   neither	   did	   K714N	  expressing	  Ba/F3	  cells	  proliferate	  independent	  of	  IL-­‐3	  (data	  not	  shown).	  A	  second	  case	   harboring	   the	   same	   EGFR	  K714N	  mutation	   also	   had	  mutations	   at	   positions	  E709	  and	  G719	  on	  the	  same	  allele.89	  It	  is	  therefore	  most	  likely	  that	  the	  true	  driver	  in	  these	  tumors	  is	  mutant	  KRAS	  or	  the	  compound	  E709	  and	  G719	  EGFR	  mutation,	  but	  not	  K714N.	  	  	  
5. Genetic	  alterations	  in	  histological	  subtypes	  of	  lung	  cancer	  Several	   cancer	   genes	   are	   frequently	   altered	   in	   specific	   subtypes	   of	   lung	   cancer,	  suggesting	  their	  important	  role	  in	  developing	  the	  specific	  malignant	  phenotype.	  In	  order	   to	   identify	   subtype-­‐specific	   genome	   alterations,	   oncogenes	   and	  TSGs	  were	  depicted	  if	  they	  were	  known	  to	  play	  an	  important	  role	  in	  tumorigenesis	  and	  were	  either	  mutated	  or	  exhibited	  significant	  chromosomal	  gains	  or	  losses	  in	  our	  data	  set	  (see	   below).	   Mutated	   genes	   were	   included	   in	   the	   analysis	   if	   at	   least	   three	   cases	  harboring	  an	  alteration	  were	  identified.	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   To	   identify	   frequently	   amplified	   or	   deleted	   regions	   per	   subtype	   the	   same	  rank	  sum-­‐based	  algorithm	  was	  used	  as	  for	  all	  lung	  tumors	  and	  applied	  to	  samples	  of	   the	   same	  histological	   subtype	   (421	  ADs,	   69	  CAs,	   101	  LCCs,	   63	   SCLCs,	   and	  338	  SQs)	   (Figure	   14).	   Significant	   copy	   number	   alterations	   across	   all	   lung	   tumors	  summarized	   in	   Table	   2	   could	   be	   assigned	   to	   histological	   subtypes	   and	   specific	  genes	  relevant	  in	  cancer	  were	  identified	  within	  these	  regions.	  Amplifications	  in	  17q	  (ERBB2)	  did	  not	  reach	  significance	  across	  all	  tumors	  but	  in	  the	  AD	  subtype.	  	  	  
	  Figure	  14	  Significantly	  amplified	  (red)	  and	  deleted	  (blue)	  regions	  plotted	  along	  the	  genome	  (y-­‐axis)	   for	   the	   five	   major	   lung	   cancer	   subclasses.	   Statistical	   significance,	   expressed	   by	  
q-­‐values	   (x-­‐axes:	   amplification,	   upper	   scale;	   deletion,	   lower	   scale;	   vertical	   dashed	   lines	  indicate	   q=0.01),	   is	   computed	   for	   each	   genomic	   location.	   Known	   or	   potential	   oncogenes	  (red)	  and	  tumor	  suppressor	  genes	  (blue)	  are	  given	  at	  respective	  locations.	  	   Significantly	  amplified	   chromosomal	   regions	   in	  AD	  affected	  5p,	   7p	   (EGFR),	  8q	  (MYC),	  11q	  (CCND1),	  12p	  (KRAS),	  12q	  (MDM2),	  14q	  (NKX2-­‐1),	  and	  17q	  (ERBB2);	  in	   SCLC	  1p	   (MYCL1),	   2p	  (MYCN),	   5p,	   8p	  (FGFR1),	  and	  19q	   (CCNE1);	   and	   in	   SQ	  1p	  (MYCL1),	   3q	   (SOX2),	   7p	  (EGFR),	   8p	   (FGFR1),	   11q	   (CCND1),	   12p	   (KRAS),	   and	   12q	  (possibly	   FRS2)83,90-­‐93	   (Figure	   14).	   Several	   amplified	   regions	   were	   specific	   for	  certain	   lung	  cancer	  subtypes,	   for	  example	  14q	  and	  17q	   in	  AD	  or	  3q	   in	  SQ.	  Others	  were	  found	  to	  be	  significantly	  amplified	  in	  various	  subtypes,	  such	  as	  amplifications	  in	  8p	  (FGFR1)	  in	  SCLC	  and	  SQ	  or	  amplifications	  in	  7p	  (EGFR)	  and	  12p	  (KRAS)	  in	  AD	  and	   SQ.	   Deletions	   in	   AD	   and	   SQ	   affected	   6p,	   8p,	   9p24	   (PTPRD),	   9p21	   (CDKN2A),	  18q,	   and	   19p,	   in	   AD	   also	   15q	   and	   22q,	   in	   SQ	   also	   4q.	   In	   SCLC	   deletions	   were	  significant	  in	  3p	  (FHIT)	  and	  13q	  (RB1).	  FHIT	  (fragile	  histidine	  triad)	  is	  discussed	  as	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a	  potential	  TSG	  whose	  inactivation	  in	  lung	  cancer	  occurs	  after	  initiation	  of	  cancer.94	  Due	   to	   its	   location	   within	   the	   most	   common	   fragile	   site	   of	   the	   human	   genome	  (where	   gaps	   and	   breaks	   affect	   several	   genes	   when	   cells	   are	   under	   replication	  stress)	   and	   the	   lack	   of	   mutations	   in	   this	   gene	   the	   relevance	   of	   FHIT	   as	   a	   TSG	  remains	   unclear.94	   In	   most	   significant	   deleted	   regions	   no	   common	   TSG	   could	   be	  determined.	  	  	   LCCs	   did	   not	   exhibit	   a	   specific	   pattern	   of	   copy	   number	   alterations	   but	  showed	  amplifications	  and	  deletions	  in	  regions	  specific	  of	  other	  subtypes,	  such	  as	  amplification	  of	  NKX2-­‐1	  (specific	  of	  AD)	  or	  MYCL1,	  SOX2	  or	  FGFR1	  (typical	  of	  SCLC	  or	  SQ)	  and	  also	  amplifications	  in	  19q	  and	  deletions	  in	  3p	  as	  in	  SCLC	  (Figure	  14).	  In	  69	  CA	  no	  significant	  SCNAs	  were	  found.	  	  	   In	  order	  to	  describe	  subtype-­‐specific	  patterns	  of	  alterations	   in	  more	  detail,	  mutated	   genes	   and	   genes	   identified	   within	   significantly	   amplified	   or	   deleted	  regions	   were	   analyzed.	  The	   final	   selection	   of	   genes	   that	   were	   frequently	   altered	  included	   20	   oncogenes	   (amplifications	   of	   CCDN1,	   CCNE1,	   ERBB2,	   EGFR,	   FGFR1,	  
KRAS,	   three	   MYC	   genes,	   NKX2-­‐1,	   SOX2;	   mutations	   in	   BRAF,	   DDR2,	   ERBB2,	   EGFR,	  
FGFR2,	   FGFR3,	   KRAS,	   NFE2L2,	   NRAS,	   PIK3CA;	   rearrangements	   affecting	   ALK	   or	  
ROS1)	  and	  five	  tumor	  suppressor	  genes	  (deletions	  in	  CDKN2A	  or	  RB1;	  mutations	  in	  
KEAP1,	  STK11	  and	  TP53)	  (Figure	  15).	  	  Cases	   with	   focal	   amplification	   or	   deletion	   of	   the	   above	   mentioned	   genes	  (Figure	  14)	  were	  identified	  by	  assigning	  a	  rank	  to	  each	  case	  according	  to	  the	  copy	  number	  amplitude	  and	  segment	   length	  for	  amplification	  with	  specific	  adaptations	  for	  cases	  with	  low	  purity.	  Therefore	  only	  copy	  numbers	  of	  the	  segments	  spanning	  the	  gene	  of	  interest	  were	  considered	  for	  each	  sample.	  If	  the	  target	  region	  had	  more	  than	  one	  segment	  the	  maximum	  copy	  number	  was	  chosen.	  The	  standard	  deviation	  was	   calculated	   for	   each	   gene	   across	   all	   samples	   to	   determine	   thresholds	   for	  amplifications	  and	  deletions;	  above	  the	  threshold	  cases	  were	  considered	  amplified,	  below	  the	   threshold	   they	  were	  considered	  deleted,	  respectively	  (Figure	  29).	  Focal	  amplifications	   in	   the	   tumor	   genome	   frequently	   involve	   oncogenes	   that	   might	   be	  important	  driver	  alterations	   is	   these	   cases.	  To	   identify	   focal	   amplifications	   in	   this	  data	   set,	   cases	  were	   ranked	   according	   the	   length	   of	   the	   segment(s)	   spanning	   the	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gene	   of	   interest	   and	  were	   modeled	   by	   an	   exponential	   function	   against	   the	   copy	  number.	  From	  this	  exponential	  function	  the	  critical	  length	  of	  focal	  amplified	  regions	  was	  derived	  for	  each	  genes.	  To	  recover	  cases	  with	  focal	  amplifications	  that	  did	  not	  reach	  the	  threshold	  due	  to	  low	  copy	  number	  (for	  example,	  due	  to	  high	  admixture	  of	  non-­‐cancerous	   cells;	   see	   in	   Figure	   29	   in	   the	   lower	   left	   part	   of	   the	   EGFR	   plot),	  genome-­‐wide	   standard	   deviation	   was	   calculated	   for	   each	   case	   to	   determine	   the	  threshold	  above	  which	  the	  case	  was	  considered	  amplified.95	  	   Histological	   subtypes	   display	   distinct	   patterns	   of	   genetic	   alterations,	   i.e.,	  alterations	   occurred	   at	   different	   frequencies	   or	   were	   exclusive	   for	   a	   certain	  subtype.	  For	  example,	  in	  AD	  mutations	  in	  KRAS	  (32.3%),	  STK11	  (17.4%)	  and	  EGFR	  (15.4%)	  as	  well	  as	  amplifications	  of	  NKX2-­‐1	  (10.5%)	  were	  more	  frequent	  than	  in	  SQ	  (2.5%,	   1.9%,	   0.5%,	   and	   4.7%,	   respectively)	   and	   SCLC	   (two	   out	   of	   60	   SCLC	   cases	  harbored	   a	   STK11	  mutation	   but	   non	   harbored	   mutations	   in	   EGFR	   and	   KRAS	   or	  amplifications	   of	   NKX2-­‐1	  were	   identified)	   (Fishers	   exact	   test	   per	   gene	   for	   each	  subtype	   combination,	   p	  <	  0.05).	   Amplifications	   of	   FGFR1	   and	   mutations	   in	   TP53	  were	   less	   frequent	   in	  AD	  (4%	  and	  45%)	  than	  in	  SCLC	  (12.7%	  and	  70.5%)	  and	  SQ	  (19.5%	  and	  69%).	   In	  SQ	  mutations	   in	  NFE2L2	  (10.6%)	  as	  well	  as	  amplification	  of	  
CCND1	  (10.4%)	  and	  SOX2	  (23.4%)	  were	  more	  frequent	  than	  in	  AD	  (1.1%,	  4.5%	  and	  1.2%,	  respectively)	  and	  amplifications	  of	  SOX2	  more	  frequent	  than	  in	  SCLC	  (4.8%).	  In	  SCLC	  amplification	  of	  MYCN	  (6.3%)	  and	  MYCL1	  (6.3%)	  and	  loss	  of	  RB1	  (63.5%)	  occurred	  more	  often	  than	  in	  AD	  (0.7%,	  0.7%	  and	  12.1%)	  and	  SQ	  (0.6%,	  1.8%	  and	  10%).	  MYC	  was	  more	  often	  amplified	  in	  AD	  (5.5%)	  than	  in	  SCLC	  and	  SQ	  (about	  3%	  in	   each).	  Mutations	   in	  ERBB2	  occurred	  more	   often	   in	   AD	   than	   in	   SQ,	   but	   did	   not	  reach	   statistical	   significance.	   In	   CA	   no	   distinctive	   genetic	   alterations	   were	  identified.	   No	   significant	   difference	   between	   AD,	   SCLC	   and	   SQ	   was	   found	   for	  mutations	  in	  ERBB2,	  FGFR2/3,	  PIK3CA,	  KEAP1,	  and	  amplifications	  of	  CCNE1,	  ERBB2,	  
KRAS,	  MDM2,	  and	  MYC	  (Fishers	  exact	  test,	  p	  >	  0.05).	  Mutations	  in	  DDR2	  and	  FGFR3	  were	  found	  primarily	  or	  exclusively	  in	  SQ,	  respectively.	  	  	  
Results	  	  
53	  
	  	  	  	  	  	  	  	  	   	  Figure	  15	  Frequencies	  of	  genetic	  alterations	  per	  histological	  subtype	  and	  across	  all	  tumors.	  Colored	  bars	   indicate	  genes	   typically	  altered	   in	   the	  respective	   lung	  cancer	   subtype	   (gene	  labels:	   mutated	   in	   black,	   amplified	   in	   red,	   deleted	   in	   blue,	   rearranged	   marked	   with	   an	  asterisk).	  	   In	   AD	  mutations	   in	  EGFR,	  KRAS,	  STK11,	  and	  TP53	  were	   the	  most	   frequent	  alterations	   and	   in	   SQ	  mutations	   in	  NFE2L2	  and	  TP53	  as	  well	   as	   amplifications	   of	  
FGFR1	   and	   SOX2	   (Figure	   15).	   Also	   rare	   SQ	   cases	   were	   identified	   harboring	  mutations	   typical	   for	   AD	   whereas	   the	   spectrum	   differed	   from	   those	   seen	   in	   AD.	  




































































































































































G12D	  (16%).	  Two	  SQ	  cases	  were	  identified	  that	  harbored	  a	  mutation	  in	  EGFR,	  one	  with	   an	   exon	   19	   deletion	   and	   a	   second	   with	   an	   exon	   18	   mutation	   at	   AA	   694	  (substitution	   from	   proline	   to	   histidine)	   that	   has	   not	   been	   described	   before.	   ALK	  rearrangements	  were	  found	  in	  AD	  except	  for	  one	  case	  that	  was	  SQ,	  in	  which	  EML4	  was	  not	  the	  fusion	  partner97.	  Three	  AD	  cases	  had	  ROS1	  rearranged.	  In	  one	  case	  the	  split	  between	  the	  two	  signals	  of	  the	  FISH	  probe	  was	  very	  narrow,	  thus,	  according	  to	  the	   interpretation	   guidelines	   this	   case	   would	   be	   negative	   for	   ROS1	   fusion	   but	  dependent	  on	  the	  fusion	  partner,	  this	  case	  could	  be	  positive.	  The	  fusion	  in	  this	  case	  was	   interpreted	   as	   positive	   but	   not	   further	   investigated.	   In	   SCLC	   the	   most	  frequently	   altered	  genes	  were	  TP53	  (70.5%)	  and	  RB1	  (63.5%).	  Only	   in	   rare	  SCLC	  cases	  KEAP1,	  PIK3CA	  or	  STK11	  was	  mutated.	  No	  mutations	  in	  the	  typical	  “AD	  and	  SQ	  oncogenes”	   such	   as	   BRAF,	   EGFR,	  KRAS	   or	   NFE2L2	   were	   found	   in	   SCLC.	   In	   LCCs	  mutations	   were	   found	   in	   most	   genes	   but	   no	   particular	   distinguishable	   pattern	  could	  be	  identified	  for	  this	  subtype	  in	  respect	  to	  AD,	  SQ	  or	  SCLC.	  TP53	  was	  the	  most	  frequently	   mutated	   gene	   in	   LCC	   (60.5%).	   In	   CA	   no	   mutation	   was	   found	   in	   the	  analyzed	  genes	  but	  rare	  cases	  had	  amplifications	  of	  EGFR	  or	  NKX2-­‐1	  or	  deletions	  of	  
RB1	  or	  CDKN2A.	  	   Overall,	   while	   AD,	   SCLC	   and	   SQ	   exhibit	   distinct	   genetic	   pattern	   with	   rare	  cases	   exhibiting	   non-­‐typical	   alterations	   of	   other	   subtypes,	   LCC	   cases	   show	   no	  unique	  pattern	  of	  genetic	  alterations.	  In	  CA	  only	  rare	  cases	  had	  genetic	  alterations	  that	  did	  not	  segregate	  specifically	  with	  this	  subtype.	  	  	  	  
6. Mutually	  exclusivity	  and	  co-­‐occurrence	  of	  genetic	  alterations	  Mutations	   that	  occur	   in	  different	  genes	  or	  signaling	  pathways	  may	   influence	  each	  other’s	   phenotypes.	   For	   example,	   mutations	   in	   EGFR	   predispose	   to	   therapeutic	  sensitivity	   to	   EGFR	   kinase	   inhibitors,	   whereas	   an	   additional	   mutation	   affecting	  
PTEN	   in	   the	   same	   signaling	   pathway	   may	   lead	   to	   resistance.98	   To	   understand	  relevant	   cancer	   mutations	   that	   suggest	   functional	   interaction	   and	   may	   predict	  clinical	   outcome,	   it	   is	   important	   to	  annotate	   co-­‐occurring	  genetic	   alterations	   in	   a	  given	   tumor.	  Associations	  between	  mutations	   and	   copy	   number	   alterations	  were	  thus	   calculated	   using	   the	   Fisher’s	   exact	   test	   and	   Benjamini	   Hochberg	  method	   in	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1,032	  tumors,	  as	  well	  as	  for	  each	  subtype	  separately	  (421	  ADs,	  62	  LCCs,	  39	  LCNECs,	  63	  SCLCs,	  and	  338	  SQs)	  in	  order	  to	  identify	  associations	  of	  genomic	  alterations.	  	  	  	  
	  	  	  	  	  	   	   	  	  Figure	  16	  Associations	  of	  gene	  copy	  number	  alterations	  and	  mutations	  in	  lung	  tumors	  with	  the	   use	   of	   Circos	   plots.	   A.	   Associations	   of	   genetic	   alterations	   in	   all	   tumor	   cases	   are	  presented.	  B.	  Associations	  of	  genetic	  alterations	  found	  in	  380	  ADs	  are	  shown.	  (Circos	  plots	  (ring:	   chromosomes	   1	   to	   22;	   outer	   ring:	   genes	   involved	   (chromosomal	   gains	   in	   red,	  deletions	  in	  blue,	  mutations	  in	  black);	  lines	  within	  the	  circle:	  significant	  co-­‐occurring	  (red)	  and	  exclusive	  (blue)	  events	  (Bonferroni	  adjusted	  Fisher’s	  exact	  test,	  p	  <	  0.05)	  between	  two	  gene	   copy	   number	   alterations	   or	   two	   frequently	  mutated	   genes	   (solid	   lines)	   or	   between	  gene	  copy	  number	  alteration	  and	  mutation	  (dashed	  lines))	  	   In	   Figure	   16	   significant	   co-­‐occurring	   genetic	   events	   are	   given	   that	   were	  identified	  in	  all	  lung	  tumors	  (left)	  and	  AD	  (right).	  Associations	  of	  genetic	  alterations	  were	   not	   significant	   in	   other	   histological	   subtypes.	   In	   lung	   tumors	   STK11	  co-­‐occurred	  with	  mutations	   in	  BRAF,	  KEAP1	  or	  KRAS	  and	  excluded	  the	  occurrence	  of	  mutations	  in	  EGFR	  (Figure	  16.A).	  Mutations	  in	  KRAS	  were	  mutually	  exclusive	  to	  mutations	   in	   EGFR,	   NFE2L2,	   TP53,	   and	   to	   amplifications	   of	   FGFR1	   and	   SOX2.	  Mutations	   in	  EGFR	  were	   exclusive	   to	  mutations	   in	  TP53.	  Mutations	   in	  TP53	  were	  only	  associated	  with	  amplifications	  of	  FGFR1.	  EGFR	  amplifications	  were	  associated	  with	  amplifications	  of	  NKX2-­‐1	  and	  CDKN2A	  as	  well	  as	  with	  mutations	  in	  EGFR.	  The	  latter	   excluded	   occurrence	   of	   amplification	   of	   FGFR1.	   Amplification	   of	   SOX2	  co-­‐occurred	  with	  mutated	  NFE2L2	  and	  amplification	  of	  CCND1.	  	  
A	   B	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In	  subtype	  specific	  analyses	  significant	  associations	  were	   identified	  only	   in	  AD	   (Figure	   16.B).	   Associations	   involving	   EGFR	   (mutation	   or	   amplification)	   that	  were	  identified	  in	  the	  analysis	  including	  all	  lung	  tumors	  were	  also	  found	  significant	  in	   AD	   except	   exclusivity	   of	   EGFR	  mutations	   with	   FGFR1	   amplifications.	   Further	  
NKX2-­‐1	   amplifications	   were	   associated	   with	   EGFR	   amplification	   but	   not	   EGFR	  mutations.	  KRAS	  mutations	  were	  found	  to	  be	  associated	  with	  STK11	  mutations	  and	  excluded	  the	  occurrence	  of	  EGFR	  mutations.	  FGFR1	  amplifications	  co-­‐occurred	  with	  
TP53	  mutations	  and	  STK11	  mutations	  with	  KEAP1	  mutations.	  	  	   Several	   co-­‐occurring	   events	   did	   not	   reach	   significance	   after	   correction	   for	  multiple	  hypothesis	  testing,	  such	  as	  PIK3CA	  mutations	  that	  were	  frequently	   found	  in	  lung	  tumors	  of	  all	  histological	  subtypes	  harboring	  another	  oncogenic	  alteration,	  for	  example	  in	  tumors	  that	  harbored	  mutations	  in	  FGFR2	  (25%	  of	  all	  FGFR2	  mutant	  cases	  had	  a	  coexisting	  mutation	  in	  PIK3CA),	  ERBB2	  (20%),	  EGFR	  (7%),	  KRAS	  (3%)	  and	   amplifications	   of	   FGFR1	   (8%)	   and	   SOX2	   (7%).	   In	   42%	   of	   SCLC	   cases	   TP53	  mutation	  occurred	   together	  with	  RB1	  deletion,	  whereas	   in	  NSCLC	  only	  6%	  of	   the	  cases	  harbored	  alterations	  in	  both	  genes.	  	  	   Overall	  several	  cases	  were	   identified	  that	  had	  alterations	   in	  more	  than	  one	  oncogene	  or	  TSG	  affecting	  the	  same	  or	  different	  cellular	  pathways.	  	  	  
7. Large	   cell	   carcinomas	  of	   the	   lung	   share	   immunohistochemical,	  genetic	  
and	  gene	  expression	  characteristics	  with	  other	  histological	  subtypes	  LCC	   is	  a	  diagnostically	   controversial	   subtype.	   It	  has	  been	   the	   focus	  of	  discussions	  for	   many	   years	  whether	   these	   tumors	   reflect	   an	   own	   entity	   or	   if	   they	   might	   be	  poorly	   or	   un-­‐differentiated	   stages	   of	   tumors	   of	   other	   subtypes.99	  Immunohistochemical	  analysis	  is	  now	  recommended	  to	  determine	  subtypes	  of	  lung	  tumors	   but	   application	   of	   this	   approach	   for	   LCC	   that	   lack	   any	   features	   of	  differentiation	   is	   still	   not	   standardized	  due	   to	   limited	  analyses.	  To	   investigate	   the	  heterogeneity	   of	   LCC,	   detailed	   genetic	   and	   immunohistochemical	   analyses	   were	  performed	  in	  169	  cases	  of	  which	  64	  were	  LCC	  with	  neuroendocrine	  differentiation	  (LCNEC).	  Mutation	  data	  were	  available	  for	  119,	  genome-­‐wide	  copy	  number	  data	  for	  101	  and	  gene	  expression	  data	   for	  31	  LCC	  cases.	  Gene	  expression	  was	  assessed	  by	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gene	  expression	  array	  and	  immunohistochemistry.	  In	  order	  to	  identify	  tumor	  types,	  immunohistochemical	   profiles	   were	   assessed	   using	   AD-­‐specific	   markers	   (TTF-­‐1	  and	  CK7),	   SQ-­‐specific	  markers	   (p63	  and	  CK5/6)	  and	  markers	   for	  neuroendocrine	  differentiation	  (CD56,	  Synaptophysin	  and	  Chromogranin	  A).	  	  As	  shown	  above	  tumors	  of	  histological	  subtypes	  AD,	  SCLC	  and	  SQ	  displayed	  distinct	  patterns	  of	  genetic	  alterations	  (Figure	  15).	  In	  contrast,	  for	  LCC	  no	  specific	  pattern	   could	   be	   identified	   but	   alterations	   occurred	   in	   genes	   typically	   altered	   in	  other	   subtypes.	   LCC	   harbored	   for	   example	   alterations	   in	   EGFR,	   KRAS,	   STK11	   as	  typically	   found	   in	  AD,	  and	  had	  amplifications	  of	  FGFR1	  and	  SOX2	  as	  typical	   for	  SQ	  (see	   Results:	   Genetic	   alterations	   in	   histological	   subtypes	   of	   lung	   cancer).	  Immunohistochemical	   analysis	   revealed	   similar	   results.	  One	   hundred	   and	   twelve	  LCC	   cases	   were	   pathologically	   reviewed	   (58	   LCC	   without	   neuroendocrine	  differentiation	  and	  54	  LCNEC)	  and	   immunohistochemical	  stainings	  performed	   for	  60	  cases	  (45	  LCCs	  and	  15	  LCNECs).	  For	  some	  cases	   immunohistochemical	  results	  were	   available	   only	   for	   diagnostically	   relevant	   marker	   (Figure	   17).	   Final	  pathological	  diagnosis	  was	  available	  for	  100	  LCC	  cases	  (48	  LCC	  and	  52	  LCNEC).	  The	  diagnosis	  LCNEC	  was	  confirmed	   in	  43	  of	  52	  cases	   (83%),	  of	  which	  12	  were	  admixed	  with	  AD,	  SQ	  or	  in	  the	  majority	  of	  cases	  with	  SCLC	  components.	  Eight	  cases	   (15%)	  were	   reclassified	  as	  SCLC	   and	  one	   case	   as	   CA.	  On	   the	   contrary	  23%	  (11/48)	   and	   27%	   (13/48)	   of	   LCC	   cases	   without	   neuroendocrine	   differentiation	  (further	   referred	   to	   in	   this	   section	   as	  LCC)	  were	   reclassified	  as	  AD	   (TTF1+,	   p63−)	  and	  SQ	  (TTF1−,	  p63+),	  respectively.	  Fourteen	  cases	  were	  tested	  positive	  for	  at	  least	  one	  neuroendocrine	  marker	  by	  IHC	  and	  were	  thereby	  reclassified	  either	  to	  LCNEC	  (in	  three	  out	  of	  ten	  cases	  with	  admixture	  of	  SCLC	  or	  SQ	  components)	  or	  SCLC	  (4/14,	  one	  with	   SQ	   component).	  Four	   cases	  were	   sarcomatoid	   (SARC).	  Three	   LCC	   cases	  were	  reclassified	  as	  AD	  (2)	  or	  SARC	  (1)	  without	  the	  need	  of	  immunohistochemistry,	  assuming	  misclassification	  by	  the	  primary	  pathologist.	  In	  only	  five	  of	  48	  cases	  the	  diagnosis	  remained	  LCC	  due	  to	  lack	  of	  glandular	  or	  squamous	  expression	  profiles.	  Only	  38	   of	   the	   48	   LCC	   cases	   described	   above	   (11	   AD-­‐like,	   13	   SQ-­‐like,	   14	  LCNEC)	  were	  considered	   true	  LCCs.	  One	  can	  assume	   that	  cases	  reclassified	  as	  CA,	  SARC	   or	   SCLC	   were	   misclassified	   by	   the	   primary	   pathologist	   since	   SCLC	   is	  morphological	  clearly	  distinct	   from	  LCC	  by	  cell	   size	   and	   fine	  granular	   chromatin2	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and	  diagnosis	  of	  SARC	  can	  be	  challenging100.	  Therefore	  these	  cases	  were	  excluded	  from	   further	   analyses.	   Considering	   only	   those	   38	   cases,	   the	   use	   of	  immunohistochemistry	  allowed	  sub-­‐classification	  of	  87%	  of	  the	  cases	  (33/38)	  into	  AD,	  SQ	  or	  neuroendocrine	  tumors	  (see	  also	  Central	  pathological	  review,	  Figure	  8).	  AD	  differentiation	  was	  supported	  by	  positive	  TTF-­‐1	  and/or	  CK7	  and	  no	  p63,	  CK5/6	  expression	  (only	  one	  case	  was	  negative	   for	  TTF-­‐1	  but	  exhibited	  CK7	  expression2)	  and	  SQ	  differentiation	  by	  positive	  p63,	  CK5/6	  and	  no	  TTF-­‐1	  and	  CK7	  expression.	  In	  Figure	   17	   results	   of	   immunohistochemistry	   and	   genetic	   analysis	   of	   69	   LCCs	   are	  illustrated.	   One	   case	   was	   positive	   for	   TTF-­‐1	   and	   p63	   expression	   and	   was	  reclassified	  as	  ADSQ.	  Cases	  with	  expression	  of	  at	  least	  one	  neuroendocrine	  marker	  were	  reclassified	  into	  LCNEC	  (CD56	  was	  positive	  in	  50%).	  CK7	  was	  expressed	  in	  all	  LCNEC	   cases,	   TTF-­‐1	   in	   40%.	   LCC	   cases	   reclassified	   into	   AD	   based	   on	   their	  immunohistochemical	  profile	  harbored	  AD-­‐typical	  alterations	  such	  as	  mutations	  in	  
KRAS	   (44%)	   and	   STK11	   (22%)	   and	   amplification	   of	   NKX2-­‐1	   (33%)	   and	   cases	  reclassified	   as	   SQ	   harbored	   amplifications	   of	   SOX2	   typical	   for	   SQ	   (28%)	   but	   no	  mutations	   in	   EGFR	   or	   KRAS.	   Thus,	   reclassifying	   cases	   based	   on	  immunohistochemistry	  is	  in	  line	  with	  genetic	  findings.	  	  	  
	  Figure	  17	  Results	  of	   central	  pathological	   review	  (CPR),	   immunohistochemistry	   (IHC)	  and	  genetic	   alterations	  of	  69	  LCC	   cases.	  Genes	  are	   arranged	  according	  mutation	   frequency	   in	  histological	   subtypes	   (background:	   orange=AD,	   blue=SQ).	   Histology	   (CPR)	   color	   code:	  orange=AD,	  green=LCC,	  grey=LCNEC,	  red=SCLC,	  blue=SQ,	  mixed	  types	  colored	  accordingly.	  	  	  	  	  











	   Further	  sub-­‐classification	  was	  not	  possible	   for	  62	  originally	  diagnosed	  LCC	  cases	  as	  for	  five	  cases	  no	  clear	  immunohistochemical	  profile	  was	  observed,	  for	  ten	  cases	  only	  H&E	  staining	  was	  available	  but	  definite	  diagnosis	  without	   IHC	  was	  not	  possible	   or	   pathological	   review	   has	   not	   been	   done.	   Of	   these	   62	   cases,	   36	  were	  tested	   for	  genetic	  alterations.	   In	  16%	  of	   these	  EGFR	  or	  KRAS	  was	  mutated,	  typical	  alterations	   observed	   in	   AD,	   one	   case	   had	   a	   DDR2	   mutation,	   two	   cases	   SOX2	  amplification	  of	  which	  one	  had	  also	  a	  mutation	  in	  NFE2L2,	  typical	  for	  SQ.	  In	  single	  cases	  NRAS	  or	  PIK3CA	  was	  mutated	  or	  ERBB2	  amplified.	  In	  total,	  45%	  of	  LCCs	  that	  were	  not	   further	  sub-­‐classified	  based	  on	   immunohistochemical	  profiles,	  harbored	  genetic	   alterations	   in	   at	   least	   one	   gene	   that	   segregate	  with	   a	   certain	  histological	  subtype	   and	   might	   be	   useful	   for	  classification	   or	   predict	   response	   to	  targeted	  therapies	  (Figure	  18).	  	   	  	  	  Figure	   18	   Distribution	   of	   subtype	   specific	  genetic	  alterations	  identified	  in	  36	  not	  further	  classified	  large	  cell	  carcinomas.	  	  	  	   Typical	  morphology	  (H&E)	  and	   immunohistochemical	  staining	  of	   the	   three	  commonly	   used	   markers	   in	   lung	   cancer	   diagnostics	   TTF-­‐1,	   p63	   and	   CD56	   are	  shown	  in	  Figure	  19	  for	  four	  LCC	  cases,	  where	  one	  case	  was	  assigned	  to	  AD	  based	  on	  TTF-­‐1	  expression,	  another	  to	  SQ	  based	  on	  p63	  expression	  and	  a	  third	  based	  on	  its	  expression	  of	  CD56	  to	  neuroendocrine	  LCC.	  The	  lowest	  panel	  in	  this	  figure	  presents	  one	   case	   without	   a	   distinctive	   marker	   profile	   that	   could	   not	   be	   further	  sub-­‐classified	  and	  remained	  LCC	  (Figure	  19,	  NOS,	  not	  otherwise	  specified).	  In	  cases	  reclassified	  as	  AD	  (AD-­‐like),	  SQ	  (SQ-­‐like)	  or	  neuroendocrine	  (NEC)	  typical	  genetic	  alterations	   for	   these	   subtypes	   were	   identified	   supporting	   the	   validity	   of	   the	  immunochemical	   interpretation,	   such	   as	   mutation	   in	   KRAS	   in	   the	   AD	   case,	  amplification	  of	  FGFR1	  in	  the	  SQ	  case,	  and	  RB1	  loss	  in	  the	  NEC	  case.	  The	  NOS	  case	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harbored	  a	  mutation	  in	  KRAS	  and	  the	  non-­‐oncogenic	  EGFR	  K714N	  mutation	  typical	  for	  AD	  as	  well	  as	  amplification	  of	  SOX2	  typical	  for	  non-­‐AD	  (Figure	  19,	  right).	  	  	  
	  	  	  	  	  	  	   	  Figure	  19	  Typical	  immunohistochemistry	  of	  LCC	  cases	  exhibiting	  characteristics	  of	  AD,	  SQ,	  NEC	   or	   no	   distinct	   pattern.	   Respective	   genetic	   alterations	   are	   depicted	   on	   the	   right.	  	   Overall	  more	  than	  90%	  of	  LCC	  cases	  could	  be	  further	  sub-­‐classified	  based	  on	  their	   immunohistochemical	   profile.	   Notably,	   the	   genetic	   alterations	   in	   these	  reassigned	   cases	   were	   in	   line	   with	   the	   newly	   assigned	   diagnostic	   category.	  However,	   in	   an	   additional	   8%	   of	   cases,	   in	   which	   IHC	   was	   inconclusive,	   genome	  alterations	  were	  present	   that	  were	   specific	   of	   any	  one	  of	   the	  other	   subtypes	   (i.e.,	  AD,	   SQ,	   etc.).	  Thus,	   in	   order	   to	   sub-­‐classify	  LCCs	   into	   clinical	   relevant	   subgroups	  detailed	  immunohistochemical	  stains	  and	  genomic	  analyses	  are	  needed.	  	  	   To	   further	   investigate	   genetic	   associations	   of	   LCC	   with	   tumors	   of	   other	  subtypes,	  copy	  numbers	  in	  20	  chromosomal	  regions	  (see	  Table	  2,	  regions	  that	  were	  significantly	   altered	   across	   all	   lung	   tumors)	   were	   compared	   between	   the	   major	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histological	   subtypes	  AD,	  SCLC	  and	  SQ	  with	  LCC	  and	  LCNEC	  using	   the	  Student’s	   t	  test	   (Figure	   20).	   Significant	   differences	   between	   LCC	   and	   LCNEC	   were	   seen	   in	  chromosomal	  regions	  3p26,	  5p15	  and	  18q21.	  LCCs	  were	  similar	  to	  AD	  and	  SQ	  and	  exhibited	  differences	   in	  copy	  number	  patterns	  only	   for	  amplifications	  on	  3q26-­‐29	  (SOX2)	   compared	   to	  AD	   and	   SQ	   and	  deletions	   on	  5q15-­‐21	   for	   AD.	  LCNEC	  on	   the	  contrary	  differed	  from	  AD	  and	  SQ	  in	  several	  regions.	  Amplifications	  on	  3q26-­‐29	  and	  deletions	   on	   3q26	   and	   18q21	   differed	   in	   LCNEC	   from	   AD	   and	   SQ.	   Additionally,	  differences	  between	  LCNEC	  and	  AD	  were	  identified	  for	  amplifications	  on	  5p15	  and	  deletions	  on	  5q15-­‐21	  and	  19p13	  and	  between	  LCNEC	  and	  SQ	  for	  deletions	  on	  1p13,	  6p22-­‐21	  and	  22q13.	  Comparing	  SCLC	  with	  LCC	  eight	  of	  the	  12	  deleted	  regions	  were	  found	  to	  be	  significantly	  different	  whereas	  no	  difference	  in	  the	  eight	  amplified	  and	  twelve	  deleted	  regions	  was	  observed	  comparing	  LCNEC	  with	  SCLC	  (Figure	  20,	  lane	  LCNEC-­‐SCLC).	  	   	  	  	  	  Figure	  20	  Comparison	  of	  significantly	  amplified	  and	   deleted	   regions	   between	   histological	  subtypes	  (405	  AD,	  62	  LCC,	  39	  LCNEC,	  63	  SCLC,	  316	   SQ)	   given	   for	   pairs.	   P-­‐values	   were	  calculated	  by	  permuting	  each	  sample	  set	  1,000	  times	   (according	   to	   the	   smallest	   observed	  subtype	  combination)	  using	  the	  student's	  t-­‐test.	  Dots	   represent	   statistical	   significance	   (size	  correlates	  with	  the	  number	  of	  significant	  events	  (p-­‐value	  <	  0.05).	  	  
Similarities	  between	  LCNEC	  and	  SCLC	  as	  well	  as	  high	  agreement	  of	  LCC	  with	  AD	   and	   SQ	   were	   found	   when	   comparing	   copy	   number	   alterations.	   To	   further	  investigate	   the	   genetic	   heterogeneity,	   unsupervised	   hierarchical	   clustering	   using	  gene	  expression	  data	  of	  the	  294	  most	  variably	  expressed	  genes	  was	  applied	  to	  261	  lung	  tumor	  cases	  comprising	  all	  histological	  subtypes	  (Figure	  21).	  Most	  cases	  of	  the	  same	  histological	  subtype	  clustered	  together	  (92%	  of	  13	  CA	  in	  cluster	  I,	  84%	  of	  25	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SCLC	  in	  cluster	  II,	  85%	  of	  95	  AD	  in	  cluster	  III	  and	  76%	  of	  86	  SQ	  cases	  in	  cluster	  IV)	  whereas	  LCCs	  did	  not	  form	  a	  distinct	  cluster	  but	  were	  grouped	  together	  with	  either	  SCLC	  (22%),	  AD	  (39%)	  or	  SQ	  (39%)	  (Figure	  21,	  colored	  triangles).	  Of	  the	  seven	  LCC	  that	  clustered	  together	  with	  SCLC	  three	  were	  histologically	  LCNECs	  (Figure	  21,	  grey	  triangles).	  Two	   of	   these	   had	  RB1	   loss,	   typical	   for	   SCLC.	   Except	   for	   one	   case	   that	  clustered	   together	   with	   SQ,	   LCC	   harbored	   genetic	   alterations	   typical	   for	   the	  respective	  histological	   subtype,	   for	  example	   four	  LCC	  cases	   that	  had	  mutations	   in	  either	   BRAF	   (one),	   ERBB2	   (one),	   or	   KRAS	   (two)	   clustered	   with	   AD	   (Figure	   21,	  orange	   triangles)	   and	   two	   LCC	   cases	   that	   harbored	   either	   a	   DDR2	   or	   NFE2L2	  mutation	  clustered	  with	  SQ	  (Figure	  21,	  blue	  triangles).	  	  	  
	  Figure	  21	  Unsupervised	  hierarchical	  clustering	  using	  294	  genes.	  (color	  code,	  histology:	  AD	  orange,	   CA	  black,	   LCNEC	   grey,	   LCC	   green,	   SCLC	   red,	   SQ	  blue).	   LCC	   cases	   are	   indicated	   as	  triangles	   at	   corresponding	   positions	   (in	   orange	   with	   AD-­‐typical	   alterations,	   blue	   with	  SQ-­‐typical	  alterations,	  grey	  if	  this	  case	  was	  initially	  diagnosed	  as	  a	  LCNEC,	  and	  green	  with	  no	  known	  alteration).	  Genetic	  alterations	  as	  vertical	  lines	  (LCC	  in	  green;	  others	  in	  black).	  	  	  	  	   Figure	   22	   Kaplan	   Meier	   Curve	   for	   overall	  	   survival	  for	  histological	  subtypes	  with	  LCNEC	  	  	   seperated	  from	  LCC.	  Survial	  was	  compared	  	   using	  a	  logrank	  test	  between	  LCNEC	  and	  SCLC	  	  	   (red,	  p-­‐value=0.6),	  as	  well	  as	  LCNEC	  and	  CA	  	   (black),	  AD	  (orange),	  LCC	  (green)	  and	  SQ	  	   (blue)	  (p-­‐values<0.01).	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In	  summary,	  tumors	  that	  were	  originally	  classified	  as	  LCC	  presented	  a	  variety	  of	   genetic	   alterations,	   heterogeneous	   immunohistochemical	   and	   gene	   expression	  profiles	   similar	   to	   other	   histological	   subtypes	   rather	   than	   a	   distinctive	   pattern.	  LCNEC	  are	  genetically	  and	  clinically	  (Figure	  22)	  more	  similar	  to	  SCLC	  than	  to	  other	  LCC	   tumors.	   In	   contrast,	   LCC	   without	   neuroendocrine	   differentiation	   show	  characteristics	  of	  either	  AD	  or	  SQ	  and	  could	  be	  further	  classified	  into	  one	  of	  them	  based	  on	  their	  immunohistochemical	  or	  genetic	  profile.	  Typical	  alterations	  of	  AD	  or	  SQ	  such	  as	  mutations	  in	  KRAS	  or	  DDR2	  respectively	  were	  identified	  in	  several	  cases	  where	   immunohistochemistry	   was	   not	   available	   or	   revealed	   no	   clear	   marker	  profile.	   Thus,	   in	   order	   to	   reclassify	   LCC	   cases	   into	   clinical	   relevant	   subgroups	  combined	  immunohistochemical	  and	  genomic	  analyses	  is	  necessary.	  	  	  	  
8. Lung	  tumors	  are	  frequently	  altered	  in	  a	  limited	  set	  of	  oncogenes	  	  In	  this	  sample	  set	  genetic	  alterations	  were	  identified	  in	  genes	  encoding	  for	  proteins	  of	  different	  classes	  and	  involved	  in	  different	  signaling	  pathways.	  Several	  oncogenes	  were	   frequently	  mutated	  or	  amplified	  but	  also	   rare	  events	  were	   identified	   in	   this	  study.	   To	   genetically	   sub-­‐classify	   lung	   tumors	   genes	   were	   chosen	   based	   their	  current	  clinical	   significance	  (targeted	   therapies	  already	  approved	  or	  clinical	   trials	  ongoing),	  important	  functional	  role	  in	  tumorigenesis	  and	  thereby	  potential	  targets	  for	   new	   targeted	   therapies	   as	   well	   as	   recurrence.	   In	   total	   	   (ALK,	   ROS,	   RET;101	  
DDR2;72	   ERBB2;34,102	   BRAF;103,104	   EGFR;4,69	   FGFR;82,105	   CDK4,	   CCNE1,	   CCND1	   their	  role	   in	   the	   cell	   cycle106;	   MDM2	   that	   inhibits	   wild-­‐type	   p53	   transactivation	  function;92	   NFE2L2	   involved	   in	   oxidative	   stress	   response,107	   and	   SOX293)	   (Figure	  23).	  In	  total	  56%	  of	  the	  tumor	  cases	  had	  a	  mutation	  and	  copy	  number	  alteration	  in	  at	   least	   one	   of	   these	   oncogenes.	   Thus,	   more	   than	   half	   of	   the	   patients	   were	  genetically	  characterized	  using	  this	  limited	  set	  of	  genes.	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  Figure	  23	  Overview	  of	  genetic	  alterations	  in	  lung	  tumors.	  Tumors	  that	  harbor	  alterations	  in	  at	   least	   two	   different	   genes	   were	   combined	   in	   the	   “multiple”	   portion	   (number	   of	  co-­‐occurring	  alterations	  given	  in	  brackets).	  Gene	  labels:	  mutated	  genes	  in	  black,	  amplified	  in	   red,	   rearranged	   marked	   with	   an	   asterisk.	   Frequency	   of	   RET	   rearrangements	   were	  adapted	  from	  Takeuchi	  et	  al	  (2012)101.	  WT	  (wild	  type)	  in	  the	  given	  genes.	  	  	   In	   cases	   with	   multiple	   alterations	   (14.8%)	   mutations	   in	   KRAS,	   NFE2L2,	  
PIK3CA	  or	  amplifications	  of	  CCND1,	  CCNE1,	  FGFR1,	  or	  SOX2	  were	   involved	   in	  80%	  (SOX2	  amplifications	  with	  about	  16%	  being	  the	  most	  frequent	  co-­‐occurring	  event).	  With	  the	  exception	  of	  ROS1,	   for	  every	  gene	  at	   least	  one	  case	  was	  identified	  with	  a	  co-­‐occurring	  alteration	  in	  another	  oncogene.	  In	  less	  than	  3%	  of	  the	  cases	  more	  than	  two	  alterations	  were	  identified	  within	  the	  same	  tumor.	  Mutations	  occurred	  rarely	  in	  
CDK4,	  DDR2,	  FGFR2,	  FGFR3,	  HRAS,	  or	  NRAS	  (<	  0.5%)	  across	  all	  lung	  tumors	  (Figure	  23).	   Frequency	   for	   rearrangements	   of	   RET	   is	   adapted	   from	   Takeuchi	   et	   al	   in	  2012101,	  who	  identified	  13	  AD	  cases	  with	  RET	  fusion	  in	  1,529	  NSCLC	  cases.	  In	  our	  cohort	  no	  case	  with	  RET	  rearrangement	  was	  identified.	  The	  most	  commonly	  altered	  genes	  were	  KRAS	  (15.2%),	  SOX2	  (10%),	  FGFR1	  (9.8%),	  and	  EGFR	  (6.4%).	  Mutation	  frequencies	  vary	  slightly	  from	  the	  before	  mentioned	  since	  only	  cases	  were	  included	  in	   this	   analysis	   that	   had	   genetic	   information	   available	   for	   at	   least	  17	  of	   the	   here	  depicted	  20	  genes	  or	  had	  co-­‐occurring	  alterations	  and	  were	   therefore	   included	   in	  the	  section	  with	  multiple	  alterations.	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Several	   of	   the	   above	   mentioned	   genetic	   alterations	   predict	   sensitivity	   to	  therapeutics	   that	   are	   currently	   in	   clinical	   use	   and	   segregate	   with	   specific	  histological	   subtypes	   in	   lung	   cancer.	   Genes	   were	   chosen	   if	   I)	   drugs	   are	   already	  approved	  for	  targeting	  the	  gene	  product	  in	  cancer	  patients	  (for	  example	  crizotinib	  against	  ALK	  in	  ALK-­‐rearranged	  NSCLC;	  erlotinib	  and	  gefitinib	  against	  mutant	  EGFR	  in	  lung	  AD),75	  II)	  for	  which	  current	  clinical	  trials	  investigate	  the	  effect	  of	  drugs	  that	  are	   approved	   for	   other	   molecular	   targets	   and	   cancer	   types	   or	   the	   effect	   of	   new	  medicinal	   products	   in	   genetically	   selected	   patient	   cohorts	   (e.g.,	   crizotinib	   against	  ROS1;	  GSK2118436	  against	  BRAF	  V600	  mutant	  NSCLC;	  dasatinib	   in	  DDR2-­‐mutant	  SQ	   of	   the	   lung;	   trastuzumab	   against	   Her2	   in	   breast	   cancer;	  NVP-­‐BGJ398	   against	  FGFR)74	   or	   III)	   that	   serve	   as	   exclusion	   criteria	   for	   certain	   therapies	   (KRAS	  mutations	   predict	   resistance	   to	   tyrosine	   kinase	   inhibitors108).	   This	   lead	   to	   a	  selection	   of	   the	   following	   genes:	   ALK,	   BRAF,	   DDR2,	   EGFR,	   ERRB2,	   KRAS,	   FGFR1,	  
PIK3CA,	  and	  ROS1.	  	  In	  60%	  of	  ADs	  at	  least	  one	  genetic	  alteration	  could	  be	  identified,	  in	  30%	  of	  SQs	   and	   14%	   of	   SCLCs	   (Figure	   24).	   In	   AD	   a	   variety	   of	   genetically	   defined	  subpopulations	  were	   identified,	  whereas	   in	  SCLC	  amplifications	  of	  FGFR1	  was	  the	  most	   prominent	   alteration.	   Only	   rare	   SCLC	   cases	   were	   identified	   harboring	   a	  
PIK3CA	   mutation.	   Similar	   in	   SQ	   FGFR1-­‐amplified	   cases	   represented	   the	   largest	  genetically	   distinctive	   group.	   In	   addition	   DDR2	   (about	   1%)	   and	   KRAS	   (2.5%)	  mutations	  were	  identified	  in	  SQ	  cases	  but	  only	  rare	  cases	  were	  altered	  in	  ALK,	  BRAF,	  
EGFR	  or	  ERBB2.	  	  	  
	  Figure	  24	  Frequencies	  of	  genetic	  alterations	  in	  genes	  per	  histological	  subtype	  (LCC	  without	  LCNEC	  on	  the	  right)	  (gene	  labels:	  mutated	  in	  black,	  amplified	  in	  red).	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9. Mutant	  FGFR3:	  a	  new	  potential	  therapeutic	  target	  in	  lung	  tumors	  Most	   therapeutic	   targets	   have	   been	   identified	   mainly	   in	   the	   AD	   subtype.	   Only	  recently	  potential	  new	  targets	  were	  identified	  in	  the	  SQ	  subtype	  and	  drugs	  directed	  against	   these	   targets	   already	   tested	   in	   clinical	   trials.	  Here	   recurrent	  mutations	   in	  the	   fibroblast	   growth	   factor	   receptor	   3	   (FGFR3)	   that	   might	   be	   a	   promising	  therapeutic	   target	   in	   SQ	   are	   described	   for	   the	   first	   time	   in	   lung	   cancer.	   A	   single	  nucleotide	  alteration	  in	  FGFR3	  that	  results	  in	  a	  change	  of	  an	  arginine	  to	  cysteine	  at	  the	  AA	  position	  248	  was	  identified	  in	  three	  SQ	  lung	  tumor	  cases.	  Similar	  to	  the	  well	  studied	  S249C	  mutation	  the	  AA	  change	  to	  cysteine	  at	  position	  248	  causes	  formation	  of	   stable	   homodimers	   through	   cysteine	   disulfide	   bridges	   in	   a	   ligand-­‐independent	  manner	   leading	   to	   constitutively	   tyrosine	   phosphorylation	   and	   thereby	  downstream	   signaling	   activation.109	   In	   this	   data	   set	   FGFR3	  mutations	   excluded	  occurrence	   of	   mutations	   in	   FGFR2.	   One	   of	   the	   three	   mutated	   cases	   also	   had	   an	  amplification	   of	   FGFR1	   as	   well	   as	   the	   PIK3CA	   E545K	   mutation	   and	   a	   missense	  mutation	   in	  TP53	  and	   a	   second	   case	   harbored	   a	  mutation	   in	   the	   tyrosine	   kinase	  domain	  of	  DDR2.	  All	  cases	  were	  early	  stage	  squamous	  cell	  carcinomas	  (Figure	  25).	  	  
	  Figure	   25	   Summary	   of	   three	   lung	   cancer	   cases	   harboring	   the	   FGFR3	   R248C	   mutation.	  Clinical	   characteristics	   are	   listed	   on	   the	   left.	   In	   the	   middle	   copy	   numbers	   (CNFGFR1)	   are	  displayed	   for	   the	   locus	   on	   chromosome	   8	   (chromosomal	   location:	   30,897,037	   to	  45,848,014)	  encompassing	  FGFR1	  (red=amplified,	   blue=deleted)	   and	  mutations	   in	  DDR2,	  
PIK3CA	  or	  TP53	  indicated	  as	  black	  squares	  per	  case	  on	  the	  right.	  	  	  	   The	  FGFR3	  R248C	  mutation	  has	  been	  described	  in	  bladder	  cancer110	  but	  not	  in	   lung	  cancer.	  Furthermore,	  data	  on	  the	  oncogenic	  properties	  of	   this	  mutation	  as	  well	  as	   its	  possible	  association	  with	  sensitivity	  to	  FGFR	  inhibition	  has	  so	  far	  been	  limited.	   In	   order	   to	   assess	   its	   role	   as	   a	   potential	   target	   of	   cancer	   therapeutics	  mutant	  and	  wild-­‐type	  FGFR3	  were	  cloned	  into	  the	  retroviral	  pBabe-­‐puro	  backbone	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and	   expressed	   stably	   in	   NIH3T3	   cells.	   These	   immortalized	   murine	   fibroblasts	  exhibit	   a	   hypertriploid	   karyotype	   but	   do	   not	   show	   a	   transformed	   phenotype.111	  Plated	   in	   soft	   agar	   non-­‐transformed	   NIH3T3	   cells	   stop	   dividing	   whereas	  oncogene-­‐expressing	  cells	  continue	  to	  grow	  and	  form	  colonies.	  	  	   The	   transforming	   ability	   of	   the	  FGFR3	  R248C	  mutation	   could	   be	   shown	   in	  cell	   line	  models	  using	  NIH3T3	  cells.	  This	  mutation	  was	  able	   to	   transform	  NIH3T3	  cells	   to	   anchorage	   independence	   as	   assayed	   by	   colony	   formation	   in	   soft	   agar	  whereas	   cells	   expressing	  wild	   type	  FGFR3	   failed	   to	   induce	   colony	   formation	   after	  four	   weeks	   (t-­‐test,	   p=1.07-­‐07)	   (Figure	   26).	   NIH3T3	   cells	   expressing	   the	   fusion	  
EML4-­‐ALK	   (used	   as	   a	   positive	   control	   for	   this	   assay)	   showed	  anchorage-­‐independent	   growth.	   NIH3T3	   transduced	   with	   an	   empty	   vector	  (negative	   control)	   formed	   isolated	   colonies	   comparable	   to	   FGFR3	   wild	   type	  expressing	   cells	   (average15wells	  =	  0.7).	   Expression	   levels	   of	  mutant	   and	   wild	   type	  
FGFR3	   and	   EML4-­‐ALK	   were	   evaluated	   by	   Western	   blot	   and	   shown	   to	   be	  approximately	  equal	  in	  the	  cell	  lines	  (data	  not	  presented).	  	  	  	  	  	  	  	  	  
	  Figure	   26	   Clonal	   NIH3T3	   cells	   expressing	   EML4-­‐ALK,	   wild	   type	   FGFR3	   or	   R248	   mutant	  
FGFR3	  and	  empty	  vector	  control	  (e.V.)	  were	  plated	  in	  soft	  agar	  and	  colonies	  counted	  after	  4	  weeks	   of	   incubation	   using	   the	   Zeiss	   Vert.A1	   microscope	   (10x	   original	   magnification).	  Median	  number	  of	  colonies	  per	  cell	  line	  is	  given	  on	  the	  right.	  Error	  bars	  indicate	  standard	  deviation	  of	  median	  determined	  by	  bootstrap	  (10,000	  sample	  drawn).	  	  	   Sensitivity	  to	  the	  selective	  FGFR	  kinase	  inhibitor	  NVP-­‐BGJ398	  was	  tested	  in	  NIH3T3	  cells	  expressing	  R248C	  mutant	  FGFR3	  using	  the	  same	  approach	  and	  adding	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increasing	  concentrations	  of	  the	  compound	  to	  the	  cells.	  NVP-­‐BGJ398	  binds	  into	  the	  cytosolic	  ATP-­‐binding	  pocket	  of	  FGFR	  and	  has	  been	  shown	  to	   inhibit	  proliferation	  in	  cell	  lines	  with	  significant	  association	  to	  FGFR	  genetic	  alterations.105,112	  Currently	  NVP-­‐BGJ398	   is	   tested	   in	   phase	   I	   clinical	   trials	   in	   patients	   with	   advanced	   solid	  tumors	  harboring	  alterations	  in	  FGFR.113	  Anchorage-­‐independent	  growth	  in	  R248C	  mutant	  cells	  was	  inhibited	  at	  a	  concentration	  of	  10	  nM	  NVP-­‐BGJ398	  (Figure	  27).	  At	  the	   concentration	   of	   1	  nM	   NVP-­‐BGJ398	   no	   significant	   difference	   of	   growth	  compared	   to	   untreated	   cells	   was	   observed.	   Growth	   of	   the	   cancer	   cell	   line	   A549	  harboring	  the	  oncogenic	  KRAS	  G12S	  mutation	  and	  no	  alterations	  in	  the	  FGFR	  genes	  was	  not	   inhibited	  at	  a	  concentration	  of	  1	  µM	  BGJ398	  (data	  not	  shown),	  ruling	  out	  possible	  toxic	  side	  effects	  of	  the	  compound	  at	  the	  given	  concentrations	   in	  this	  cell	  line	  model.	  	   In	  summary,	  the	  FGFR3	  mutation	  R248C	  has	  been	  identified	  in	  rare	  SQ	  cases.	  This	  mutation	  transformed	  cells	  in	  vitro	  and	  confers	  sensitivity	  to	  FGFR	  inhibition.	  	  	  	  	  	  	  	  	  





1. Genetic	  characterization	  of	  lung	  tumors	  This	   is	   the	   first	   study,	   where	   distribution	   and	   frequencies	   of	   genetic	   alterations	  have	   been	   comprehensively	   characterized	   across	   all	   lung	   cancer	   subtypes.	  Mutations	   in	   BRAF,	   EGFR,	   ERBB2,	   KRAS,	   STK11,	   chromosomal	   rearrangements	  affecting	   ALK	   and	   ROS1,	   as	   well	   as	   amplifications	   of	   NKX2-­‐1	   and	   MDM2	   were	  associated	  with	   the	  AD	  subtype	  confirming	  previous	   findings.18,38,101,114	  Mutations	  in	  DDR2	  and	  NFE2L2,	   amplifications	   of	   CCND1,	  FGFR1	  and	   SOX2	   segregated	   with	  SQ,72,82,115	  and	  RB1	  and	  the	  genes	  of	  the	  MYC	  family	  were	  typically	  altered	  in	  SCLC81.	  LCC	   on	   the	   contrary	   did	   not	   reveal	   a	   distinct	   genetic	   or	   histopathologic	   pattern.	  Instead	   the	   majority	   of	   LCC	   cases	   retained	   expression	   of	   differentiation	   tumor	  markers	  supporting	  their	  biological	  similarity	  to	  AD,	  SCLC	  and	  SQ,	  which	  is	  further	  supported	  by	  the	  presence	  of	  genetic	  alterations	  typical	  for	  these	  subtypes	  in	  many	  cases.	   LCCs	   that	   exhibited	   neuroendocrine	   differentiation	   were	   found	   to	   be	  biologically	  and	  clinically	  more	  similar	  to	  SCLC	  than	  to	  other	  LCCs.	  	  	   With	   the	   increasing	   understanding	   of	   cancer	   biology,	   treatment	   strategies	  shift	  towards	  a	  personalized	  approach	  based	  on	  genomic	  and	  molecular	  alterations	  rather	  than	  the	  “one	  fits	  all”	  chemotherapeutic	  approach.	  Thus,	  the	  findings	  of	  this	  study	   could	   motivate	   the	   development	   of	   new	   diagnostic	   strategies	   for	   patient	  stratification	  into	  genetically	  defined	  subgroups.	  	  	   	  
1.1. Therapeutically	  important	  signature	  alterations	  in	  AD,	  SCLC	  and	  SQ	  are	  
rare	  events	  in	  other	  lung	  cancer	  subtypes	  Most	  genetic	  alterations	   that	  are	  or	  might	  be	  suitable	   for	   targeted	  therapies	  were	  identified	   in	  AD.76,83,114	   In	   SQ	  only	   recently	   therapeutic	   targets	  were	   identified	  by	  others	  and	  us,	  showing	  that	  the	  genes	  DDR2	  and	  FGFR1	  are	  recurrently	  mutated	  or	  amplified.72,82	   DDR2	  mutations	   were	   associated	   with	   sensitivity	   to	   dasatinib	   (a	  multi-­‐target	   kinase	   inhibitor)	   in	   xenograft	   models	   and	   in	   patients.72,116	   FGFR	  inhibition	   (for	   instance	   using	   the	   selective	   FGFR	   inhibitors	   PD173074	   or	  NVP-­‐BGJ398)	   lead	   to	   shrinkage	   of	   tumors	   that	   harbored	   FGFR	   alterations	   (i.e.	  amplifications	  or	  mutations	  affecting	  one	  of	   the	  FGFR	   family	  members).105	   In	   this	  study	   the	  oncogenic	  FGFR3	  R248C	  mutation	  has	   been	   identified	   in	   rare	   SQ	   cases	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and	   sensitivity	   to	   the	  FGFR	   inhibitor	  BGJ398	   identifies	   this	   alterations	   as	   a	   novel	  therapeutic	   target	   in	   lung	  cancer.	  The	  most	   frequently	  altered	  pathway	   in	  SQ	  was	  the	   Nrf2-­‐KEAP1	   pathway.115	   Mutations	   in	   the	   transcription	   factor	   Nrf2	   and	   its	  negative	   regulator	   KEAP1	   (the	   E3	   ubiquitin	   ligase)	  were	   also	   found	   in	   AD	   and	  
KEAP1	  in	  few	  SCLC	  cases.	  Nrf2	  up-­‐regulation	  has	  been	  associated	  with	  resistance	  to	  chemotherapeutic	  agents	  (for	  example	  to	  cisplatin).117,118	  Therefore,	  alterations	   in	  the	   Nrf2-­‐KEAP1	   pathway	   might	   serve	   as	   predictive	   markers	   for	   the	   response	   to	  chemotherapy.	  	  	   Several	   therapeutic	   targets	  were	   found	   in	  AD	  and	  SQ	  that	  could	  already	  be	  translated	   into	   clinical	   application.	   By	   contrast,	   only	   few	   such	   targets	   have	   been	  identified	  in	  SCLC.	  Most	  SCLCs	  did	  not	  exhibit	  mutations	  in	  genes	  that	  are	  typically	  altered	   in	   AD	   (such	   as	   ALK,	   BRAF,	   EGFR,	   ERBB2	   or	   KRAS)	   and	   SQ	   (NFE2L2).	  However,	  few	  SCLC	  cases	  harbored	  alterations	  that	  were	  also	  found	  in	  AD	  and	  also	  in	  SQ,	  such	  as	  mutations	  in	  KEAP1	  or	  PIK3CA.	  The	  genes	  FGFR1,	  MYC	  and	  SOX2	  were	  frequently	   amplified	   in	   SCLC,80,81	   but	   the	   design	   of	   potent	   inhibitors	   is	   still	  challenging	  for	  the	  transcription	  factors	  MYC	  and	  SOX2	  because	  of	  their	  ubiquitous	  functional	  relevance	  in	  cells.	  Typical	  genetic	  alterations	  in	  SCLC	  were	  chromosomal	  loss	  of	  RB1	  and	  mutations	  in	  TP53	  that	  frequently	  co-­‐occur119	  and	  predict	  for	  worse	  outcomes	  in	  patients	  harboring	  such	  alterations.	  	  	   In	   line	   with	   other	   studies,	   rare	   lung	   cancer	   cases	   were	   identified	   that	  harbored	  alterations	  typical	  for	  other	  tumor	  subtypes.	  These	  rare	  cases	  revealed	  a	  spectrum	  of	   genetic	   alterations	   that	   is	  different	   from	   those	  subtypes,	  where	   such	  signature	   alterations	   were	   most	   frequently	   found.	   For	   instance,	   AD-­‐typical	  alterations	  were	  found	  in	  SQ	  cases,	  such	  as	  EGFR	  (<1%),	  BRAF	  (0.5%)104	  and	  KRAS	  (<3%)	   mutations	   or	   ALK	   rearrangement	   (<0.5%)115,120.	   One	   of	   the	   two	   EGFR	  mutations	   has	   been	   associated	   with	   sensitivity	   to	   erlotinib	   and	   gefitinib121.	  Currently,	   EGFR	   inhibitors	   are	   approved	   for	   EGFR-­‐mutant	   AD	   only.	   Even	   though	  clinical	   outcome	   in	   SQ	   patients	   has	   not	   been	   tested	   in	   a	   prospective	   study,	  
EGFR-­‐mutant	   non-­‐AD	   patients	  might	   also	   benefit	   from	   such	   treatment.	   Similarly,	  one	  SQ	  case	  had	  an	  ALK	  rearrangement;	  those	  cases	  might	  be	  sensitive	  to	  crizotinib.	  The	  two	  BRAF-­‐mutant	  SQ	  cases	  harbored	  the	  V600E	  (E,	  glutamate)	  mutation	   that	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has	   been	   associated	   with	   increased	   overall	   survival	   and	   PFS	   in	   patients	   with	  advanced	   melanoma	   treated	   with	   vemurafenib	   compared	   to	   standard	  chemotherapy122.	  Promising	  results	  have	  recently	  been	  published	  also	  for	  a	  lung	  AD	  patient.125	  However,	  preclinical	  data	  show	  that	  acquired	  resistance	  can	  be	  caused	  by	  EGFR	   activation	   and	   formation	   of	   RAF	   dimers	   that	   in	   turn	   are	   insensitive	   to	  vemurafenib.123	  EGFR	  overexpression	  is	  frequently	  observed	  in	  lung	  carcinoma	  and	  might	  cause	  primary	  resistance	  to	  BRAF	  inhibition.124,125	  	  	   Similarly,	   typical	   SQ	   alterations	   occur	   also	   at	   low	   frequencies	   in	   other	  subtypes,	  such	  as	  mutations	  in	  NFE2L2	  in	  AD	  and	  amplifications	  of	  FGFR1	  in	  SCLC.	  Other	  than	  in	  SQ	  where	  focal,	  high	  copy	  amplifications	  pinpoint	  FGFR1	  as	  one	  of	  the	  main	   oncogenes	   in	   this	   region,	   gains	   in	   SCLC	   affect	   more	   frequently	   large	  chromosomal	  regions.	  Amplification	  of	  genes	  adjacent	  to	  FGFR1	  implies	  that	  FGFR1	  may	   not	   be	   the	   driver	   gene	   in	   these	   cases.	   Relatively	   low	   level	   amplification	   of	  
FGFR1	  in	  most	  SCLC	  cases	  compared	  to	  SQ	  further	  puts	   its	  importance	  as	  a	  driver	  oncogene	   in	   SCLC	   tumorigenesis	   in	   question.	   Nonetheless,	   evaluation	   of	   such	  alterations	  as	  molecular	  targets	  might	  be	  reasonable	  in	  certain	  SCLC	  cases.74	  To	  date,	  diagnostic	  screening	  is	  recommended	  for	  ALK	  and	  EGFR	  in	  AD	  only.	  Since	  many	   (potential)	  molecular	   targets	   in	   lung	   cancer	   segregate	  with	   a	   specific	  histological	   subtype,	   clinical	   trials	   are	   conducted	   for	   these	   subtypes	   accordingly.	  Thus,	   response	   rates	   to	   specific	   therapeutics	   are	   not	   available	   in	   tumors	   of	   a	  different	   histological	   subtype	   that	   harbor	   the	   same	   oncogenic	   driver	   alteration.	  However,	   it	   is	   possible	   that	   for	   instance	   SQ	   tumors	   harboring	   activating	   EGFR	  mutations	   or	   ALK	   rearrangements	   might	   be	   sensitive	   to	   EGFR	   inhibitors	   or	  crizotinib,	   respectively.	   With	   the	   increasing	   understanding	   of	   the	   diversity	   of	  molecular	   mechanisms	   underlying	   tumor	   development	   and	   drug	   resistance	   in	  different	   subtypes,	   applicability	   of	   therapeutic	   that	   are	   successful	   in	   a	   certain	  tumor	  subtype	  to	  other	  subtypes	  will	  most	  likely	  be	  better	  predictable	  in	  the	  near	  future.	  	  Thus,	  in	  order	  to	  make	  well-­‐informed	  treatment	  decisions	  clinically	  relevant	  alterations	   should	   be	   tested	   in	   all	   lung	   tumors	   irrespective	   of	   the	   histological	  subtype.	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1.2. The	  revocation	  of	  large	  cell	  carcinoma	  of	  the	  lung	  	  To	  date,	  no	  classification	  system	  is	  available	   for	  the	  clinically	  and	  morphologically	  heterogeneous	   group	   of	   LCC	   that	   describes	   therapeutically	   relevant	   subgroups.	  Discussions	   about	   a	   re-­‐evaluation	   of	   this	   subtype	   are	   ongoing	   since	  immunohistochemistry	   became	   a	   standard	   tool	   in	   cancer	   diagnostics	   and	   certain	  LCC	   were	   found	   to	   retain	   immunohistochemical	   marker	   profiles	   of	   AD	   (TTF-­‐1+,	  p63—,	   neuroendocrine	   markers—)	   and	   SQ	   (TTF-­‐1—,	   p63+,	   neuroendocrine	  markers—).126-­‐128	  LCC	  with	  neuroendocrine	  differentiation	  were	  grouped	  with	  other	  LCC	   in	   1999	   based	   on	  morphology	   but	   the	   detailed	   analysis	   rather	   suggests	   that	  LCNEC	   is	  biologically	  more	  similar	   to	  other	  neuroendocrine	   tumors	   than	   to	  other	  LCCs.129-­‐131	  In	   our	   sample	   set	   90%	   of	   LCCs	   were	   reassigned	   based	   on	   their	  immunohistochemical	   profile	   to	   AD,	   SQ	   or	   neuroendocrine	   tumors	  (neuroendocrine	   markers+)	   comparable	   to	   other	   studies.128,132	   Remaining	   cases	  were	  not	  further	  specified	  due	  to	  inconclusive	  IHC	  profile.	  In	  a	  study	  analyzing	  gene	  expression	  in	  LCCs,	  SQ	  lineage	  was	  correlated	  with	  high	  expression	  of	  thymidylate	  synthase,	  the	  enzyme	  that	  is	  associated	  with	  reduced	  sensitivity	  to	  pemetrexed.133	  Thus,	   marker-­‐based	   classification	   of	   LCC	   might	   be	   useful	   to	   select	   patients	   for	  approved	   therapies.	   LCC	   tumors	   were	   reassigned	   to	   other	   subtypes	   with	   high	  concordance	   of	   signature	   alterations.	  Mutations	   in	  KRAS	  or	   STK11	  were	   found	   in	  LCCs	   that	  were	   reassigned	   to	  AD,	  and	  mutations	   in	  DDR2	  and	  NFE2L2	  as	  well	   as	  amplification	   of	   FGFR1	  were	   found	   in	   cases	   that	   were	   reclassified	   as	   SQ	   (Figure	  21)99,134.	   In	   total,	   one	   third	  of	   LCC	   cases	   that	  were	   reassigned	   to	   either	  AD	  or	   SQ	  based	   on	   immunohistochemistry	   (potential)	   therapeutically	   relevant	   alterations	  could	  be	  identified	  (Figure	  17).	  Furthermore,	  in	  almost	  half	  of	  the	  LCC	  cases	  where	  immunohistochemistry	   was	   not	   available	   (for	   example	   due	   to	   insufficient	   tumor	  tissue)	   genetic	   alterations	   were	   identified	   that	   might	   be	   useful	   for	   patient	  stratification	   into	   clinically	   relevant	   subgroups,	   such	   as	  mutations	   in	  BRAF,	  EGFR	  and	   PIK3CA	   as	   well	   as	   amplifications	   of	   ERBB2	   and	   SOX2.	   In	   cases	   where	  immunohistochemical	   profiles	   revealed	   inconclusive	   results	   and	   thus	   diagnosis	  remained	  to	  be	  LCC,	  subtype	  specific	  genetic	  alterations	  were	  identified	  in	  most	  of	  these	  cases.	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LCCs	  with	  neuroendocrine	  differentiation	  were	   found	  to	  be	  genetically	  and	  clinicopathologically	   different	   from	   other	   LCCs.	   Instead	   these	   tumors	   share	  characteristics	  with	  those	  of	  the	  SCLC	  subtype.	  Retrospective	  studies	  show	  that	  the	  response	   rates	   of	   LCNEC	   to	   cisplatin-­‐based	   chemotherapeutic	   regimes	   are	  comparable	   to	   SCLC135-­‐137	   underlining	   biological	   similarities	   of	   both	   lung	   cancer	  subtypes.	  Sun	  et	  al	  described	  in	  2009	  that	   immunohistochemical	  staining	  of	  three	  neuroendocrine	   markers	   (CD56,	   Synaptophysin,	   Chromogranin	   A)	   was	   not	  signiﬁcantly	   different	   between	   LCNEC	   and	   SCLC	   but	   these	   results	   remain	  controversial.129,130,138,139	   In	   our	   study	   statistical	   similarity	   was	   observed	   for	   the	  typical	   immunomarkers	   except	   CD56	   (Appendix,	  Figure	  31).	  Furthermore	   typical	  alterations	   found	   in	   AD	   or	   SQ	   such	   as	  mutations	   in	  KRAS	   and	  NFE2L2	  were	   also	  found	   in	   rare	   LCNEC	   cases	   but	   not	   in	   SCLC.	   Nonetheless	   striking	   similarities	  between	   LCNEC	   and	   SCLC	  were	   observed	   on	   the	   genomic	   and	  on	   the	   expression	  level.	  RB1	  and	  TP53	  were	   found	   significantly	   altered	   in	   SCLC81	   and	   LCNEC	  when	  compared	   to	   AD114	   and	   SQ115.	   Also,	   LCNEC	   and	   SCLC	   showed	   the	   highest	  concordance	   with	   regard	   to	   significantly	   amplified	   and	   deleted	   regions	   in	  comparison	  to	  all	  the	  other	  lung	  cancer	  subtypes	  (Figure	  20,	  Figure	  21).	  Survival	  of	  LCNEC	  patients	  was	   comparable	  with	   SCLC	  but	   not	  with	   other	   LCC	   cases	   (Figure	  22).	  	   Overall,	  LCCs	   seem	   to	  be	  undifferentiated	   forms	  of	   other	   subtypes	  and	   thus	  might	  benefit	  from	  therapy	  options	  already	  approved	  for	  AD	  or	  SQ.	  LCNEC	  showed	  more	   similarities	   on	   genomic	   and	   expression	   level	   with	   other	   neuroendocrine	  tumors	  in	  particular	  with	  SCLC	  and	  should	  therefore	  be	  separated	  from	  other	  LCC	  in	  the	  WHO	  classification.	  Of	  cases	  initially	  diagnosed	  as	  LCC	  less	  than	  1%	  remained	  LCC	   in	   our	   setting	   after	   immunohistochemical	   and	   genetic	   re-­‐assignment.	   Our	  findings	   suggest	   that	   patients	   with	   LCC	   should	   also	   be	   included	   for	   routinely	  molecular	   testing	   to	   identify	   patients	   that	   are	   eligible	   for	   targeted	   therapies.	  Immunophenotyping	   might	   be	   a	   useful	   diagnostic	   approach	   to	   further	   classify	  tumors	  where	  no	  clinically	  relevant	  alteration	  is	  identified.	  Clinical	  relevance	  of	  the	  stratification	   into	  genetically	  or	   immunohistochemically	  defined	   subgroups	  needs	  to	   be	   investigated	   in	   a	   prospective	   patient	   cohort	  where	  AD-­‐like	   and	   SQ-­‐like	   LCC	  cases	  receive	  treatment	  accordingly.	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1.3. A	  comprehensive	  profile	  of	  alterations	  in	  cellular	  signaling	  pathways	  is	  
required	  for	  optimal	  treatment	  strategies	  In	  tumor	  cells	  the	  complexity	  and	  redundancy	  of	  signaling	  pathways	  involved	  in	  cell	  proliferation	   and	   survival	   complicate	   successful	   inhibition	   of	   either	   of	   the	  pathways.140	  Initial	  responses	  to	  single-­‐agent	  therapeutics	  can	  be	  spectacular,	  as	  for	  example	  shown	  for	  the	  use	  of	  erlotinib	  in	  EGFR-­‐mutant	  lung	  tumors,	  but	  all	  tumors	  reappear	  within	  few	  months	  and	  typically	  they	  are	  resistant	  to	  the	  initially	  applied	  regimen.141	   Several	   resistance	  mechanisms	   have	   been	   described	   for	  most	   cancer	  types;	   typically	   the	   signaling	   pathway	   that	   is	   specifically	   targeted	   can	   be	  re-­‐activated	   through	   signaling	   of	   bypass	   effectors	   or	   acquired	   resistance	   of	   the	  target	   protein	   to	   the	   inhibitor	   (e.g.,	   acquired	  mutation	   in	   the	   binding	   site	   of	   the	  crizotinib	   in	  ALK	  rearranged	   tumors142),	   or	   alternative	   signaling	  pathways	   can	  be	  activated.	  For	  example,	  tumor	  cells	  with	  deregulated	  FGFR	  exhibit	  activation	  of	  the	  PI3K-­‐AKT	   pathway	   and	   also	   the	   RAS-­‐RAF-­‐MAPK	   pathway.	   These	   tumors	   develop	  some	  degree	  of	  addiction	  to	  signaling	  through	  the	  downstream	  component	  ERK	  and	  become	   sensitive	   to	   ERK	   signaling	   inhibitors.143	   In	   order	   to	   overcome	   signaling	  through	  the	  PI3K-­‐AKT	  pathway,	  inactivation	  of	  the	  upstream	  driver	  oncoprotein	  (in	  this	   case	   FGFR)	   or	   simultaneous	   inhibition	   of	   the	   PI3K-­‐AKT-­‐mTOR	   and	   the	  RAS-­‐RAF-­‐MEK-­‐ERK	  pathway	  might	  be	  more	  effective.144	  Also	  tumors	  with	  alterations	  in	  FGFR	  frequently	  had	  additional	  alterations	  in	  other	   oncogenes:	  PIK3CA	  or	  HRAS	  mutations	  were	   found	   in	  FGFR2-­‐mutant	   cases,	  
PIK3CA	   or	   DDR2	   mutations	   in	   FGFR3-­‐mutant	   cases,	   and	   KRAS	   mutations	   were	  identified	   in	   tumors	   that	  had	  FGFR1	  amplified.	   In	  cell	   line	  models	  KRAS	  predicted	  insensitivity	   to	   BGJ398	   in	   FGFR1-­‐amplified	   cases.105	   Thus,	   tumors	   that	   harbor	  additional	   oncogenic	   alterations	  might	   be	   insensitive	   to	   FGFR	   inhibition	   through	  bypass	  activation	  of	  downstream	  components	   in	  signaling	  pathways.105	  Therefore,	  combinatory	  inhibition	  of	  FGFR	  and	  PI3K	  in	  case	  of	  additional	  mutations	  in	  PIK3CA	  or	   PTEN,	   or	   combinatory	   inhibition	   of	   FGFR	   and	   MEK	   in	   case	   of	   additional	  alterations	  in	  components	  of	  the	  RAS-­‐RAF-­‐MAPK	  pathway	  might	  be	  effective.	  	  Furthermore,	   in	  this	  study	   lung	  tumors	  have	  been	   identified	   that	  harbored	  co-­‐occurring	  oncogenic	   alterations	  affecting	   signaling	  molecules	   in	   the	   same	  or	   a	  different	   signaling	   pathway	   that	   might	   cause	   resistance	   to	   targeted	   therapies.	   In	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contrast	   to	   the	   confirmed	  mutually	   exclusivity	   of	  BRAF	  with	  KRAS,103,145,146	   cases	  with	   alterations	   in	   both	   genes	   were	   found	   in	   our	   sample	   set.	   In	   such	   cases	  inhibiting	  BRAF	  may	  lead	  to	  the	  activation	  of	  other	  members	  of	  the	  RAF	  family	  in	  a	  RAS-­‐dependent	  manner	   that	  mediate	   transduction	  of	   cellular	   signals	   to	   ERK	   and	  thus	  lead	  to	  the	  activation	  of	  the	  MEK-­‐ERK	  pathway.147	  Instead,	  inhibition	  of	  all	  RAF	  molecules	  using	  a	  pan-­‐RAF	  inhibitor	  or	  inhibition	  of	  MEK,	  downstream	  of	  RAS/RAF	  might	  be	  successful	  therapy	  options	  in	  double	  mutant	  cases.	  	  These	   findings	   underline	   the	   importance	   of	   simultaneously	   genotyping	   all	  clinically	   relevant	   genes,	   instead	   of	   testing	   single	   genes,	  because	   complex	   results	  might	  necessitate	  advanced	  treatment	  strategies.	  	  	  	  
2. Genetically	  informed	  diagnosis	  of	  lung	  tumors	  becomes	  pivotal	  Lung	  cancer	  is	  one	  of	  the	  genomically	  most	  diverse	  of	  all	  cancers.	  On	  the	  one	  hand	  this	  complicates	  treatment	  strategies,	  on	  the	  other	  hand	  offers	  many	  opportunities	  to	   classify	   patients	   into	   genetically	   defined	   subclasses	   for	   targeted	   therapies.	  Making	   treatment	   decisions	   based	   on	   genomic	   alterations	   is	   relatively	   new	   but	  became	   standard	   of	   care	   in	   advanced-­‐stage	   lung	   AD	   in	   case	   of	   activating	   EGFR	  mutations	   and	   ALK	   rearrangements.63	   Several	   new	   molecular	   targets	   were	  identified	   within	   the	   past	   few	   years	   in	   AD,	   SQ	   and	   SCLC.63,65,148	   In	   this	   study	  approximately	  70%	  of	  AD,	  50%	  of	  SQ	  and	  20%	  of	  SCLC	  cases	  could	  be	  assigned	  to	  genetically	  defined	  subgroups;	  most	  of	  which	  had	  important	  implications	  in	  current	  clinical	  settings.	  The	  clinical	  significance	  of	  re-­‐assignments	  from	  histomorphologic	  AD	  or	  SQ	  to	  other	  subtypes	  according	  to	  their	  genetic	  make-­‐up	  needs	  to	  be	  assessed	  in	   a	   prospective	   study	   where	   treatment	   decisions	   are	   based	   solely	   on	   genetics	  instead	  of	  morphology.	  In	  cases	  with	  multiple	  alterations	  that	  predict	  for	  different	  histological	   subtypes,	   individual	   assessment	   by	   the	   treating	   physician	   would	   be	  required.	  Here,	  immunohistochemistry	  could	  add	  further	  information.	  Especially	  in	  cases	  with	   controversial	   results,	   treatment	   decisions	  will	   strongly	   depend	   on	   the	  updated	  knowledge	  of	  the	  physician	  on	  current	  treatment	  options.	  Successful	   translation	  of	  molecular	  screening	   into	  clinical	  routine	  has	  been	  demonstrated	   in	   a	   collaboration	  of	   the	  Center	   for	   Integrated	  Oncology	   (CIO),	   the	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joint	  comprehensive	  cancer	  center	  of	  the	  University	  Hospitals	  of	  Cologne	  and	  Bonn	  in	   North	   Rhine	   Westphalia.	   This	   network	   has	   been	   initiated	   in	   2010	   to	   offer	  molecular	  diagnostics	   to	   lung	  cancer	  patients	   in	   the	  catchment	  area	  of	   the	  cancer	  center.	   Based	   on	   alterations	   identified	   in	   the	   CLCGP	   a	   screening	   strategy	   was	  devised	  for	  centralized	  genotyping.	  Advanced	  stage	  AD	  tumors	  were	  analyzed	  in	  a	  single	   gene-­‐based	   and	   consecutive	   approach	   first	   testing	   for	   alterations	   in	  BRAF,	  
KRAS	  and	  PIK3CA.	  If	  these	  genes	  were	  found	  to	  be	  wild	  type	  then	  EGFR	  and	  ERBB2	  were	  tested	  and	   if	   these	  were	  wild	   type	  as	  well,	  ALK	  was	  tested	   for	  chromosomal	  rearrangements.	   Advanced	   stage	   SQ	   tumors	   were	   tested	   simultaneously	   for	  alterations	   in	  DDR2	  and	  FGFR1.	  To	   test	   for	  mutations	   in	  BRAF,	  DDR2,	  EGFR,	  KRAS,	  and	   PIK3CA	   conventional	   technics	   such	   as	   the	   high	   resolution	   melting	   curve	  approach	  or	  Sanger	   sequencing	  were	  used.	  Genome	  copy	  number	  alterations	  and	  chromosomal	  rearrangements	  in	  ALK,	  ERBB2	  and	  FGFR	  were	  analyzed	  using	  FISH.	  Overall	  70%	  of	  new	  cases	  were	   genotyped	  accordingly	   and	   in	   almost	  40%	  of	   the	  cases	   alterations	   in	   at	   least	   one	   of	   the	   genes	   has	   been	   identified.	   Treatment	  recommendations	   were	   given	   to	   the	   treating	   physicians	   and	   patients	   received	  targeted	   therapeutics,	   if	   applicable.	   EGFR-­‐mutant	   lung	   tumor	   patients	   routinely	  received	   approved	   EGFR	   inhibitors,	   whereas	   patients	   with	   ALK	   rearrangements	  were	   enrolled	   in	   clinical	   trials	   (www.lungcancergroup.de)	   before	   crizotinib	   was	  approved	   in	   summer	   2012	   for	   the	   European	   market	   for	   advanced	   lung	   AD.	  Treatment	  with	  targeted	  therapeutics	  significantly	  increased	  overall	  survival	  when	  compared	  to	  standard	  chemotherapy	  (EGFR-­‐mutant	  AD:	  median	  OS	  of	  31.5	  vs.	  9.6	  months,	   p	  <	  0.001;	   ALK-­‐rearranged	   AD:	   median	   OS	   of	   23	   vs.	   11	   months,	   p	   =	  0.024).95	  Here	   the	   feasibility	   and	   significance	   of	  molecular	   diagnostics	   in	   clinical	  routine	  has	  been	  impressively	  shown.	  Major	  limitation	  in	  this	  setting	  were	  first,	  the	  consecutive	   approach	   of	   genotyping	   for	   alterations	   in	   several	  genes,	  which	   could	  take	  up	  to	  one	  month	  for	  completion	  and	  second,	  the	  selection	  of	  tumors	  for	  genetic	  testing	  based	  on	  histology.	  A	  multiplex	  approach	  would	  minimize	   labor	  costs	  and	  time	  until	  results	  are	  available.	  It	  would	  also	  require	  less	  tumor	  material	  and	  would	  leave	   enough	   tissue	   for	   immunohistochemistry	   to	   provide	   a	   complete	   profile	   for	  diagnosis.	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  Discovery	  of	  new	  targetable	  drivers	  seems	  to	  have	  reached	  a	  plateau,	  because	  only	  small	   numbers	   of	   cases	   harboring	   new	   oncogenic	   alterations	   are	   identified	   in	  current	   genomic	   studies.65,141	   Previous	   screening	   efforts	   mainly	   focused	   on	  analyzing	  coding	  regions.	  Since	  not	  in	  all	  tumors	  alterations	  were	  identified,	  it	  can	  be	   assumed	   that	   the	   spectrum	   of	   alterations	   that	   are	   associated	   with	   malignant	  phenotypes	  will	   increase.	  It	   is	   likely	  that	  alterations	  affecting	  non-­‐coding	  genomic	  regions	  and	  regulatory	  elements,	  such	  as	  promoters,	  enhancers	  and	  silencers,	  play	  an	   important	   role	   in	   tumorigenesis.	  Since	  Hanahan	   and	  Weinberg	   first	  published	  the	  Hallmarks	  of	  Cancer	  in	  2000	  a	  more	  complex	  picture	  of	  cancer	  biology	  emerged	  where	   tumor	  microenvironment	   and	   immune	   system	  were	   found	   to	   play	   critical	  roles	   in	   tumorigenesis.22	   Also	   the	   role	   of	   DNA	   methylation	   in	   transcriptional	  regulation	   is	   currently	   investigated.	   Cancer	   is	   much	   more	   complex	   than	   initially	  thought.	   The	   straightforward	   inhibition	   of	   oncogenic	   drivers	   inevitable	   leads	   to	  recurrence	   of	   the	   tumor	   and	   resistance	   in	   almost	   all	   cases.141	   Several	   resistance	  mechanisms	   –	   pre-­‐existing	   in	   a	   minor	   tumor	   cell	   population	   or	   acquired	   -­‐	   have	  already	  been	  identified	  and	  second	  generation	  drugs	  are	  designed	  with	  the	  aim	  to	  avoid	  or	  overcome	  such	  resistances.149,150	  Many	  clinical	   trials	  are	  already	  initiated	  to	  evaluate	  which	  single	  and	  combined	  agents	   in	  selected	  patient	  groups	  have	  the	  highest	   potential	   and	   should	   be	   further	   investigated.74	  Many	  more	   strategies	   to	  specifically	  inhibit	  tumor	  drivers	  and	  critical	  pathways	  will	  probably	  be	  found.	  With	  this	  vision	  in	  mind,	  it	  is	  now	  time	  to	  adapt	  traditional	  diagnostic	  and	  more	  general	  treatment	  strategies	  to	  tumor-­‐specific	  and	  thus	  individualized	  molecular	  diagnostic	  and	  treatment.	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1. Workflow	  	  An	   overview	   of	   the	   project	   experimental	   workflow	   is	   given	   in	   Figure	   28.	   Fresh	  frozen	  lung	  tumor	  samples	  were	  pathologically	  reviewed	  regarding	  tumor	  content	  and	   tissue	   quality.	   If	   suitable,	   DNA	   and	   RNA	   were	   extracted	   for	   mutation,	   copy	  number	  and	  gene	  expression	  analysis.	  Tumor	  samples	  embedded	  in	  paraffin	  were	  processed	   for	   detection	   of	   rearrangements	   in	   ALK,	   RET	   and	   ROS1	   using	  fluorescence	   in	  situ	  hybridization.	  Further,	   two	   lung	   cancer	  pathologists	   reviewed	  cases	  histomorphological	  and	  immunohistochemical.	  	  
	  Figure	  28	  The	  experimental	  workflow	  of	  the	  CLCGP.	  	  	  	  
2. Source	  of	  patient	  material	  and	  cell	  lines	  Tissue	   from	   resected	   primary	   lung	   tumors	   of	   all	   histologies	   and	   stages	   was	  provided	  by	  multiple	  institutions	  (Lung	  Cancer	  Group	  Cologne,	  Cologne,	  Merheim;	  Jena	   University	   Hospital,	   Friedrich-­‐Schiller-­‐University,	   Jena,	   Germany;	  Thoraxklinik-­‐Heidelberg	   gGmbH,	   Heidelberg,	   Germany;	   VU	   University	   Medical	  Center	   Amsterdam,	   Amsterdam,	   The	   Netherland;	   University	   Medical	   Centre	  Groningen,	  Groningen,	  The	  Netherlands;	  Department	  of	  Medicine,	  Institute	  Gustave	  Roussy,	   Villejuif,	   France;	   Université	   Joseph	   Fourier,	   Grenoble,	   France;	   University	  Hospital	   Zürich,	   Zürich,	   Switzerland;	   The	   University	   of	   Liverpool,	   Liverpool,	   UK;	  Norwegian	  Radium	  Hospital,	  Oslo,	  Norway;	  University	  Hospital	  Bologna,	  Bologna,	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Italy;	  Istituto	  di	  Ricovero	  e	  Cura	  a	  Carattere	  Scientifico	  (IRCCS)	  Casa	  Sollievo	  della	  Sofferenza,	   San	   Giovanni	   Rotondo,	   Italy	   and	   St	   Vincent’s	  Hospital	   &	   The	   Peter	  MacCallum	   Cancer	   Center,	   Melbourne,	   Australia)	   in	   form	   of	   fresh	   frozen	   biopsy	  samples,	   frozen	   sections	   or	   extracted	   genomic	   DNA	   depending	   on	   the	   individual	  institutional	   review	   board	   approval	   decisions.	   Tissue	   was	   snap-­‐frozen	   within	  30	  min	  post	  surgery	  and	  stored	  at	   -­‐80°C.	  For	  autopsy	  cases,	   tumors	  were	  derived	  within	   a	   few	   hours	   after	   death.	   Cases	   were	   staged	   according	   the	   TNM	   system	  version	  6.	  	  Normal	   HapMap	   cell	   lines	   were	   purchased	   from	   the	   Coriell	   Institute	  (GM12144C,	   GM18504B,	   GM18508B,	   GM18517C,	   GM18857B,	   GM18863B,	  GM18870B,	   GM18871B,	   GM18912B,	   GM19099B,	   GM19137B,	   GM19142B,	  GM19143B,	  GM19153B,	  GM19194B).	  	  NIH3T3	  and	  HEK293T	  cells	  were	  purchased	  from	  ATCC,	  Ba/F3	  cells	  were	  a	  kind	  gift	  from	  Nikolas	  von	  Bubnoff.	  	  	  
3. Pathology	  review	  	  1,860	   primary	   lung	   tumors	  were	   submitted	   for	   the	   CLCGP.	   If	   paraffin	   embedded	  tumor	   material	   was	   available	   hematoxylin	   and	   eosin-­‐stained	   sections	   were	  histomorphologically	   reviewed	   by	   a	   team	   of	   expert	   lung	   cancer	   pathologists	  (Elisabeth	  Brambilla,	  CHU	  Albert	  Michallon	  and	  William	  D.	  Travis,	  Memorial	  Sloan	  Kettering	  Cancer	  Center	  (MSKCC))	  to	  confirm	  the	  initial	  diagnosis	  or	  reclassify	  the	  tumor.	   Immunohistochemical	   staining	   for	   TTF-­‐1,	   CK7,	   p63,	   CK5/6,	   CD56,	  Synaptophysin,	  and	  Chromogranin	  A	  was	  utilized	   to	  reclassify	  cases	  where	  a	   final	  diagnosis	   based	   on	   morphology	   alone	   was	   not	   possible.	   FFPE	   sections	   were	  mounted	  on	  X-­‐tra®	  slides	  (Leica)	  and	  routinely	  stained	  using	  the	  following	  clones:	  8G7G3/1	   (TTF-­‐1),	   4A4	   (p63),	   D5&16B4	   (CK5/6),	   OV-­‐TL	   12/30	   (CK7),	   N-­‐CAM	  (CD56),	   polyclonal	   (Synaptophysin),	   DAK-­‐A3	   (Chromogranin	   A)	   in	   the	   pathology	  department	  of	   the	  University	  Hospital	   of	   Cologne.	   Stained	   sections	  were	   scanned	  using	   the	   Pannoramic	   250	   Flash	   (3DHistech,	   Hungary)	   and	   reviewed	   using	   the	  Pannoramic	  Viewer.	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4. Sample	  inclusion	  criteria	  From	   1,438	   out	   of	   1,860	   collected	   tumor	   specimens	   histologic	   sections	   were	  obtained	   and	   reviewed	   by	   a	   board-­‐certified	   pathologist	   (Prof.	   Sven	   Perner,	  Pathology	  of	  the	  University	  of	  Bonn,	  Germany)	  to	  identify	  areas	  with	  high	  content	  of	  tumor	  nuclei.	  1,320	  lung	  tumor	  cases	  had	  a	  confirmed	  minimum	  of	  70%	  tumor	  cell	  nuclei	  in	  sufficient	  quantity	  for	  further	  analysis.	  	  	   In	  total	  1,255	  samples	  were	  morphologically	  confirmed	  as	  lung	  tumors,	  with	  a	  minimum	  of	  70%	  tumor	  cell	  nuclei,	  with	  less	  then	  10%	  necrosis	  required	  to	  meet	  further	   inclusion	   criteria	   for	   mutation,	   copy	   number	   and/	   or	   gene	   expression	  analysis	  (e.g.,	  sufficient	  DNA,	  RNA	  quantity	  and	  quality,	  affirmed	  agreement	  of	  the	  patient)	  and	  were	  therefore	  suitable	  for	  data	  analysis.	  	  	  
5. Estimation	  of	  specimen	  mix-­‐up	  frequency	  The	   ratio	   between	   the	   average	   copy	   number	   of	   X-­‐	   and	   Y-­‐chromosome	   was	  calculated.	  In	  order	  to	  predict	  the	  sex	  of	  each	  sample,	  this	  ratio	  was	  clustered	  into	  two	  partitions	  using	   the	  K-­‐means	   algorithm.	  Cases	  with	   ambiguity	  were	   adjusted	  manually.	  The	  total	  mix-­‐up	  rate	  was	  computed	  using	  𝜇 = 𝜇!, 𝑓2𝜇!𝜇!	  where	  µm	  was	   the	   fraction	  of	  male	  samples,	  µf	   the	   fraction	  of	   female	  samples	  and	  µm,f	  was	  the	  observed	  mix-­‐up	  rate	  between	  male	  and	  female	  samples.	  	  	  
6. DNA	  and	  RNA	  procedures	  Standard	   procedures	   including	   polymerase	   chain	   reaction	   (PCR),	   whole	   genome	  amplification,	  gel	  electrophoresis,	  restriction	  enzyme	  digestion,	  DNA	  ligations	  and	  bacterial	   transformations	   were	   carried	   out	   according	   to	   the	   manufacturers	  protocol.	  Preparation	  of	  plasmid	  DNA	  was	  performed	  using	  the	  NucleoSpin	  mini-­‐kit	  (Machery	  Nagel).	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DNA	  and	  RNA	  preparation	  	  If	   the	   whole	   surface	   of	   the	   frozen	   tumor	   sample	   comprised	   a	   minimum	   of	   70%	  tumor	  cells,	  15	  and	  30	  sections	  each	  20	  µm	  thick	  were	  prepared	  using	  the	  cryostat	  (Leica)	   at	   -­‐20°C	   for	   DNA	   and	   RNA	   extraction.	   Otherwise,	   tumor	   rich	   areas	   were	  punched	  using	  sterile	  disposable	  biopsy	  punches	  (1.5mm	  in	  diameter)	  not	  deeper	  than	  1.5	  mm	  into	  the	  frozen	  tissue	  to	  avoid	  lower	  layers	  that	  might	  be	  admixed	  with	  higher	  content	  of	  fibrotic,	  necrotic	  or	  other	  non-­‐tumor	  cells.	  Punched	  material	  was	  used	   for	   DNA	   extraction	   only,	   whereas	   sections	   were	   used	   for	   DNA	   and	   RNA	  extraction.	  HapMap	  normal	  cell	  lines	  were	  cultured	  at	  37°C	  in	  RPMI	  1640	  medium	  supplemented	  with	  10%	  fetal	  calf	  serum.	  For	  harvesting	  the	  cells	  were	  washed	  two	  times	  in	  phosphate-­‐buffered	  saline	  and	  2x107	  cells	  collected	  for	  DNA	  extraction.	  DNA	  was	  extracted	  using	  Puregene	  Extraction	  Kit	   (Qiagen,	  Germany).	  DNA	  was	  eluted	  in	  75	  µl	  1xTE	  buffer	  (pH	  8.0).	  Sections	  prepared	  for	  RNA	  extraction	  were	  disrupted	   and	   homogenized	   for	   2	  min	   at	   20	  Hz	   with	   the	   Tissue	   Lyser	   (Qiagen,	  Germany)	  and	  centrifuged	  for	  3	  min	  at	  maximum	  speed.	  RNA	  was	  extracted	  using	  Qiagen	  RNeasy	  Mini	  Kit	  (Qiagen,	  Germany).	  	  	  
Quality	  and	  quantity	  control	  of	  DNA	  and	  RNA	  	  High	  molecular	  weight	  of	  genomic	  DNA	  (>10kb)	  was	  confirmed	  by	  electrophoresis	  using	  a	  0.7%	  agarose	  gel.	  DNA	  concentration	  was	  measured	  in	  1	  µl	  of	  the	  molecular	  analyte	   using	   the	   Quant-­‐iT™	   Picogreen®	   Assay	   (Invitrogen)	   and	   fluorescence	  emission	   intensity	  measured	  at	  520	  nm	  using	  a	  multimode	  reader	  Mithras	  LB940	  (Berthold	   Technologies).	   DNA	   was	   further	   diluted	   in	   1xTE	   buffer	   (pH	   8.0)	   to	   a	  concentration	  between	  75	  and	  150	  ng/µl.	  If	  DNA	  concentration	  was	  below	  75	  ng/µl	  precipitation	  was	  performed	  as	  recommended	  (Puregene	  Extraction	  Kit,	  Qiagen).	  	   RNA	   quality	   was	   assessed	   using	   the	   Bioanalyzer	   2100	   DNA	   Chip	   7500	  (Agilent)	  and	  samples	  with	  a	  RIN>8	  were	  processed	   for	  gene	  expression	  analysis.	  RNA	  and	  DNA	  stocks	  were	  stored	  at	  -­‐80°C.	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Phi29-­‐based	  whole	  genome	  amplification	  (WGA)	  Genomic	  DNA	  (100	  ng)	  was	  amplified	  using	  the	  Repli-­‐g	  Midi	  Kit	  (Qiagen).	  Amplified	  DNA	   was	   diluted	   1:10	   in	   1xTE	   buffer	   (pH	   8.0)	   and	   hydrated	   for	   24	  h	   at	   room	  temperature	  and	  further	  diluted	  to	  a	  working	  concentration	  of	  5	  ng/µl	  in	  water.	  	  	  	  
7. Mutation	  detection	  and	  validation	  
Mutation	  detection	  Mutations	   were	   detected	   in	   whole	   genome-­‐amplified	   DNA	   using	   a	   mass	  spectrometry-­‐based	  single	  base	  extension	  technique	  (Sequenom,	  Inc.)	  as	  described	  previously18.	   Primer	   sequences	   of	   detection	   assays	  were	   applied	   from	  Thomas	   et	  al18.	   Additional	   assays	   detecting	   mutations	   that	   were	   described	   as	   somatic	   in	  several	  cancer	  studies	  from	  2008	  to	  201016,83,106	  (Table	  3)	  were	  designed	  using	  the	  Sequenom	   Assay	   Design	   Software	   leading	   to	   a	   set	   of	   327	  mutations	   in	   26	   genes	  (primer	   sequences	   for	   new	   assays	   are	   not	   provided	   here,	   since	   table	   extended	  reasonable	   size).	   Primers	   were	   purchased	   from	   Integrated	   DNA	   Technologies	  (Belgium).	  Following	  target	  site	  amplification,	  phosphatase	  treatment	  and	  mutation	  site	  specific	  probe	  elongation	  analytes	  were	  spotted	  on	  SpectroCHIPs	  I	  and	  masses	  detected	  using	  a	  Bruker	  matrix-­‐assisted	  laser	  desorption/ionization–time	  of	  flight	  mass	  spectrometer	  (Sequenom).	  Mass	  signals	  of	  mutant	  and	  wild	  type	  alleles	  were	  analyzed	  using	  the	  Typer4.0	  software	  (Sequenom).	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Table	   3	   Mutation	   sites	   by	   which	   the	   Oncomap	   panel18	   for	   mass	   spectrometry-­‐based	  mutation	  detection	  has	  been	  extended.	  	  
	  	   In	   addition,	   selected	   exons	   in	  BRAF	  (exons	   11	   and	  15),	  EGFR	   (exons	   18	   to	  21),	  ERBB2	  (exons	  19	  and	  20),	  FGFR2	  (exons	  3,	  5,	  6,	  7,	  8,	  10,	  11,	  12,	  13,	  14,	  15,	  16,	  and	  17),	  KRAS	  (exons	  2	  and	  3),	  KEAP1	  (exons	  3	  to	  6),	  NFE2L2	  (exon	  2),	  PIK3CA	  (10	  and	   21),	   STK11	   (exons	   1	   to	   10),	   and	   TP53	   (exons	   5	   to	   9)	   were	   analyzed	   using	  bidirectional	  Sanger	  sequencing	   (Beckman	  Coulter	  Genomics,	  USA).	  Primers	  were	  
Gene Protein_change Nucleotide_change Gene Protein_change Nucleotide_changeALK p.A1234T c.3700G>A FGFR2 p.G272V c.815G>TALK p.D1091N c.3271G>A FGFR2 p.H544Q c.1632C>AALK p.F1174I c.3520T>A FGFR2 p.N211I c.632A>TALK p.F1174L c.3522C>A FGFR2 p.N211I c.632A>TALK p.F1174V c.3520T>G FGFR2 p.N549K c.1647T>AALK p.F1245C c.3734T>G FGFR2 p.P253R c.758C>GALK p.F1245V c.3733T>G FGFR2 p.Q212K c.634C>AALK p.I1171N c.3512T>A FGFR2 p.R203C c.607C>TALK p.I1250T c.3749T>C FGFR2 p.R496T c.1487G>CALK p.M1166R c.3497T>G FGFR2 p.S252W c.755C>GALK p.R1275Q c.3824G>A FGFR2 p.W290C c.870G>CALK p.V1135E c.3404T>A FGFR2 p.W290C c.870G>CDDR2 p.C580Y c.1739G>A FGFR2 p.Y375C c.1124A>GDDR2 p.G253C c.757G>T FGFR3 p.T79S c.235A>TDDR2 p.G505A c.1514G>C FGFR4 p.A729G c.2186C>GDDR2 p.G774E c.2321G>A FGFR4 p.E681K c.2041G>ADDR2 p.I120M c.360C>G FGFR4 p.H192fs c.576delTDDR2 p.I638F c.1912A>T FGFR4 p.P672T c.2014C>ADDR2 p.L239R c.716T>A FGFR4 p.R183S c.547C>ADDR2 p.L63V c.187C>G FGFR4 p.R411fs c.1230_1240delCCGCTTCCCTCDDR2 p.T765P c.2293A>C FGFR4 p.R616G c.1846C>GEPHA3 p.A435S c.1303G>T FGFR4 p.S732N c.2195G>AEPHA3 p.D446Y c.1336G>T FGFR4 p.V510M c.1528G>AEPHA3 p.D678E c.2034C>A KDR p.A248G c.743C>GEPHA3 p.G518L c.1552_1553GG>TT KDR p.G1145E c.3434C>TEPHA3 p.G766E c.2297G>A KDR p.G1308* c.3922C>AEPHA3 p.K761N c.2283G>T KDR p.L1140M c.3418G>TEPHA3 p.M269I c.807G>A KDR p.Q2R c.5A>GEPHA3 p.N379K c.1137T>G KDR p.S984T c.2951C>GEPHA3 p.R728L c.2183G>T KIT p.554J559delEVQWKV c.1660_1678delGAAGTACAGTGGAAGGTTEPHA3 p.S229Y c.686C>A KIT p.A829P c.2485G>CEPHA3 p.T166N c.497C>A KIT p.K558N c.1674G>CEPHA3 p.T166N c.497C>A KIT p.N495I c.1484A>TEPHA3 p.T393K c.1178C>A KIT p.N566D c.1696A>GEPHA3 p.W250R c.748T>A KIT p.N567K c.1701T>AEPHA5 p.D493Y c.1477C>A KIT p.Y823D c.2467T>GEPHA5 p.M1034I c.3102C>T NTRK1 p.A107V c.320C>TEPHA5 p.P1036A c.3106G>C NTRK1 p.D776E c.2328T>GEPHA5 p.R1007Q c.3020C>T NTRK1 p.G368C c.1102G>TEPHA5 p.S566Y c.1697G>T NTRK1 p.Q80* c.238C>TEPHA5 p.S810I c.2429C>A NTRK1 p.R119H c.356G>AERBB2 p.C334S c.1000T>A NTRK1 p.S326R c.978C>GERBB2 p.D326G c.977A>G NTRK1 p.V422L c.1264G>TERBB2 p.E321G c.962A>G NTRK3 p.H677Y c.2029C>TERBB2 p.L49H c.146T>A NTRK3 p.I783N c.2348A>TERBB2 p.M774_A775insAYVM c.2322_2322insGCATACGTGATG NTRK3 p.L152I c.454G>TERBB2 p.N319D c.955A>G NTRK3 p.L270M c.808G>TERBB2 p.S310F c.929C>T NTRK3 p.R678Q c.2033G>AERBB2 p.T216S c.646A>T NTRK3 p.R721F c.2161_2162CG>TTERBB2 p.T216S c.646A>T NTRK3 p.T283K c.848G>TERBB2 p.V750E c.2249T>A PDGFR p.A210V c.629C>TERBB2 p.W906* c.2718G>A PDGFR p.A210V c.629C>TERBB2 p.W906* c.2718G>A PDGFR p.D480E c.1440C>GERBB4 p.D931Y c.2791C>A PDGFR p.E338Q c.1012G>CERBB4 p.H618P c.1853T>G PDGFR p.L580M c.1738C>AERBB4 p.V348L c.1042G>T PDGFR p.M133K c.398T>AERBB4 p.Y285C c.854T>C PDGFR p.V193I c.577G>AFGFR1 p.V664L c.1990G>T PDGFR p.W549* c.1647G>AFGFR2 p.C382R c.1144T>C PIK3CA p.M1043V c.3127A>GFGFR2 p.D283N c.847G>A
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designed	  by	  Beckman	   Coulter	   (primer	   sequences	   listed	   in	   Table	  4).	   Either	   1,141	  WGA	   samples	   (EGFR,	   KRAS,	   STK11,	   TP53)	   or	   844	   WGA	   samples	   (BRAF,	   ERBB2,	  
FGFR2,	   KEAP1,	  NFE2L2,	   PIK3CA)	   were	   sent	   for	   analysis.	   Sequencing	   results	   were	  manually	  revised	  using	  the	  Mutation	  Surveyor®	  v.2.61	  (Soft	  Genetics).	  	  	   Results	   of	   both	   sequencing	   methods	   (mass	   spectrometry	   and	   dideoxy	  sequencing)	  per	   gene	  were	   combined	  and	  a	   tumor	   sample	  was	   considered	   to	  be:	  mutated,	  if	  a	  mutation	  was	  detected	  by	  mass	  spectrometry	  or	  dideoxy	  sequencing;	  wild	   type,	   if	  at	   least	  one	  method	  covered	  all	  mutation	  sites	  given	   in	   the	  Oncomap	  panel	  v.1x	  but	  no	  mutation	  was	  called	  by	  neither	  of	  these	  two	  methods;	  failed,	  if	  no	  mutation	  was	  called	  by	  neither	  of	  these	  two	  methods	  and	  coverage	  of	  the	  analyzed	  region	  was	  incomplete	  for	  both	  methods.	  	  	  Table	  4	  Primers	  used	   for	  sequencing	  specific	  exons	   in	  BRAF,	  EGFR,	  ERBB2,	  FGFR2,	  KEAP1,	  
NFE2L2,	  PIK3CA,	  STK11,	  and	  TP53.	  
Gene	   Exon	   Primer	  Sequence_forward	   Primer	  Sequence_reverse	  BRAF	   11	   GTAAAACGACGGCCAGTTGTATCCCTCTCAGGCATAAGG	  	   CAGGAAACAGCTATGACCACAAAATAAAAGTTGTTAAACATATCC	  	  BRAF	   15	   GTAAAACGACGGCCAGTTTCATAATGCTTGCTCTGATAGG	  	   CAGGAAACAGCTATGACCAGTAACTCAGCAGCATCTCAGG	  	  EGFR	   18	   GTAAAACGACGGCCAGTAGGCGTACATTTGTCCTTCC	  	   CAGGAAACAGCTATGACCGCCTTTGGTCTGTGAATTGG	  EGFR	   19	   GTAAAACGACGGCCAGTCGCAGCATCATTAAATTCTGG	  	   CAGGAAACAGCTATGACCGGCCAGTGCTGTCTCTAAGG	  	  EGFR	   20	   GTAAAACGACGGCCAGTCCCTGTGCTAGGTCTTTTGC	  	   CAGGAAACAGCTATGACCTTGATGAGAGTTTCCACATGC	  	  EGFR	   21	   GTAAAACGACGGCCAGTGCTCCTGCTCTTCTTTGTCC	  	   CAGGAAACAGCTATGACCACCCAGAATGTCTGGAGAGC	  	  ERBB2	   19	   GTAAAACGACGGCCAGTGTGAAGGTGCTTGGATCTGG	  	   CAGGAAACAGCTATGACCGGAGTCATATCTCCCCAAACC	  	  ERBB2	   20	   GTAAAACGACGGCCAGTAGGGTTTCACCATGTTGTCC	  	   CAGGAAACAGCTATGACCACTCTTGACCAGCACGTTCC	  	  FGFR2	   3	   GTAAAACGACGGCCAGTCAGAGCAAGAACAGCTTCTCC	   CAGGAAACAGCTATGACCTTAATGATCGGCCTTTCTGG	  FGFR2	   5	   GTAAAACGACGGCCAGTCATGAACCATCCCTCTCTGG	   CAGGAAACAGCTATGACCTGAAAGCTTAATTCTACCTTGTAGCC	  FGFR2	   6	   GTAAAACGACGGCCAGTCCTTTCTTGCCTCCTTCAGC	   CAGGAAACAGCTATGACCCCATGAGGATCATGCAAAGC	  FGFR2	   7	   GTAAAACGACGGCCAGTAGGCTTTTCTGGCATGAGG	   CAGGAAACAGCTATGACCGAGAATCATCCTCTCTCAACTCC	  FGFR2	   8	   GTAAAACGACGGCCAGTTTTCCATGCGTTTGATTGC	   CAGGAAACAGCTATGACCTTCCAAGGCAGTTTTCTTATCC	  FGFR2	   10	   GTAAAACGACGGCCAGTTCTGGTACTGCATGGACTGG	   CAGGAAACAGCTATGACCCCTGCTGACATCATCACACC	  FGFR2	   11	   GTAAAACGACGGCCAGTACCGCACTAGCAAGGATACC	   CAGGAAACAGCTATGACCCCGAGATGCTGATTTATACCG	  FGFR2	   12	   GTAAAACGACGGCCAGTGAGGCAGTTCCCTGTGTAGG	   CAGGAAACAGCTATGACCATAAGGAGGCTGCCTTTTCC	  FGFR2	   13	   GTAAAACGACGGCCAGTAAAAATGTTTTGCTGAATTGC	   CAGGAAACAGCTATGACCGGTTTATGAGGCTGCTTTGG	  FGFR2	   14	   GTAAAACGACGGCCAGTAACATCAGCTATATTTTCTATCTGC	   CAGGAAACAGCTATGACCAGTCAAAAGAACGGGAATCG	  FGFR2	   15	   GTAAAACGACGGCCAGTTTTTATTAACGGCCCAGACC	   CAGGAAACAGCTATGACCAGCAGTTCCACCTTCTGTGC	  FGFR2	   16	   GTAAAACGACGGCCAGTGGCAGGAAAGAGCACATAGG	   CAGGAAACAGCTATGACCAAGTAATGGTTGTCGGTGTCG	  FGFR2	   17	   GTAAAACGACGGCCAGTCCCCCTAATCTAGTTGCTTGG	   CAGGAAACAGCTATGACCTTCCCACTCTCCCACATACC	  KEAP1	   3	   GTAAAACGACGGCCAGTCTGCAGAAGTGCGAGATCC	  	   CAGGAAACAGCTATGACCTCCCTGAAGACAGGAAGAGG	  	  KEAP1	   4	   GTAAAACGACGGCCAGTAAGTATTCCACGAAGGTCAGC	  	   CAGGAAACAGCTATGACCGGGGAGAGAGAGAAGCTTGG	  	  KEAP1	   5	   GTAAAACGACGGCCAGTCACAGCAATGAACACCATCC	  	   CAGGAAACAGCTATGACCAGCAAAAGCAAAAGCAGTCC	  	  KEAP1	   6	   GTAAAACGACGGCCAGTCAATCCTCCTGCCTCAGC	  	   CAGGAAACAGCTATGACCCAGGCTGTCTTGGACACTCC	  	  KRAS	   2	   GTAAAACGACGGCCAGTTTTTTCTTAAGCGTCGATGG	  	   CAGGAAACAGCTATGACCGCACAGAGAGTGAACATCATGG	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Gene	   Exon	   Primer	  Sequence_forward	   Primer	  Sequence_reverse	  KRAS	   3	   GTAAAACGACGGCCAGTTTTCAAGTCCTTTGCCCATT	  	   CAGGAAACAGCTATGACCTCTAAAAAGTTTAAAGTCTTGCTTTT	  	  NFE2L2	   2	   GTAAAACGACGGCCAGTTTTGTAATCTCCCCACTTCC	  	   CAGGAAACAGCTATGACCATCAGGAGGCTGAGGTTGG	  	  PIK3CA	   10	   GTAAAACGACGGCCAGTCCTGTCTCTGAAAATAAAGTCTTGC	  	   CAGGAAACAGCTATGACCAAGCATTTAATGTGCCAACTACC	  	  PIK3CA	   21	   GTAAAACGACGGCCAGTAAAGGGAATCAAAAGATGTTGG	  	   CAGGAAACAGCTATGACCATGCTGTTCATGGATTGTGC	  	  STK11	   1	   GTAAAACGACGGCCAGTAAGTCGGAACACAAGGAAGG	  	   CAGGAAACAGCTATGACCCCTTGCCTGAGTGAAAGTCC	  	  STK11	   2	   GTAAAACGACGGCCAGTGGCCGATGACAGACTAGAGG	  	   CAGGAAACAGCTATGACCGCAGACCGTGGCTACACC	  	  STK11	   3	   GTAAAACGACGGCCAGTCCAAGAGTCAGCCCTGTCC	   CAGGAAACAGCTATGACCCCTTCATGTCAATGAATATCAGG	  	  STK11	   4	   GTAAAACGACGGCCAGTCTGCTGGACCTAGCCTTTCC	  	   CAGGAAACAGCTATGACCAGTGTGCGTGTGGTGAGTGC	  	  STK11	   5	   GTAAAACGACGGCCAGTGCCTGGAGTACCTGCATAGC	  	   CAGGAAACAGCTATGACCCTCTGTGAAGATCCCTGACG	  	  STK11	   6	   GTAAAACGACGGCCAGTGGTGTCCTTGAGTCCACAGG	  	   CAGGAAACAGCTATGACCCCCCAACCCTACATTTCTGC	  	  STK11	   7	   GTAAAACGACGGCCAGTGTCCTGCTGCACTTCCTACG	  	   CAGGAAACAGCTATGACCCTCACTCAGACCCCAGTTCG	  	  STK11	   8	   GTAAAACGACGGCCAGTACATGGCTGAGCTTCTGTGG	  	   CAGGAAACAGCTATGACCGAGAGACGCCTGAGGAACC	  	  STK11	   9	   GTAAAACGACGGCCAGTGATACACCTGGGCCTGACC	  	   CAGGAAACAGCTATGACCACACGTAGGCCTCCATGACC	  	  STK11	   10	   GTAAAACGACGGCCAGTCCCCAGGAGTCCGGTAGC	  	   CAGGAAACAGCTATGACCATGCATGGCGGGGTCAGG	  	  TP53	   5	   GTAAAACGACGGCCAGTTGAGGTGTAGACGCCAACTCT	   CAGGAAACAGCTATGACCACACGCAAATTTCCTTCCAC	  TP53	   6	   GTAAAACGACGGCCAGTTTGCTTTATCTGTTCACTTGTGC	   CAGGAAACAGCTATGACCCACATCTCATGGGGTTATAGGG	  TP53	   7	   GTAAAACGACGGCCAGTCTGCTTGCCACAGGTCTCC	   CAGGAAACAGCTATGACCGGCTCCATCTACTCCCAACC	  TP53	   8+9	   GTAAAACGACGGCCAGTAGGCTCCAGAAAGGACAAGG	   CAGGAAACAGCTATGACCTGTCTTTGAGGCATCACTGC	  
	  
Mutation	  validation	  Putative	   mutations	   detected	   in	   WGA	   samples	   were	   validated	   in	   genomic	   DNA	  utilizing	  exon-­‐wise	  dideoxy	   sequencing.	  Primers	   spanning	   the	  mutation	   site	  were	  designed	   using	   Primer3	   v.0.4.0	   software	   (http://frodo.wi.mit.edu/primer3/)	   and	  synthesized	   by	   Eurofins	   MWG	   Operon	   (Germany).	   Sequencing	   was	   performed	   at	  the	   Cologne	   Center	   for	   Genomics	   (CCG)	   using	   standard	   dideoxy-­‐sequencing	  (BigDye®	  Terminator	  v3.1	  Cycle	  Sequencing	  Kit	  (Applied	  Biosystems))	  and	  results	  manually	  revised	  using	  the	  Mutation	  Surveyor®.	  	  Alterations	   detected	   by	   mass	   spectrometry	   were	   considered	   technically	  validated	   if	   they	  were	   detected	   in	   at	   least	   two	   independent	   analyses	   of	  which	   at	  least	   one	  was	   performed	   in	   genomic	   DNA.	   Alterations	   found	   in	   sequenced	   genes	  using	  Sanger	  sequencing	  were	  filtered	  for	  variants	  using	  dbSNP.	  For	  a	  small	  set	  of	  alterations	   that	   were	   not	   described	   as	   somatic	   in	   cancer	  (http://www.sanger.ac.uk/genetics/CGP/cosmic/),	   normal	   tissue	   was	   requested	  from	  collaborators	   and	  validation	  performed	  as	  described	   above.	  The	  majority	   of	  
TP53	  mutations	  found	  were	  not	  validated81.	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8. Fluorescence	  in	  situ	  hybridization	  	  To	  determine	  genomic	  rearrangements	  affecting	  ALK,	  RET	  or	  ROS1	  a	  subset	  of	   the	  specimens	  were	  analyzed	  using	  Fluorescence	  in	  situ	  hybridization	  (FISH).	  	  Tissue	   microarrays	   were	   constructed	   as	   previously	   described.151	   In	   brief,	  sections	   from	   formalin-­‐fixed	   paraffin-­‐embedded	   (FFPE)	   primary	   lung	   carcinoma	  samples	  were	  stained	  with	  hematoxylin	  and	  eosin	  to	  determine	  normal	  and	  tumor	  areas.	  Three	  representative	  cylindrical	  tissue	  cores	  (each	  0.6	  mm	  in	  diameter)	  per	  patient	  were	  taken	  to	  assemble	  a	  tissue	  microarray	  (TMA)	  using	  the	  semiautomatic	  Tissue	   Arrayer	   MTA‑1	   (Beecher	   Instruments,	   USA).	   Identically,	   for	   a	   subset	   of	  cases,	   benign	   tissue	   samples	   were	   included	   in	   the	   TMA	   as	   controls.	   4	   μm	   thick	  sections	   were	   cut	   from	   these	   TMA	   blocks	   and	   mounted	   onto	   positively	   charged	  glass	  slides.	  	  	  
ALK	  and	  ROS1	  FISH	  (in	   collaboration	   with	  Toni-­‐Maree	   Rogers	   and	  Ben	   Solomon,	   Peter	   MacCallum	  Cancer	   Centre,	   Melbourne,	   Australia	   and	   Hans-­‐Ulrich	   Schildhaus,	   Institute	   of	  Pathology,	  Cologne)	  In	  brief,	  TMA	  sections	  were	  de-­‐paraffinized	  (124°C	  for	  2min),	  treated	  with	  protease	  (30	   min	   at	   room	   temperature),	   washed	   in	   distilled	   water	   and	   dehydration	  performed	   in	   graded	   alcohol	   (70%,	   85%	   and	   100%).	   After	   pretreatment	   the	  sections	  were	  denatured	   in	   the	  presence	  of	  10	  µl	  probe	   for	  5	  min	  at	   appropriate	  temperature	  and	  hybridized	  at	  37°C	  over	  night.	  After	  hybridization	  sections	  were	  washed	   (2xSSC),	   counterstained	   with	   4,6-­‐Diamidino-­‐2-­‐phenylindole,	  dihydrochlorid	   (DAPI)	  and	  mounted.	  Sections	  were	  hybridized	  with	   the	  Vysis	  LSI	  ALK	   Dual	   Color	   Break	   Apart	   Rearrangement	   Probe	   (Abbott	   Molecular,	   USA)	   or	  Cytocell	   Aquarius	   ROS1	  Break	  Apart	   probe	   (Cytocell,	   UK).	   To	   determine	   the	  ALK	  and	  ROS1	  fusion	  status	  50	  tumor	  cells	  were	  counted	  per	  specimen.	  	  	   Cells	  were	  considered	  FISH-­‐positive	  if	  orange	  (ALK)	  or	  red	  (ROS1)	  and	  green	  signals	  are	  at	  least	  two	  signal	  widths	  apart	  or	  at	  least	  one	  set	  of	  orange	  and	  green	  signals	  are	  two	  or	  more	  signal	  widths	  apart	  and	  there	  was	  a	  single	  orange	  signal	  (3’	  end)	  without	  a	  corresponding	  green	  signal	  in	  addition	  to	  fused	  and/or	  split	  signals.	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A	   case	   was	   considered	   ALK	   or	   ROS1	   fusion	   positive	   if	   ≥15%	   of	   the	   tumor	   cells	  showed	  a	  positive	  signal	  pattern.	  
ALK	   fusion	   status	   was	   analyzed	   for	   additional	   70	   lung	   tumor	   samples	   as	  described	  in	  Perner	  et	  al	  2008.152	  	  
ALK	  FISH	  was	  repeated	  for	  four	  ALK-­‐rearranged	  cases	  (patient	  IDs:	  S00006,	  S00054,	   S00092,	   S01339)	   to	   identify	   EML4-­‐ALK	   fusions.	   FFPE	   sections	   were	  hybridized	   with	   the	   Zytolight®	   SPEC	   ALK/EML4	   TriCheck™	   Probe	   (ZytoVision,	  Bremerhaven,	   Germany).	   Sections	   were	   analyzed	   using	   63x	   and	   100x	   objectives	  (DM5500	   fluorescent	   microscope,	   Leica).	   In	   S00006	   and	   S00054	   EML4	   was	  confirmed	   as	   the	   fusion	   partner.	   In	   three	   additional	   cases	   (patient	   IDs:	   S01122,	  S01124,	  S01320)	  EML4	  was	   identified	  as	   the	   fusion	  partner	   in	  ALK	  positive	  cases	  using	   RNAseq	   (by	   Lynnette	   Fernandez	   Cuesta).	   EML4-­‐ALK	   fusions	   were	  confirmed	  in	  five	  out	  of	  seven	  tested	  cases.	  	  	  
RET	  FISH	  (in	  collaboration	  with	  Sven	  Perner,	  Pathology	  of	  the	  University	  of	  Bonn,	  Germany)	  In	  brief,	  RET	  FISH	  probes	  were	  denatured	  at	  73°C	  for	  5	  min	  and	  immediately	  placed	  on	  ice.	  After	  de-­‐paraffinization	  and	  protease	  treatment	  (Digest-­‐All	  III	  (1:2)	  at	  37°C	  for	   14	  min)	   sections	   were	   hybridized	   with	   the	   biotin	   labeled	   centromeric	   BAC	  clones	  CTD2105E16	  and	  the	  digoxigenin	  labeled	  telomeric	  BAC	  clone	  CTD2348B12	  (Invitrogen,	  CA,	  USA)	  overnight	  at	  37°C.	  After	  hybridization	  sections	  were	  washed	  (2xSSC)	   and	   fluorescence	   detection	  was	   carried	   out	   using	   streptavidin-­‐Alexa-­‐594	  conjugates	   (dilution	   1:200)	   and	   anti-­‐digoxigenin-­‐FITC	   (dilution	   1:200).	   Sections	  were	  counterstained	  with	  DAPI.	  Samples	  were	  analyzed	  under	  a	  63x	  oil	  immersion	  objective	   using	   a	   fluorescence	   microscope	   (Zeiss,	   Jena,	   Germany).	   At	   least	   100	  nuclei	  per	   case	   were	   evaluated.153	   No	   case	   with	   a	   RET	   rearrangement	   could	   be	  identified	  in	  the	  samples	  tested.	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9. Copy	  number	  analysis	  Copy	  number	  analysis	  was	  performed	  using	  data	  of	  1,032	  cases.	  Genomic	  DNA	  of	  tumor	  samples	  and	  HapMap	  or	  matched	  normal	  DNA	  were	  hybridized	  to	  Affymetrix	  Genome	  Wide	  Human	  SNP	  array	  6.0	  following	  manufacturers’	  instructions.	  Per	  79	  tumor	   cases	  15	  normal	   cases	  were	  analyzed	   in	   the	   same	  batch	  as	  a	   reference	   for	  following	   data	   processing.	   Raw	   signal	   intensities	   were	   processed	   as	   described	  previously82.	   Segmented	   copy	   number	   data	   were	   visualized	   in	   the	   integrated	  genome	   viewer	   (http://www.broadinstitute.org/igv/).	   SNP,	   gene	   and	   cytogenetic	  band	  locations	  are	  based	  on	  the	  hg18	  (March	  2006)	  genome	  build.	  To	  determine	  significantly	  amplified	  and	  deleted	  regions	  a	  rank-­‐sum	  based	  algorithm	   was	   applied	   as	   described	   previously.81	   To	   further	   quantify	   significant	  copy	   number	   aberrations	   an	   algorithm	   was	   implemented	   to	   identify	   samples	  altered	   in	   these	   regions.	   In	  brief,	   a	   representative	  copy	  number	  segment	   for	  each	  region	   of	   interest	   was	   selected:	   the	   segment	   of	   the	   highest	   copy	   number	   for	  amplifications	  and	  the	  lowest	  in	  case	  of	  deletions.	  Then	  the	  standard	  deviation	  from	  location-­‐representative	  copy	  numbers	  was	  calculated	  across	  all	  samples	  to	  define	  a	  region-­‐dependent	   copy	  number	   threshold	  of	  1.96	   times	  standard	  deviation	  above	  copy	  number	  two	  for	  amplifications	  and	  1.65	  times	  standard	  deviation	  below	  copy	  number	   two	   in	   case	   of	   deletions.	   To	   further	  distinguish	   between	   high-­‐level	   focal	  amplification	   events	   a	   criterion	   that	   allowed	   discrimination	   between	   focal	   and	  broad	   amplifications	  was	  defined.	  This	   criterion	   is	   based	  on	   the	  observation	   that	  segment-­‐length	   and	   copy	   number	   is	   correlated81	   and	   fitted	   an	   exponentially	  decaying	  curve	  to	  segment-­‐length	  rank	  ordered	  copy	  numbers.	  The	  segment-­‐length	  rank	  where	  the	  exponential	  reaches	  5%	  of	  its	  initial	  value	  was	  then	  taken	  as	  focality	  threshold.	   Finally,	   to	   sensitize	   the	   algorithm	   to	   impure	   samples	   (e.g.,	   due	   to	   the	  admixture	  of	  non-­‐tumor	  cells),	   the	  copy	  number	  of	  each	  region	  was	  screened	   if	   it	  was	  sticking	  out	  of	  the	  genome-­‐wide	  total	  variation	  using	  the	  same	  procedure	  and	  parameters	   as	   within	   the	   location.	   All	   samples	   that	   were	   identified	   as	   being	  amplified	  had	  to	  fulfill	  the	  focality	  criterion.	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  Figure	  29	  Examples	   for	   selection	  of	   amplified	   (EGFR,	   left)	   and	  deleted	   (RB1,	   right)	   cases.	  Each	  dot	  represents	  a	  case.	  Green	  lines	  indicate	  copy	  number	  cutoffs	  (CNc/o)	  and	  in	  case	  of	  amplifications	  also	  the	  focality	  cutoff.	  Cases	  in	  red	  are	  determined	  amplified	  or	  deleted	  by	  the	  defined	  criteria.	  	   To	  assess	  the	  purity	  and	  absolute	  copy	  numbers	  in	  a	  subset	  of	  920	  samples,	  a	   recently	  published	  algorithm	  was	   applied	   to	   the	   SNP	  6.0	  data1.	   Assessing	   these	  values	  was	  technically	  possible	  for	  696	  samples	  using	  this	  approach.	  	  To	  determine	  the	  copy	  number	  of	  specific	  genomic	  regions	  (genes	  and	  larger	  regions)	   the	   median	   copy	   number	   was	   calculated	   using	   segmented	   data.	   If	   one	  region	   comprises	  more	   than	   one	   segment,	   the	   fractions	  were	  weighed	   according	  their	  lengths	  (Figure	  20).	  	   𝐶𝑁! = (𝑙𝑒𝑛𝑔𝑡ℎ!   ×  𝐶𝑁!)! (𝑙𝑒𝑛𝑔𝑡ℎ!)! 	  The	   cutoff	   used	   to	   specify	   a	   copy	   number	   amplification	   was	   2.7	   and	   1.3	   for	   a	  deletion	  (loss)	  based	  on	  these	  calculated	  median	  copy	  numbers	  per	  gene/	  region.	  	  	  
10. Exclusivity	  of	  genomic	  alterations	  	  Significant	  associations	  between	  copy	  number	  alterations	  and	   frequently	  mutated	  genes	  across	  all	   lung	   tumors	  and	  histological	   subtypes	  were	  determined	  applying	  the	  Fisher’s	  exact	  test	  (p-­‐value	  ≤	  0.05)	  and	  the	  Benjamini	  and	  Hochberg	  algorithm	  to	  correct	  for	  multiple	  comparisons	  (q-­‐value	  ≤	  0.05).	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11. Expression	  analysis	  	  
Expression	  arrays	  Array-­‐based	   gene	   expression	   analysis	   of	   261	   tumor	   samples	   was	   performed	   on	  Illumina®	  Human	  HT-­‐12	  V3	   Expression	   BeadChips	   according	   standard	   protocols	  (Illumina).	  For	  data	  collection,	  we	  used	  Illumina	  BeadStudio	  3.1.1.0	  software.	  	  
Data	  processing	  and	  gene	  selection	  for	  hierarchical	  clustering	  To	  identify	  variable	  genes	  the	  standard	  deviation	  of	  expression	  data	  was	  calculated	  per	  gene	  across	  261	  tumor	  samples	  and	  the	  data	  normalized	  by	  standardizing	  each	  gene	  to	  the	  mean.	  Using	  the	  cutoff	  of	  2.1	  resulted	  in	  294	  genes	  (Appendix	  Table	  5)	  that	   were	   further	   used	   for	   unsupervised	   hierarchical	   clustering	   using	   the	   dCHIP	  software	   (http://biosun1.harvard.edu/complab/dchip/).	   Values	   were	   analyzed	  using	   an	   average-­‐linkage	   hierarchical	   algorithm	   that	   resulted	   in	   four	   major	  expression	  clusters.	  	  	  Table	   5	   294	   genes	   selected	   for	   hierarchical	   clustering.	   Genes	   are	   listed	   that	   show	   high	  variance	  of	  gene	  expression	  across	  261	  cases	  of	  all	  lung	  cancer	  subtypes	  that	  were	  used	  for	  unsupervised	  hierarchical	  clustering.	  
ABCC8	   CXCL6	   GNRHR	   LOC728910	   PGC	   SPANXB2	  
ADCYAP1	   CYP4F11	   GP2	   LOC730994	   PHACTR3	   SPANXC	  
ADH1A	   DCT	   GPC5	   LOR	   PHOX2B	   SPANXE	  
ADH1C	   DDC	   GRIA2	   LY6H	   PI3	   SPHKAP	  
ADH7	   DEFA5	   GRM3	   MAGEA8	   PIGR	   SPINK1	  
AGT	   DEFB1	   GRM8	   MAPK4	   PIP	   SPINK5	  
ALB	   DEFB4	   GRP	   MEG3	   PLA2G10	   SPRR1A	  
ALDH3A1	   DHRS2	   GSTA1	   MMP1	   PLA2G1B	   SPRR2A	  
AMY1B	   DIRAS3	   GUCA2B	   MMP10	   PLUNC	   SPRR2C	  
ANXA10	   DLK1	   H19	   MMP3	   POMC	   SPRR2D	  
APCDD1L	   DLX5	   HAND1	   MS4A8B	   POU4F1	   SPRR2E	  
APOH	   DNER	   HLA-­‐DQB2	   MSMB	   POU4F2	   SPRR2F	  
ART3	   DRD1IP	   HMGCS2	   MT1G	   PPY	   SPRR2G	  
ASCL1	   DSCR6	   HOXD1	   MT1H	   PRPH	   SPRR3	  
AVP	   EBF3	   HPGD	   MUC13	   PRSS2	   SRL	  
BHMT	   ECEL1	   IGFBP1	   MUC5AC	   PRSS3	   SST	  
BPIL1	   ELMOD1	   IL13RA2	   MUCL1	   PTHLH	   STATH	  
C20ORF114	   F5	   IL1F7	   NDST4	   PTPRN	   STMN2	  
C4ORF7	   FABP4	   IL1F9	   NEFL	   RALYL	   SYT13	  
C6ORF15	   FABP7	   INSM1	   NEFM	   RCVRN	   SYT4	  
C6ORF205	   FAIM2	   INSM2	   NELL1	   RDH12	   TAC1	  
C7ORF16	   FBN2	   ISL1	   NEUROG2	   REG4	   TAGLN3	  
C8ORF46	   FEV	   KCNS1	   NGB	   RNASE7	   TCEAL2	  
CABP7	   FGA	   KIR2DL3	   NKD1	   RPRM	   TCN1	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12. Statistical	  analysis	  	  Survival	  was	  calculated	  from	  the	  day	  of	  diagnosis	  until	  death	  or	  the	  last	  follow-­‐up	  visit.	   Associations	  between	   clinical	   characteristics	  were	   analyzed	  with	   the	   use	   of	  the	  Chi-­‐square	  test	  or	  Fisher’s	  exact	   test.	  Survival	  curves	  were	  constructed	  by	  the	  Kaplan–Meier	  method	   and	   compared	  with	   the	  use	   of	   the	   log-­‐rank	   test.	  Statistical	  tests	  were	  performed	  using	  SPSS	  version	  21.	  	  	  	  
13. Cell	  culture	  techniques	  and	  required	  molecular	  biological	  methods	  Standard	   procedures	   including	   restriction	   enzyme	   digestion	   and	   bacterial	  transformations	  were	  carried	  out	  according	  to	  the	  manufacturers	  protocol.	  	  
Site	  directed	  mutagenesis	  Site	  directed	  mutagenesis	  (SDM)	  was	  used	  to	  introduce	  mutations	  at	  specific	  sites	  into	  the	  pBabe-­‐puro	  (pBp)	  plasmid	  harboring	  the	  EGFR	  wild	  type	  cDNA.	  Mutagenic	  oligonucleotides	   were	   designed	   using	   the	   QuikChange	   Primer	   Design	  (www.agilent.com/genomics/qcpd)	   (Primers	   listed	   in	   Table	   6)	   and	   reactions	  
CALCA	   FGB	   KIR2DL4	   NKX2-­‐2	   S100A7	   TF	  
CARTPT	   FGFBP2	   KIR2DL5A	   NNAT	   S100A7A	   TFF1	  
CBLN2	   FGG	   KIR2DS5	   NOL4	   SBSN	   TFF2	  
CCL17	   FGL1	   KLK12	   NOS2A	   SCG2	   TFPI2	  
CD7	   FLJ23834	   KLK5	   NOTUM	   SCG5	   THBS4	  
CDH10	   FMO3	   KRT13	   NPAS4	   SCGB1A1	   TKTL1	  
CDH17	   FRMPD1	   KRT14	   NPPA	   SCGB2A1	   TM4SF4	  
CEL	   GABBR2	   KRT15	   NPTX2	   SCGB3A1	   TM4SF5	  
CGA	   GABRB1	   KRT34	   NRSN1	   SCGN	   TMED6	  
CHGA	   GABRP	   KRT6C	   NT5E	   SERPINA3	   TMEFF2	  
CHGB	   GAGE12G	   KRT81	   NTS	   SERPINB3	   TMEM100	  
CHODL	   GAGE12I	   KRTDAP	   OLFM4	   SERPINB4	   TPRX1	  
CLCA4	   GAGE2A	   LBP	   OTP	   SFRP1	   TRH	  
CLDN11	   GAGE4	   LECT1	   OTX2	   SHISA3	   TRPM8	  
CLDN18	   GAGE5	   LEFTY1	   PAEP	   SLC18A1	   TSPY2	  
CLDN2	   GAGE6	   LGALS4	   PAGE2	   SLC1A7	   TTR	  
CPB2	   GAGE7	   LGALS7	   PCK1	   SLC35D3	   UPK1A	  
CPNE4	   GAGE8	   LOC284422	   PCSK1	   SLC8A2	   VGF	  
CPS1	   GAL	   LOC645037	   PCSK1N	   SNAP25	   VSIG1	  
CRABP1	   GC	   LOC651898	   PDE6H	   SNAP91	   VSIG2	  
CRYBA2	   GFRA3	   LOC652102	   PDK4	   SOST	   VTN	  
CSN1S1	   GJB6	   LOC652683	   PDYN	   SOX10	   WIF1	  
CST1	   GKN2	   LOC653178	   PEG10	   SOX8	   WT1	  
CTCFL	   GNAT2	   LOC728403	   PEG3	   SPANXA2	   ZCCHC12	  
CXCL13	   GNGT1	   LOC728454	   PENK	   SPANXB1	   ZIC2	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performed	   using	   the	   QuikChange	   II	   Site-­‐Directed	   Mutagenesis	   Kit	   according	  manufacturer’s	   instructions	  (Stratagene).	  Emanating	   from	  the	  EGFR	  wild	  type	  pBp	  plasmid	   the	   plasmids	   pBp	  EGFR	  K714N,	  pBp	  EGFR	  E709K+V717E+G719R	   (further	  referred	   to	  as	  pBp	  EGFR+3),	   and	  pBp	  EGFR	  E709K+K714N+V717E+G719R	  (further	  referred	  to	  as	  pBp	  EGFR+4)	  were	  generated.	  	  	  
Bacterial	  transformation	  Molecules	   containing	  EGFR	  mutant	   variants	   produced	   by	   SDM	  were	   transformed	  into	  bacterial	  XL10-­‐Gold	  ultracompetent	   cells.	  Plasmids	  with	  FGFR3IIIB	  wild	   type	  and	  FGFR3IIIB	  harboring	  the	  R248C	  mutation	  (FGFR3	  plasmids	  were	  received	  as	  a	  kind	  gift	  from	  Margaret	  Knowles,	  Professor	  of	  Experimental	  Cancer	  Research	  of	  the	  University	  of	  Leeds,	  England)	  were	  transformed	   into	  DH5α	  cells.	   In	  brief,	  45	  µl	  of	  cells	   and	   2	  µl	   Dpn	  I-­‐treated	   DNA	   or	   plasmid	   were	   incubated	   for	   30	  min	   on	   ice	  followed	   by	   a	   30	  sec	   heat-­‐pulse	   in	   a	   42°C	   water	   bath.	   Transformed	   cells	   were	  plated	  on	  LB-­‐agar	  plates	  containing	  Ampicillin.	  	  	   Genotypes	  were	  verified	  in	  all	  plasmids	  using	  standard	  dideoxy-­‐sequencing	  (BigDye®	   Terminator	   v3.1	   Cycle	   Sequencing	   Kit	   (Applied	   Biosystems)).	   For	   this	  purpose	   five	   clones	   per	   plasmid	   were	   picked	   from	   LB	   agar	   plates	   24	  h	   after	  transformation	  and	  cells	  transferred	  into	  the	  reaction	  mix	  for	  target	  amplification	  using	  cDNA	  specific	  primers	  (primers	  are	  listed	  in	  Table	  6).	  	  	  Table	  6	  Primers	   used	   for	   site	   directed	  mutagenesis	   to	   introduce	  mutations	   into	   the	  wild	  type	  EGFR	  pBabe-­‐puro	  plasmid	  and	  cDNA	  sequencing	  of	  EGFR	  and	  FGFR3.	  
gene	   oligoname	   Primer	  Sequence	  
SDM	   K714N	   GGATCTTGAAGGAAACTGAATTCAAAAATATCAAAGTGCTGGGC	  
SDM	   K714N_anti	   GCCCAGCACTTTGATATTTTTGAATTCAGTTTCCTTCAAGATCC	  
SDM	   E709K	   CAAGCTCTCTTGAGGATCTTGAAGAAAACTGAATTCAAAAATATCAAAG	  
SDM	   E709K_anti	   CTTTGATATTTTTGAATTCAGTTTTCTTCAAGATCCTCAAGAGAGCTTG	  
SDM	   V717E_G719R	   TGAATTCAAAAATATCAAAGAGCTGCGCTCCGGTGCGTTCG	  
SDM	   V717E_G719R_anti	   CGAACGCACCGGAGCGCAGCTCTTTGATATTTTTGAATTCA	  
Sanger	   EGFR_ATG-­‐73_F	   GTAAAACGACGGCCAGGCCTCGATCCTCCCTTTATC	  
Sanger	   EGFR_1_90_F	   GTAAAACGACGGCCAGCTGGAGGAAAAGAAAGTTTGC	  
Sanger	   EGFR_1_630_R	   CAGGAAACAGCTATGACCTGGCACAGATGATTTTGGTCA	  
Sanger	   EGFR_2_590_F	   GTAAAACGACGGCCAGGTGATCCAAGCTGTCCCAAT	  
Sanger	   EGFR_2_1150_R	   CAGGAAACAGCTATGACCTTGTGGATCCAGAGGAGGAGT	  
Sanger	   EGFR_3_1090_F	   GTAAAACGACGGCCAGCAAAAACTGCACCTCCATCA	  
Sanger	   EGFR_3_1770_R	   CAGGAAACAGCTATGACCTGGCAGGTCTTGACGCAGT	  
Sanger	   EGFR_4_1740_F	   GTAAAACGACGGCCAGGACGGGGACCAGACAACTG	  
Sanger	   EGFR_4_2400_R	   CAGGAAACAGCTATGACCTGTCTTTGTGTTCCCGGACAT	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gene	   oligoname	   Primer	  Sequence	  
Sanger	   EGFR_5_2380_F	   GTAAAACGACGGCCAGAGCTCATCACGCAGCTCAT	  
Sanger	   EGFR_5_3030_R	   CAGGAAACAGCTATGACCTATGAGGTACTCGTCGGCATC	  
Sanger	   EGFR_6_3000_F	   GTAAAACGACGGCCAGACTTCTACCGTGCCCTGATG	  
Sanger	   EGFR_6_3600_R	   CAGGAAACAGCTATGACCTTGCTCCAATAAATTCACTGCTT	  
Sanger	   EGFR_TGA+137_R	   CAGGAAACAGCTATGACACTTTCCACACCTGGTTGCT	  	  
Sanger	   FGFR3_1_ATG-­‐93_F	   CCACTGCTTACTGGCTTATCG	  
Sanger	   FGFR3_1_228_R	   ATCCTTGACCCAGACAGTGG	  
Sanger	   FGFR3_2_233_F	   ACTGTCTGGGTCAAGGATGG	  
Sanger	   FGFR3_2_672_R	   CCACGACGCAGGTGTAGTT	  
Sanger	   FGFR3_3_618_F	   CATTGGAGGCATCAAGCTG	  
Sanger	   FGFR3_3_1135_R	   GGATGCCTGCATACACACTG	  
Sanger	   FGFR3_4_1028_F	   CTCTGTCGAGCCACCAATTT	  
Sanger	   FGFR3_4_1772_R	   ACACCAGGTCCTTGAAGGTG	  
Sanger	   FGFR3_5_1702_F	   AAGGGTAACCTGCGGGAGT	  
Sanger	   FGFR3_5_2361_R	   GTGGGCAAACACGGAGTC	  
Sanger	   FGFR3_6_2209_F	   ACGAGTACCTGGACCTGTCG	  
Sanger	   FGFR3_6_TGA+77_R	   TCTCTCCATGTGCAGTGAGTCT	  	  
Midi-­‐Prep	   	  Positive	   clones	   were	   cultured	   in	   100	  ml	   LB	   medium	   containing	   100	  ng/ml	  Ampicillin	   at	   37°C	   for	   18	  h	   and	   midi-­‐preparations	   were	   performed	   using	   the	  NucleoBond	   Xtra	   Midi	   EF	   kit	   (Machery	   Nagel)	   according	   to	   manufacturer’s	  instructions.	  	  	   	  
Virus	  production	  and	  transduction	  of	  Ba/F3	  and	  NIH3T3	  cells	  HEK293T	   cells	   cultured	   in	  DMEM	  medium	  with	  10%	   fetal	   calf	   serum	   (FCS)	  were	  transfected	   with	   retroviral	   plasmids	   (pBp	   empty	   vector,	   pBp	   EML4-­‐ALK	   variant1	  (produced	   by	   Johannes	   Heuckmann),	   pBp	  EGFR	  wild	   type,	   pBp	  EGFR	  K714N,	  pBp	  
EGFR+3,	  and	  pBp	  EGFR+4,	  and	  pBp	  FGFR3	  IIIb	  wild	  type	  and	  pBp	  FGFR3	  IIIb	  R248C	  each	   mixed	   with	   packaging	   plasmid	   pCL-­‐eco	   in	   Opti-­‐Mem)	   using	   TransIT®LTI	  Transfection	  Reagent	  (Mirus,	  USA).	  After	  24	  h	  medium	  was	  changed	  to	  3	  ml	  DMEM	  +	   30%	  FCS	   +	   1%	  Penicillin/Streptavidin	   (P/S).	  Medium	  was	   collected	   after	   24	   h,	  3	  ml	  new	  medium	  added	  to	  the	  cells	  and	  collected	  after	  additional	  24	  h.	  Combined	  supernatants	  were	  filtered	  through	  0.45	  µm	  filters.	  	  NIH3T3	   cells,	   cultured	   in	   DMEM	   +	   10%	   FCS	   +	   1%	   P/S	   and	   Ba/F3	   cells,	  cultured	  in	  RPMI	  +	  20%	  FCS	  +	  1%P/S,	  were	  transduced	  at	  50%	  confluence	  in	  a	  60	  mm	  dish	  with	  1	  ml	  virus	  using	   the	  cross	   linker	  Polybren®.	   IL-­‐3	  was	  added	  to	   the	  Ba/F3	   cells	   and	   cells	   cultured	   for	   two	   days,	   before	   centrifuging	   and	   transferring	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cells	  in	  IL-­‐3	  free	  medium.	  NIH3T3	  cells	  were	  transferred	  one	  day	  after	  transfection	  into	  a	  25	  cm	  culture	  bottle	  and	  puromycin	  (2.5	  µg/ml)	  added	  for	  selection.	  	  
Protein	  quantification	  and	  Western	  blot	  Cells	   were	   lysed	   in	   lysis	   buffer	   (20	   mM	   Tris-­‐HCl	   (pH	   7.5),	   150	   mM	  NaCl,	   1	   mM	  Na2EDTA,	  1	  mM	  EGTA,	  1%	  TritonX-­‐100	  2.5	  mM	  sodium	  pyrophosphate,	  1	  mM	  beta-­‐glycerophosphate,	   1	   mM	   Na3VO4,	   1	   μg/ml	   leupeptin,	   1	   mM	   PMSF,	   complete	  Protease	  Inhibitors	  Cocktail	  and	  Phosphatase	  Inhibitors	  Cocktail	  Set	  II)	  and	  protein	  concentration	  measured	  using	  the	  BCA	  Protein	  Assay	  (Thermoscientific)	  using	  5	  µl	  of	  the	  lysate.	  	  A	  mixture	  of	  40	  µg	  proteins	  and	  5x	  Laemmli	  buffer	  (5x	  SDS	  sample	  buffer:	  250	  mM	  Tris	  (pH	  6.8),	  50%	  glycerol,	  5%	  β-­‐mercaptoethanol,	  10%	  SDS	  and	  0.05%	  bromophenol	  blue)	  was	  incubated	  at	  95°C	  for	  10	  min.	  Proteins	  were	  separated	  on	  Novex®	  4-­‐12%	  Tris-­‐Glycin	  polyacrylamide	  gel	   (Invitrogen)	   in	  SDS	   running	  buffer	  (192	   mM	   Glycin,	   25	   mM	   Tris-­‐HCl,	   0.1%	   SDS)	   at	   100V	   in	   XCell	   SureLock	   Gel	  Chambers	   (Invitrogen)	   by	   electrophoresis.	   As	   a	   standard	   PageRulerTM	   Plus	  Prestained	  Protein	  Ladder	  (Fermentas)	  was	  used.	  	  
Soft	  Agar	  Anchorage-­‐Independent	  Growth	  Assay	  Agarose	  Type	  IX	  ultra	  low	  (Sigma	  Aldrich)	  was	  prepared	  using	  ddH2O	  as	  a	  2%	  and	  1.2%	  stock.	  Agar	  was	  heated	   to	  95	   °C	   for	  30	  minutes	  using	  a	   thermo	  block.	  After	  cooling	  down	  to	  approximately	  60°C	  25	  µl	  of	  the	  2%	  agar	  and	  25	  µl	  of	  pre-­‐warmed	  2x	  DMEM	  medium	  with	   20%	   FCS	   and	   2%	  P/S	  were	   prepared	   for	   each	  well	   of	   a	  96-­‐well	   plate.	   The	   1%	   agar	   was	   added	   to	   the	   wells	   and	   hardened	   at	   room	  temperature.	  	  For	   the	   top	   layer	   the	   1.2%	   agar	  was	   further	   cooled	   to	   40°C.	   NIH3T3	   cells	  were	   detached	   by	   trypsin	   and	   cell	   numbers	   determined	   using	   the	   Z2-­‐Coulter	  counter	  (Beckman	  Coulter).	  For	  each	  well	  of	  a	  96-­‐well	  plate	  1,000	  cells	  were	  mixed	  with	  25	  µl	  of	  1.2%	  agar	  and	  pre-­‐warmed	  2x	  DMEM	  medium	  with	  20%	  FCS	  and	  2%	  P/S	   to	   a	   total	   volume	   of	  50	  µl.	   The	   cell-­‐agar-­‐mix	  was	   plated	   on	   the	   bottom	   agar	  layer	  and	  solidified	  for	  10	  min	  at	  4°C.	  DMEM	  medium	  with	  10%	  FCS	  +	  1%	  P/S	  (and	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Table	  7	  Patient	  characteristics	  for	  ALK	  and	  ROS1	  fusion	  positive	  cases.	  
	  	  
	  Figure	   30	   Mutation	   frequencies	   for	   major	   lung	   cancer	   subtypes	   (AD,	   SCLC	   and	   SQ)	   in	  sample	   sets	   defined	   by	   the	   original	   histology	   (black)	   or	   the	   reclassified	   histology	   (grey)	  plotted	   per	   subtype	   and	   gene.	   Mutation	   frequencies	   in	   both	   groups	   are	   highly	   similar	  (t-­‐test	  for	  each	  gene	  per	  histological	  subtype,	  p>0.05).	  	   Mutation	  frequencies	  described	  in	  the	  results	  section	  were	  calculated	  based	  on	   the	   original	   histological	   subtypes	   as	   these	   reflect	  best	   the	   real	   distribution	   in	  todays	   clinical	   diagnostics	   routine	   where	   diverse	   reasons	   might	   lead	   to	  misclassifications	   (see	  Figure	  8).	  To	   rule	   out	  major	  misinterpretations	   that	  might	  affect	   mutation	   frequencies	   and	   thereby	   bias	   analysis	   of	   signature	   alterations	  mutation	   frequencies	   were	   compared	   between	   original	   and	   reviewed	   diagnosis	  
PatID Gene Histology Sex Age Smoking_Hx Stage6(UICC) Rearrangement6comment
S01124 ALK AD female 52 never IA EML45ALK
S00300 ALK AD female 59 never IA ALK_rearrangement
S01320 ALK AD female 62 never IB EML45ALK
S00462 ALK AD female 55 current IIB ALK_rearrangement@(no@EML45ALK)
S00006 ALK AD female 79 never IIB EML45ALK
S01122 ALK AD female 42 never IIIB EML45ALK
S01339 ALK AD male 71 former IB ALK_rearrangement@(no@EML45ALK)
S00388 ALK AD male 56 current IIIA EML45ALK
S00054 ALK AD male 52 never IIIA EML45ALK
S00092 ALK SQ male 79 former IB ALK_rearrangement@(no@EML45ALK)
S00545 ROS1 AD female 68 never IIIB ROS1@rearrangement@
S01345 ROS1 AD male 74 former IB ROS1@rearrangement@
S00310 ROS1 AD male 66 former IB narrow@split@(signals@<2@signal@widths@apart)
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(Figure	   30,	   Fishers	   Exact	   test,	   p<0.05).	   No	   significant	   differences	   of	   mutation	  frequencies	  between	  these	  two	  groups	  were	  found.	  	  	  	  
	  Figure	  31	  Comparison	  of	  expression	  of	  seven	  typical	  immunohistochemical	  markers	  in	  32	  LCNEC	  with	  22	  SCLC	  cases.	  Relationship	  between	  LCNEC	  and	  SCLC	  was	  calculated	  using	  the	  Pearson's	  Chi-­‐square	  test	  (*p-­‐value	  >	  0.05,	  **p-­‐value	  <	  0.05).	  	  
Table	  8	  Mutations	  per	  case.	  
PatID	   Histology	   Gene	   Aminoacid_change	  
S00006	   AD	   ALK	   EML4-­‐ALK	  
S00054	   AD	   ALK	   EML4-­‐ALK	  
S00300	   AD	   ALK	   ALK	  
S00388	   AD	   ALK	   EML4-­‐ALK	  
S00462	   AD	   ALK	   ALK	  
S01122	   AD	   ALK	   EML4-­‐ALK	  
S01124	   AD	   ALK	   EML4-­‐ALK	  
S01320	   AD	   ALK	   EML4-­‐ALK	  
S01339	   AD	   ALK	   no	  EML4-­‐ALK	  
S00092	   SQ	   ALK	   no	  EML4-­‐ALK	  
S00406	   AD	   BRAF	   p.G464V	  
S00423	   AD	   BRAF	   p.K601N	  
S00427	   AD	   BRAF	   p.G466V	  
S00576	   AD	   BRAF	   p.G469V	  
S00586	   AD	   BRAF	   p.V600E	  
S00591	   AD	   BRAF	   p.V600E	  
S00651	   AD	   BRAF	   p.G469A	  
S00698	   AD	   BRAF	   p.G466A	  
S01057	   AD	   BRAF	   p.G469V	  
S01159	   AD	   BRAF	   p.G464V	  
S01201	   AD	   BRAF	   p.V600E	  
S01259	   AD	   BRAF	   p.G464V	  
S01707	   AD	   BRAF	   p.V600E	  
S00438	   ADSQ	   BRAF	   p.G469V	  
S00496	   LCC	   BRAF	   p.G464V	  
S00613	   LCNEC	   BRAF	   p.V600E	  
S00713	   LCNEC	   BRAF	   p.G469V	  
S00073	   SQ	   BRAF	   p.V600E	  
S00117	   SQ	   BRAF	   p.G464V	  
S00997	   SQ	   BRAF	   p.V600E	  
S00402	   UNKNOWN	   BRAF	   p.G469V	  
S00593	   AD	   CDK4	   p.R24H	  
S00754	   AD	   CDK4	   p.R24H	  
S00727	   AD	   DDR2	   p.L63V	  
S01571	   LCC	   DDR2	   p.G253C	  
PatID	   Histology	   Gene	   Aminoacid_change	  
S00069	   SQ	   DDR2	   p.G774E	  
S00145	   SQ	   DDR2	   p.C580Y	  
S00281	   SQ	   DDR2	   p.I120M	  
S00434	   SQ	   DDR2	   p.T765P	  
S00005	   AD	   EGFR	   p.E746_A750del_1A	  
S00027	   AD	   EGFR	   p.L747P	  
S00082	   AD	   EGFR	   p.exon20indel	  
S00106	   AD	   EGFR	   p.L858R	  
S00113	   AD	   EGFR	   p.L858R	  
S00116	   AD	   EGFR	   p.L747_S752>S	  
S00123	   AD	   EGFR	   p.E746_A750del_1A	  
S00142	   AD	   EGFR	   exon	  20	  insertion	  
S00155	   AD	   EGFR	   p.E746_A750del_1B	  
S00156	   AD	   EGFR	   p.(R776H(+)L858R)	  
S00299	   AD	   EGFR	   p.E746_A750del_1B	  
S00302	   AD	   EGFR	   p.(T790M(+)L858R)	  
S00304	   AD	   EGFR	   p.L858R	  
S00308	   AD	   EGFR	   p.(S768I(+)V774M)	  
S00398	   AD	   EGFR	   p.T751_I759>N	  
S00403	   AD	   EGFR	   exon	  20	  insertion	  
S00411	   AD	   EGFR	   p.D770_N771insSVD	  
S00413	   AD	   EGFR	   p.E746_A750del;insQP	  
S00416	   AD	   EGFR	   p.E746_A750>A	  
S00430	   AD	   EGFR	   exon	  20	  insertion	  
S00436	   AD	   EGFR	   p.L858R	  
S00464	   AD	   EGFR	   p.(L747_P753del>S(+)T790M)	  
S00465	   AD	   EGFR	   p.L747_A750>P	  
S00561	   AD	   EGFR	   p.E746_A750del_1A	  
S00565	   AD	   EGFR	   p.G719S	  
S00590	   AD	   EGFR	   p.E746_A750del_1A	  
S00610	   AD	   EGFR	   p.E746_A750del_1B	  
S00616	   AD	   EGFR	   p.E746_A750del_1B	  
S00623	   AD	   EGFR	   exon	  20	  insertion	  
S00624	   AD	   EGFR	   p.E746_S752>V	  
S00633	   AD	   EGFR	   p.E746_	  S752>V	  
S00652	   AD	   EGFR	   p.(S768I(+)V774M)	  
S00654	   AD	   EGFR	   p.L858R	  
S00659	   AD	   EGFR	   p.E746_S752>V	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S00660	   AD	   EGFR	   p.L747_T751>N	  
S00662	   AD	   EGFR	   p.L858R	  
S00665	   AD	   EGFR	   p.L858R	  
S00667	   AD	   EGFR	   p.L858R	  
S00669	   AD	   EGFR	   p.L747P	  
S00670	   AD	   EGFR	   p.L858R	  
S00678	   AD	   EGFR	   p.E709A	  
S00692	   AD	   EGFR	   p.E746_A750del_1A	  
S00730	   AD	   EGFR	   p.L858R	  
S00735	   AD	   EGFR	   p.L858R	  
S00741	   AD	   EGFR	   p.L858R	  
S00745	   AD	   EGFR	   p.L858R	  
S01048	   AD	   EGFR	   p.L747_T751del	  
S01058	   AD	   EGFR	   p.L858R	  
S01078	   AD	   EGFR	   p.(L833F(+)L858R)	  
S01087	   AD	   EGFR	   p.G779F	  
S01096	   AD	   EGFR	   p.L858R	  
S01098	   AD	   EGFR	   p.L858R	  
S01125	   AD	   EGFR	   p.E746_A750del_1A	  
S01134	   AD	   EGFR	   p.E746_P753>VS	  
S01136	   AD	   EGFR	   p.E746_A750del_1B	  
S01139	   AD	   EGFR	   p.E746_A750del_1A	  
S01157	   AD	   EGFR	   p.E746_A750delB	  
S01166	   AD	   EGFR	   p.(E709K[+]K714N[+]V717E[+]G719R)	  
S01172	   AD	   EGFR	   p.L858R	  
S01186	   AD	   EGFR	   p.L858R	  
S01217	   AD	   EGFR	   p.E746_A750del_1B	  
S01218	   AD	   EGFR	   p.T751_I759>N	  
S01227	   AD	   EGFR	   p.E746_A750del_1A	  
S01244	   AD	   EGFR	   p.E746_A750del_1A	  
S01328	   AD	   EGFR	   p.(T790M(+)L858R)	  
S01362	   AD	   EGFR	   p.E746_A750del_1A	  
S01373	   AD	   EGFR	   p.E746_S752>V	  
S01414	   AD	   EGFR	   p.E746_A750del_1A	  
S01507	   AD	   EGFR	   p.E746_A750del_1A	  
S01634	   AD	   EGFR	   p.L747_S752>S	  
S01645	   AD	   EGFR	   p.E746_S752>V	  
S01646	   AD	   EGFR	   p.L858R	  
S01718	   AD	   EGFR	   p.(G719A(+)S768I)	  
S00066	   ADSQ	   EGFR	   p.L858R	  
S00498	   ADSQ	   EGFR	   p.E746_A750del_1B	  
S00195	   LCC	   EGFR	   p.K714N	  
S00215	   LCC	   EGFR	   p.V774M	  
S00824	   LCC	   EGFR	   p.N771>TT	  
S00510	   SQ	   EGFR	   p.E746_A750del_1B	  
S00769	   SQ	   EGFR	   p.P694H	  
S00393	   UNKNOWN	   EGFR	   exon	  20	  insertion	  
S00058	   AD	   ERBB2	   p.D742N	  
S00405	   AD	   ERBB2	   p.D769N	  
S00684	   AD	   ERBB2	   p.M774_A775insAYVM	  
S00734	   AD	   ERBB2	   p.M774_A775insAYVM	  
S00750	   AD	   ERBB2	   p.M774_A775insAYVM	  
S00752	   AD	   ERBB2	   p.M774_A775insAYVM	  
S00757	   AD	   ERBB2	   p.M774_A775insAYVM	  
S01341	   AD	   ERBB2	   p.M774_A775insAYVM	  
S00084	   LCC	   ERBB2	   p.S310F	  
S01168	   LCC	   ERBB2	   p.S310F	  
S00030	   SQ	   ERBB2	   p.S310F	  
S01402	   SQ	   ERBB2	   p.G818A	  
S00197	   AD	   FGFR2	   p.N767S	  
S00286	   AD	   FGFR2	   p.N184S	  
S00900	   AD	   FGFR2	   p.I348F	  
S01190	   AD	   FGFR2	   p.Y375C	  
S01586	   LCNEC	   FGFR2	   p.A568G	  
S00045	   SQ	   FGFR2	   p.N549T	  
S01112	   SQ	   FGFR2	   p.Y375C	  
S01245	   SQ	   FGFR2	   p.R61C	  
S00325	   SQ	   FGFR3	   p.R248C	  
S00434	   SQ	   FGFR3	   p.R248C	  
S00674	   SQ	   FGFR3	   p.R248C	  
S01581	   LCNEC	   HRAS	   p.G13R	  
S01245	   SQ	   HRAS	   p.G12D	  
S00003	   AD	   KEAP1	   p.Q620del	  
PatID	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S00071	   AD	   KEAP1	   p.R362W	  
S00085	   AD	   KEAP1	   p.R459X	  
S00099	   AD	   KEAP1	   p.I425F	  
S00120	   AD	   KEAP1	   p.Y584fs	  
S00161	   AD	   KEAP1	   p.R362Q	  
S00165	   AD	   KEAP1	   p.G332R	  
S00205	   AD	   KEAP1	   p.A322fs	  
S00206	   AD	   KEAP1	   p.N382D	  
S00240	   AD	   KEAP1	   p.G332C	  
S00267	   AD	   KEAP1	   p.T309A	  
S00286	   AD	   KEAP1	   p.G332C	  
S00292	   AD	   KEAP1	   p.G364C	  
S00425	   AD	   KEAP1	   p.G379V	  
S00459	   AD	   KEAP1	   p.E441X	  
S00488	   AD	   KEAP1	   p.G364C	  
S00495	   AD	   KEAP1	   p.G511V	  
S00499	   AD	   KEAP1	   p.S431F	  
S00694	   AD	   KEAP1	   p.G423V	  
S00900	   AD	   KEAP1	   p.R362P	  
S01057	   AD	   KEAP1	   p.G464V	  
S01152	   AD	   KEAP1	   p.V418fs	  
S01235	   AD	   KEAP1	   p.S508R	  
S01241	   AD	   KEAP1	   p.Q620del	  
S01266	   AD	   KEAP1	   p.Q315fs	  
S01306	   AD	   KEAP1	   p.N397del	  
S01368	   AD	   KEAP1	   p.G462W	  
S01398	   AD	   KEAP1	   p.G367C	  
S01404	   AD	   KEAP1	   p.D389Y	  
S01409	   AD	   KEAP1	   p.R320P	  
S01608	   AD	   KEAP1	   p.G603R	  
S01646	   AD	   KEAP1	   p.W497C	  
S00469	   ADSQ	   KEAP1	   p.Y490X	  
S00084	   LCC	   KEAP1	   p.G509V	  
S00799	   LCNEC	   KEAP1	   p.R362Q	  
S01318	   LCNEC	   KEAP1	   p.?	  
S00188	   SCLC	   KEAP1	   p.V370M	  
S01524	   SCLC	   KEAP1	   p.K323fs	  
S00013	   SQ	   KEAP1	   p.G570E	  
S00041	   SQ	   KEAP1	   p.V359L	  
S00160	   SQ	   KEAP1	   p.T576M	  
S00223	   SQ	   KEAP1	   p.S486T	  
S00280	   SQ	   KEAP1	   p.G511C	  
S00316	   SQ	   KEAP1	   p.Y567X	  
S00317	   SQ	   KEAP1	   p.P384L	  
S00344	   SQ	   KEAP1	   p.S338L	  
S00437	   SQ	   KEAP1	   p.Q620del	  
S00475	   SQ	   KEAP1	   p.P322H	  
S00720	   SQ	   KEAP1	   p.R470H	  
S00721	   SQ	   KEAP1	   p.R320L	  
S00769	   SQ	   KEAP1	   p.G379F	  
S00785	   SQ	   KEAP1	   p.Q620del	  
S01054	   SQ	   KEAP1	   p.R565X	  
S01189	   SQ	   KEAP1	   p.I304M	  
S01472	   SQ	   KEAP1	   p.P612_K615del	  
S01651	   SQ	   KEAP1	   p.R320W	  
S00002	   AD	   KRAS	   p.G12D	  
S00003	   AD	   KRAS	   p.G12V	  
S00015	   AD	   KRAS	   p.G12D	  
S00018	   AD	   KRAS	   p.G12V	  
S00019	   AD	   KRAS	   p.G12S	  
S00025	   AD	   KRAS	   p.G12C	  
S00029	   AD	   KRAS	   p.G12D	  
S00048	   AD	   KRAS	   p.G12C	  
S00057	   AD	   KRAS	   p.G12C	  
S00063	   AD	   KRAS	   p.G12V	  
S00071	   AD	   KRAS	   p.G12D	  
S00074	   AD	   KRAS	   p.G12C	  
S00077	   AD	   KRAS	   p.G12F	  
S00078	   AD	   KRAS	   p.Q61H	  
S00080	   AD	   KRAS	   p.G12C	  
S00085	   AD	   KRAS	   p.G12V	  
S00091	   AD	   KRAS	   p.Q61L	  
S00099	   AD	   KRAS	   p.G12C	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S00100	   AD	   KRAS	   p.G12V	  
S00103	   AD	   KRAS	   p.G12D	  
S00114	   AD	   KRAS	   p.G12C	  
S00120	   AD	   KRAS	   p.G12V	  
S00124	   AD	   KRAS	   p.G12C	  
S00133	   AD	   KRAS	   p.G12C	  
S00135	   AD	   KRAS	   p.G12C	  
S00138	   AD	   KRAS	   p.G12C	  
S00146	   AD	   KRAS	   p.Q61H	  
S00153	   AD	   KRAS	   p.G12V	  
S00170	   AD	   KRAS	   p.G13D	  
S00171	   AD	   KRAS	   p.G12C	  
S00172	   AD	   KRAS	   p.G12C	  
S00178	   AD	   KRAS	   p.G12C	  
S00180	   AD	   KRAS	   p.G12C	  
S00190	   AD	   KRAS	   p.G12C	  
S00191	   AD	   KRAS	   p.Q61H	  
S00205	   AD	   KRAS	   p.Q61H	  
S00206	   AD	   KRAS	   p.G12A	  
S00207	   AD	   KRAS	   p.G12C	  
S00211	   AD	   KRAS	   p.G12C	  
S00240	   AD	   KRAS	   p.G12V	  
S00256	   AD	   KRAS	   p.G12A	  
S00261	   AD	   KRAS	   p.G12C	  
S00275	   AD	   KRAS	   p.G13C	  
S00278	   AD	   KRAS	   p.G12R	  
S00282	   AD	   KRAS	   p.G12C	  
S00284	   AD	   KRAS	   p.G12D	  
S00288	   AD	   KRAS	   p.G12D	  
S00290	   AD	   KRAS	   p.G12C	  
S00301	   AD	   KRAS	   p.G12C	  
S00305	   AD	   KRAS	   p.G12D	  
S00307	   AD	   KRAS	   p.G12F	  
S00309	   AD	   KRAS	   p.G12C	  
S00351	   AD	   KRAS	   p.G12V	  
S00352	   AD	   KRAS	   p.G12C	  
S00353	   AD	   KRAS	   p.G12V	  
S00357	   AD	   KRAS	   p.G12C	  
S00359	   AD	   KRAS	   p.G13C	  
S00361	   AD	   KRAS	   p.G13C	  
S00397	   AD	   KRAS	   p.G13C	  
S00418	   AD	   KRAS	   p.G12D	  
S00425	   AD	   KRAS	   p.G12D	  
S00431	   AD	   KRAS	   p.G12L	  
S00432	   AD	   KRAS	   p.G12C	  
S00435	   AD	   KRAS	   p.G12V	  
S00445	   AD	   KRAS	   p.G12C	  
S00452	   AD	   KRAS	   p.G12C	  
S00462	   AD	   KRAS	   p.G12D	  
S00483	   AD	   KRAS	   p.G12C	  
S00484	   AD	   KRAS	   p.G12V	  
S00486	   AD	   KRAS	   p.Q61H	  
S00488	   AD	   KRAS	   p.G12C	  
S00489	   AD	   KRAS	   p.G12D	  
S00490	   AD	   KRAS	   p.G12D	  
S00492	   AD	   KRAS	   p.Q22K	  
S00493	   AD	   KRAS	   p.G12C	  
S00494	   AD	   KRAS	   p.G12C	  
S00499	   AD	   KRAS	   p.G12C	  
S00562	   AD	   KRAS	   p.G12C	  
S00569	   AD	   KRAS	   p.G12V	  
S00573	   AD	   KRAS	   p.G13D	  
S00574	   AD	   KRAS	   p.G13C	  
S00576	   AD	   KRAS	   p.G13C	  
S00583	   AD	   KRAS	   p.G13C	  
S00588	   AD	   KRAS	   p.G12D	  
S00589	   AD	   KRAS	   p.G12C	  
S00592	   AD	   KRAS	   p.Q61H	  
S00593	   AD	   KRAS	   p.G12C	  
S00597	   AD	   KRAS	   p.G12C	  
S00603	   AD	   KRAS	   p.G12V	  
S00604	   AD	   KRAS	   p.G12C	  
S00605	   AD	   KRAS	   p.G12D	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S00607	   AD	   KRAS	   p.G12D	  
S00618	   AD	   KRAS	   p.G13C	  
S00619	   AD	   KRAS	   p.G12V	  
S00621	   AD	   KRAS	   p.G12D	  
S00631	   AD	   KRAS	   p.G12V	  
S00642	   AD	   KRAS	   p.G12C	  
S00643	   AD	   KRAS	   p.G12C	  
S00644	   AD	   KRAS	   p.G12V	  
S00645	   AD	   KRAS	   p.G12A	  
S00653	   AD	   KRAS	   p.G12C	  
S00657	   AD	   KRAS	   p.G12D	  
S00677	   AD	   KRAS	   p.G12C	  
S00694	   AD	   KRAS	   p.G12C	  
S00699	   AD	   KRAS	   p.G12C	  
S00702	   AD	   KRAS	   p.G12V	  
S00704	   AD	   KRAS	   p.G12V	  
S00724	   AD	   KRAS	   p.G12D	  
S00740	   AD	   KRAS	   p.G12D	  
S00742	   AD	   KRAS	   p.G12D	  
S01056	   AD	   KRAS	   p.G12V	  
S01074	   AD	   KRAS	   p.Q61H	  
S01108	   AD	   KRAS	   p.G12C	  
S01119	   AD	   KRAS	   p.G12C	  
S01147	   AD	   KRAS	   p.G12D	  
S01163	   AD	   KRAS	   p.G13C	  
S01171	   AD	   KRAS	   p.Q61H	  
S01232	   AD	   KRAS	   p.G12D	  
S01234	   AD	   KRAS	   p.G13D	  
S01235	   AD	   KRAS	   p.G13V	  
S01241	   AD	   KRAS	   p.G12C	  
S01250	   AD	   KRAS	   p.G12C	  
S01253	   AD	   KRAS	   p.G12V	  
S01258	   AD	   KRAS	   p.G12C	  
S01259	   AD	   KRAS	   p.G13D	  
S01290	   AD	   KRAS	   p.G12C	  
S01316	   AD	   KRAS	   p.L19F	  
S01329	   AD	   KRAS	   p.Q61L	  
S01331	   AD	   KRAS	   p.G12C	  
S01342	   AD	   KRAS	   p.G12C	  
S01350	   AD	   KRAS	   p.R68M	  
S01354	   AD	   KRAS	   p.G12V	  
S01357	   AD	   KRAS	   p.G13C	  
S01359	   AD	   KRAS	   p.G12A	  
S01365	   AD	   KRAS	   p.G12C	  
S01380	   AD	   KRAS	   p.(G12V(+)G13C)	  
S01387	   AD	   KRAS	   p.G12C	  
S01403	   AD	   KRAS	   p.G12C	  
S01404	   AD	   KRAS	   p.G12C	  
S01409	   AD	   KRAS	   p.G12C	  
S01413	   AD	   KRAS	   p.G12C	  
S01455	   AD	   KRAS	   p.G12C	  
S01467	   AD	   KRAS	   p.G12C	  
S01470	   AD	   KRAS	   p.G12V	  
S01482	   AD	   KRAS	   p.G12D	  
S01486	   AD	   KRAS	   p.G12V	  
S01498	   AD	   KRAS	   p.G12C	  
S01500	   AD	   KRAS	   p.Q61H	  
S01609	   AD	   KRAS	   p.G12V	  
S01610	   AD	   KRAS	   p.G12V	  
S01632	   AD	   KRAS	   p.G12C	  
S01647	   AD	   KRAS	   p.G12V	  
S01729	   AD	   KRAS	   p.G12F	  
S01906	   AD	   KRAS	   p.G12C	  
S00909	   ADSQ	   KRAS	   p.G12C	  
S01192	   ADSQ	   KRAS	   p.G12V	  
S00046	   LCC	   KRAS	   p.A59E	  
S00125	   LCC	   KRAS	   p.G13E	  
S00195	   LCC	   KRAS	   p.G12C	  
S00336	   LCC	   KRAS	   p.G12C	  
S00627	   LCC	   KRAS	   p.G12V	  
S01097	   LCC	   KRAS	   p.G12V	  
S01141	   LCC	   KRAS	   p.G12V	  
S01353	   LCC	   KRAS	   p.G12C	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S01575	   LCC	   KRAS	   p.G12S	  
S01654	   LCC	   KRAS	   p.G12C	  
S00570	   LCNEC	   KRAS	   p.G13C	  
S00713	   LCNEC	   KRAS	   p.G12C	  
S01120	   SARC	   KRAS	   p.G12C	  
S00117	   SQ	   KRAS	   p.G13D	  
S00149	   SQ	   KRAS	   p.G12A	  
S00223	   SQ	   KRAS	   p.G12D	  
S00314	   SQ	   KRAS	   p.G12C	  
S00318	   SQ	   KRAS	   p.G12D	  
S00338	   SQ	   KRAS	   p.G15S	  
S00412	   SQ	   KRAS	   p.G12D	  
S00513	   SQ	   KRAS	   p.G12D	  
S01447	   SQ	   KRAS	   p.G12D	  
S00269	   UNKNOWN	   KRAS	   p.G12C	  
S00272	   UNKNOWN	   KRAS	   p.G12D	  
S00366	   UNKNOWN	   KRAS	   p.G12C	  
S00517	   UNKNOWN	   KRAS	   p.G12D	  
S00453	   AD	   NFE2L2	   p.L23I	  
S01031	   AD	   NFE2L2	   p.P88L	  
S01142	   AD	   NFE2L2	   p.R34Q	  
S01252	   AD	   NFE2L2	   p.D77Y	  
S01277	   ADSQ	   NFE2L2	   p.D29N	  
S01100	   LCC	   NFE2L2	   p.S97G	  
S01687	   LCC	   NFE2L2	   p.E79K	  
S00799	   LCNEC	   NFE2L2	   p.G31A	  
S00045	   SQ	   NFE2L2	   p.L23V	  
S00064	   SQ	   NFE2L2	   p.G81V	  
S00139	   SQ	   NFE2L2	   p.R34P	  
S00144	   SQ	   NFE2L2	   p.T80K	  
S00173	   SQ	   NFE2L2	   p.R34Q	  
S00200	   SQ	   NFE2L2	   p.I28T	  
S00222	   SQ	   NFE2L2	   p.D29H	  
S00224	   SQ	   NFE2L2	   p.R34G	  
S00247	   SQ	   NFE2L2	   p.R34G	  
S00281	   SQ	   NFE2L2	   p.G81V	  
S00355	   SQ	   NFE2L2	   p.E79K	  
S00424	   SQ	   NFE2L2	   p.D29N	  
S00509	   SQ	   NFE2L2	   p.E79K	  
S00512	   SQ	   NFE2L2	   p.R34Q	  
S00705	   SQ	   NFE2L2	   p.E79K	  
S00760	   SQ	   NFE2L2	   p.E79K	  
S00983	   SQ	   NFE2L2	   p.G31A	  
S01106	   SQ	   NFE2L2	   p.Q73H	  
S01109	   SQ	   NFE2L2	   p.I20F	  
S01110	   SQ	   NFE2L2	   p.D29N	  
S01236	   SQ	   NFE2L2	   p.D29N	  
S01245	   SQ	   NFE2L2	   p.V32P	  
S01282	   SQ	   NFE2L2	   p.E79Q	  
S01385	   SQ	   NFE2L2	   p.R34P	  
S01475	   SQ	   NFE2L2	   p.W24C	  
S01481	   SQ	   NFE2L2	   p.I28T	  
S01598	   SQ	   NFE2L2	   p.D29H	  
S01635	   SQ	   NFE2L2	   p.R34P	  
S01650	   SQ	   NFE2L2	   p.(E55Q(+)E79K)	  
S01655	   SQ	   NFE2L2	   p.R34P	  
S00635	   AD	   NRAS	   p.Q61L	  
S00438	   ADSQ	   NRAS	   p.G12A	  
S01450	   LCC	   NRAS	   p.G13V	  
S00506	   SQ	   NRAS	   P.G12C	  
S01085	   SQ	   NRAS	   p.G12D	  
S00027	   AD	   PIK3CA	   p.E545K	  
S00065	   AD	   PIK3CA	   p.H701P	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S00074	   AD	   PIK3CA	   p.F1002L	  
S00105	   AD	   PIK3CA	   p.E545K	  
S00299	   AD	   PIK3CA	   p.E545K	  
S00348	   AD	   PIK3CA	   p.E545K	  
S00386	   AD	   PIK3CA	   p.H1047L	  
S00398	   AD	   PIK3CA	   p.E545K	  
S00459	   AD	   PIK3CA	   p.H1047Q	  
S00561	   AD	   PIK3CA	   p.E545K	  
S00562	   AD	   PIK3CA	   p.E545K	  
S00590	   AD	   PIK3CA	   p.E545K	  
S00598	   AD	   PIK3CA	   p.E545K	  
S00604	   AD	   PIK3CA	   p.H1047Y	  
S00662	   AD	   PIK3CA	   p.E545K	  
S00750	   AD	   PIK3CA	   p.R88Q	  
S00770	   AD	   PIK3CA	   p.H1047L	  
S01111	   AD	   PIK3CA	   p.Y1038F	  
S01190	   AD	   PIK3CA	   p.E545K	  
S01334	   AD	   PIK3CA	   p.E545Q	  
S01473	   AD	   PIK3CA	   p.E545K	  
S00047	   ADSQ	   PIK3CA	   p.E542K	  
S00909	   ADSQ	   PIK3CA	   p.E545K	  
S01000	   ADSQ	   PIK3CA	   p.E545K	  
S00102	   LCC	   PIK3CA	   p.E545K	  
S00110	   LCC	   PIK3CA	   p.E542K	  
S01066	   LCNEC	   PIK3CA	   p.E545K	  
S01410	   LCNEC	   PIK3CA	   p.E545K	  
S00213	   SCLC	   PIK3CA	   p.S1003L	  
S00538	   SCLC	   PIK3CA	   p.E542K	  
S00008	   SQ	   PIK3CA	   p.E542K	  
S00030	   SQ	   PIK3CA	   p.(E542K(+)E545K)	  
S00044	   SQ	   PIK3CA	   p.E545Q	  
S00068	   SQ	   PIK3CA	   p.E542K	  
S00069	   SQ	   PIK3CA	   p.E545K	  
S00093	   SQ	   PIK3CA	   p.E545K	  
S00145	   SQ	   PIK3CA	   p.E542K	  
S00157	   SQ	   PIK3CA	   p.E545K	  
S00198	   SQ	   PIK3CA	   p.E542K	  
S00199	   SQ	   PIK3CA	   p.E545K	  
S00252	   SQ	   PIK3CA	   p.E542K	  
S00321	   SQ	   PIK3CA	   p.Q546K	  
S00330	   SQ	   PIK3CA	   p.E542K	  
S00408	   SQ	   PIK3CA	   p.E542Q	  
S00480	   SQ	   PIK3CA	   p.H1047R	  
S00674	   SQ	   PIK3CA	   p.E545K	  
S00743	   SQ	   PIK3CA	   p.Y1021C	  
S00758	   SQ	   PIK3CA	   p.E542K	  
S01085	   SQ	   PIK3CA	   p.E542K	  
S01164	   SQ	   PIK3CA	   p.E542K	  
S01178	   SQ	   PIK3CA	   p.E545K	  
S01229	   SQ	   PIK3CA	   p.E542K	  
S01245	   SQ	   PIK3CA	   p.E542K	  
S01299	   SQ	   PIK3CA	   p.E545K	  
S01457	   SQ	   PIK3CA	   p.E542K	  
S00366	   UNKNOWN	   PIK3CA	   p.Q546H	  
S00310	   AD	   ROS1	   narrow	  split	  
S00545	   AD	   ROS1	   ROS1	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